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ABSTRACT 
 
The normal function of the urinary bladder is to store and void urine in a controlled 
manner. During the filling stage the bladder exhibits spontaneous non-voiding 
contractions yet the mechanisms underlying these contractions are unclear. The 
internal lining of the bladder (urothelium/lamina propria) is an important regulator of 
bladder function by its involvement in sensory mechanisms and via releasing 
chemical mediators. In addition, the urothelium/lamina propria also exhibits 
spontaneous contractions which are mediated by unknown mechanisms. This activity 
may influence contractions of the bladder and play an important role in bladder 
function. The present study aimed to investigate the spontaneous contractions of the 
urothelium/lamina propria to identify receptors which modulate the activity. 
 
In the absence of any neuronal input, strips of urothelium/lamina propria developed 
spontaneous contractions with a frequency of 3.72 cycles min-1 and an amplitude of 
0.65g. The frequency and tension of contractions was increased by stimulation of 
muscarinic receptors and α1-adrenoceptors, and inhibited by β-adrenoceptor 
stimulation. Each of these receptor systems is a target for clinical therapies used to 
treat bladder dysfunction, and these results identify the urothelium/lamina propria as 
a potential site of action for these agents. Using RT-PCR all α1- and β-adrenoceptor 
subtypes were present at the mRNA level in the urothelium/lamina propria, whilst 
organ bath experiments with receptor subtype selective agonists and antagonists 
demonstrated that the main functional adrenoceptors in the tissue were the α1A/L- and 
β2-adrenoceptors. Functional experiments also showed that nitric oxide donors 
decreased the rate of spontaneous contractions and inhibited responses to muscarinic 
receptor stimulation or electrical field stimulation. However, nitric oxide was not 
released spontaneously in response to stretch, EFS or muscarinic receptor 
stimulation. Activation of the nerves innervating the urothelium/lamina propria 
results in tissue contraction, yet the dominant neurotransmitter released does not 
activate muscarinic, adrenergic, or purinergic receptors.  Upon removal of the 
urothelium the baseline frequency and tension of spontaneous contractions, and the 
response to muscarinic and β-adrenergic receptor activation remained unchanged. 
This identified the lamina propria as the layer responsible for the contractile activity. 
 
In conclusion, the urothelium/lamina propria exhibits spontaneous contractile activity 
that may influence bladder activity. The rate of contraction was higher in the 
urothelium/lamina propria compared to the detrusor; however, it is possible that in 
diseased states of the bladder, these tissues may be more tightly coupled leading to 
lower urinary tract dysfunction. Therefore, the receptors within the 
urothelium/lamina propria present novel therapeutic targets for the treatment of 
bladder disorders. 
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GENERAL INTRODUCTION 
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1.1 ANATOMY OF THE LOWER URINARY TRACT 
 
1.1.1  The lower urinary tract 
 
The lower urinary tract consists of the urinary bladder (Figure 1-1), the ureters, urethra, and 
prostate (in males).  The umbilical, posterior and anterior ligaments stabilise the bladder 
through their attachments to the pubic and pelvic bones.  Situated inferior to the peritoneum 
and posterior to the pubic symphysis, the bladder temporarily stores urine until it is 
convenient to void.  It is a hollow organ with walls of smooth muscle, internally lined by an 
epithelial layer and externally protected by a serosal layer.  Although it is capable of storing 
up to 1 litre of urine, the bladder holds an average maximum volume of 500mL during the 
normal filling stage. 
 
The spherical shape of the bladder varies as it fills and empties.  The pressure of its own 
contents and that of neighbouring organs affects the bladder’s shape and position.  During 
filling it changes from a tetrahedral shape and becomes pear-shaped, rising into the 
abdominal cavity.  When empty the bladder is reduced in size and held entirely in the lower 
region of the pelvis.   
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Figure 1-1: The location and regions of the female (top images) and male (bottom image) 
lower urinary tract.  
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The bladder is composed of three distinct regions (Figure 1-1) which include:  
 
  The trigone: The triangular area of tissue at the base of the posterior wall. The slit-like 
openings of the ureters are approximately 2.5cm apart, and these openings form the top of 
the trigone, the inferior point of which is located just above the internal urethral sphincter.  
The epithelial layer here is smooth and the trigone acts as a funnel that assists in 
channelling urine into the urethra. 
 
  The bladder neck and urethral entrance:  The lower areas of the bladder that do not form 
the trigone.   
 
  The dome: The main body of the bladder.  The detrusor muscle is thickest in the dome 
and produces the strongest and most significant contractions during micturition. 
 
The bladder wall is made up of several layers (Figure 1-2).  The detrusor muscle forms the 
main bulk of the bladder and is externally protected by a layer of connective serosa, the 
adventitia.  The detrusor consists of intermingled smooth muscle fibres arranged in a middle 
circular layer, with inner and outer longitudinal layers. 
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Figure 1-2: Illustration of the layers in the bladder.  The black ‘cutout’ within the lamina 
propria layer has been enhanced to demonstrate the networks of interstitial cells within this 
cell layer. 
 
 
Internally lining the bladder lumen are layers of specialised transitional epithelium, known as 
the urothelium (Figure 1-2).  Underlying the urothelium is the lamina propria, which receives 
a rich innervation and blood supply (Dickson et al., 2006, Hossler and Monson, 1995, 
Hossler and Kao, 2007, Miodonski et al., 2001, Miodonski and Litwin, 1999).  The 
terminology used when describing this layer varies.  The layer of epithelial cells lining the 
inside of the bladder wall (and are in contact with the urine), is termed the urothelium.  The 
underlying layers between these cells and the detrusor are termed the lamina propria.  The 
urothelium/lamina propria is often referred to as the bladder mucosa or the 
urothelium/suburothelium. 
 
Three layers of transitional epithelium comprise the urothelium (Figure 1-3).  Each layer has 
morphologically distinct cell types due to the changes in cell shape and environment as the 
bladder fills and empties.  The superficial layer contains “umbrella cells” that are able to 
flatten out to increase the surface area as the bladder fills (Figure 1-4).  These large 
(diameters of 25-250 µm) hexagonal cells are interconnected by tight junctions (Apodaca, 
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2004, Lewis, 2000), which help prevent urine or dissolved chemicals in the bladder lumen 
contacting the underlying tissues.  As the bladder empties, the umbrella cells reform back to 
their original shape, decreasing the surface area.  When empty, the urothelial lining is 
arranged in folds called rugae that spread out as the bladder fills (Figure 1-5).  These changes 
in surface area allow the bladder to enlarge, storing more urine without a significant rise in 
internal pressure. 
 
 
Figure 1-3: The layers of the urothelium.  Image depicting the umbrella cells, intermediate 
layer and basal layer. 
 
 
Figure 1-4: Depiction of the transitional nature of the bladder umbrella cells as a result of 
stretching as the bladder fills.  These cells are required to maintain their protective coatings 
and tight-junctions during the shape transformations. 
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Figure 1-5: Haematoxylin and eosin stain of a transverse section of the bladder.  The 
apical layers of the bladder, including the urothelial and lamina propria layers are labelled 
(Magnification: 100x). 
 
 
1.1.2  The urethra and ureters 
 
Urine is expelled from the bladder and leaves the body through the urethra.  The urethra is a 
hollow tube with thick and elastic walls.  It commences at the internal urethral sphincter, 
inferior to the bladder, and runs through the external urethral sphincter to the external orifice.  
It is composed of smooth muscle which comprises an outer longitudinal layer, a circular layer 
and an inner longitudinal layer (Dass et al., 2001).  As a circular and striated band of skeletal 
muscle, the external urethral sphincter is under voluntary control and must be relaxed in order 
to permit the outlet of urine.  The urethra varies in size, length and strength between males 
and females.  In males, the urethra is longer and passes through the centre of the prostate 
gland (Figure 1-1).   
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surface (Rugae) 
Umbrella 
cells 
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cells 
Inner muscular 
layer 
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Urine is filtered by each kidney into the urinary bladder through the ureters.  These 30 cm 
long hollow tubes run from the renal pelvis and descend behind the peritoneum.  The exact 
paths taken differ between males and females, due to the position of the reproductive organs 
(Figure 1-1).  The ureters enter the lower side of the bladder through slit-shaped holes. 
Backflow of urine is prevented as the increase in bladder pressure causes the ureteral 
openings to close.  The ureters facilitate the flow of urine from the kidneys to the bladder 
through peristaltic waves, induced within its walls.  This peristaltic action is enhanced in 
frequency and strength if there are increases in the volume of urine released from the kidneys 
(Osman et al., 2009).   
 
1.1.3  Barrier function of the urothelium 
 
The most important role of the urothelium is maintaining an intact barrier to protect the 
bladder throughout the filling and voiding stages.  The umbrella cells maintain tight junctions 
between adjacent cells which prevent urine or other chemicals (urea, protons and dissolved 
excreted substances) in the bladder lumen from contacting the underlying tissues (Peter, 
1978).  The surface of these cells is also protected by a crystalline protein layer which forms 
hexagonal plaques called uroplakins (Lewis, 2000, Apodaca, 2004, Wang et al., 2003, 
Tammela et al., 1993, Sun, 2006, Parsons et al., 1990).  These plaques develop a unique 
permeability barrier which not only prevents nearly all normally permeable substances from 
passing through the apical urothelial surface, but also stabilises and protects the umbrella 
cells during bladder wall stretching (Hu et al., 2002, Negrete et al., 1996, Southgate et al., 
1994). 
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The umbrella cells are further protected by their ability to produce a glycosaminoglycan 
(GAG) layer created from sulfated polysaccharide glycosaminoglycans (Romih et al., 2005, 
Parsons et al., 1979).  The GAG layer consists of strings of proteoglycans composed of 
chondroitin sulfate and sodium hyaluronate.  These molecules extend from the apical surface 
of the umbrella cells (Figure 1-6) and intertwine to act as a mucous-like barrier (Hurst and 
Zebrowski, 1994, Grist and Chakraborty, 1994, Nickel and Cornish, 1994).  This layer binds 
to water molecules and forms an insulating layer between dissolved chemicals in the bladder 
lumen and the umbrella cells, further preventing damage to the urothelium and underlying 
tissues. 
 
During the filling stage these protective layers are configured to avoid damage from the 
transitional changes in shape undergone by the umbrella cells.  The umbrella cells in 
particular have complex mechanisms in place that allow for the internalisation and 
subsequent reinsertion of plaque membranes.  This is achieved through the endocytosis and 
subsequent exocytosis of uroplakins (Apodaca, 2002, Truschel et al., 2002).  These 
mechanisms allow the urothelium to maintain a highly specialised and effective protective 
role throughout the filling and voiding stages of the micturition cycle which is unique to the 
bladder. 
 
 
 
 
 
 
 
 Page | 10 
 
 
 
 
 
 
Figure 1-6: The apical urothelial layer.  The figure demonstrates the urothelial cells, the 
protein backbone composed of sulfated polysaccharide glycosaminoglycans and the 
uroplakin layer. 
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1.2 INTERSTITIAL CELLS 
 
The layer between the urothelial cells and the detrusor smooth muscle is termed the lamina 
propria and this region contains a diverse collection of cells and tissues.  These include 
connective tissue, blood vessels, and afferent nerve fibres; as well as a range of cells types 
including interstitial cells and fibroblasts (Johnston et al., 2010, McCloskey, 2010, 
Rasmussen et al., 2009, Wiseman et al., 2003, Yu et al., 2011b, Woodman et al., 2011).  
Additionally, a range of immune cells are also present in the lamina propria, such as mast 
cells and dendritic cells (Christmas and Rode, 1991, Gardiner et al., 1986, Kummer et al., 
2007, Yu and Hill, 2011).  However, of most interest are the networks of interstitial cells, 
which are particularly evident directly below the urothelium (Wiseman et al., 2002, Blyweert 
et al., 2004, Wu et al., 2004, Kuijpers et al., 2007, Roosen et al., 2009). 
 
The interstitial cells in the lamina propria have also been termed myofibroblasts (Sadananda 
et al., 2008, Fry et al., 2007) or interstitial cells of Cajal -like cells (McCloskey et al., 2009, 
Sui et al., 2002).  There is considerable controversy and debate regarding the naming 
convention for these cells, yet they will henceforth be referred to as “interstitial cells”. Due to 
their appearance and location (Figure 1-7), the bladder’s interstitial cells were thought to be 
similar to the interstitial cells of Cajal in the gut, which act as pacemakers in the intestinal 
mucosa, generating peristaltic contractions (Sanders, 1996, Hirst and Ward, 2003, Gillespie et 
al., 2004).  The lamina propria interstitial cells share some similarities to the ICC cells in the 
gut, such as their unique position under the basal cell layers in the lamina propria, and their 
similar immunohistochemical staining for c-kit, connexion-43 and vimentin, although 
individually, these markers are not specific to the cells (Gevaert et al., 2011, Johnston et al., 
2010, van der AA et al., 2004, Cheng et al., 2011b, Kim et al., 2011).  However, their 
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localisation in the bladder lamina propria, adjacent cell types, and potential functions in 
mediating bladder activity sets them apart from those in the intestinal tract. 
 
There is evidence to suggest the role of the lamina propria interstitial cells as regulators of 
bladder spontaneous activity (Fry et al., 2004b, Montgomery and Fry, 1992, Sui et al., 2008).  
This activity is thought to be mediated by electrical and calcium transients across the lamina 
propria layer (Fry et al., 2012, Hashitani et al., 2004a) and the involvement of interstitial cells 
presents a novel target for its modulation (Ikeda and Kanai, 2008).  Although interstitial cells 
in the lamina propria may have the potential to regulate the phasic contractile activity, their 
exact role is unclear (Wiseman et al., 2003, Fry et al., 2004a, Gillespie et al., 2006b).  
However, it is possible that these cells facilitate spontaneous activity through modulating the 
amplitude or acting as pacemakers (Kubota et al., 2011). 
 
Historically, the presence of interstitial cells was determined through their histological 
structure (Gabbiani et al., 1971, Eyden, 1993) along with the presence of smooth muscle actin 
(Powell et al., 1999).  It has been noted that past identifications of bladder interstitial cells 
had not conclusively shown the fibronexus (Eyden, 2009) or the full complement of 
organelles, which are common identifying features for “myofibroblasts” using contemporary 
techniques (Gabbiani et al., 1971, Ryan et al., 1974).  Bladder urothelial/lamina propria 
interstitial cells are elongated spindle-shaped (Cheng et al., 2011b), and contain a rough 
endoplasmic reticulum, actin filaments and fibronectin fibrils (Drake et al., 2006).  In 
addition, they have been shown to exhibit a basal lamina, which is usually lacking in 
fibroblasts.  These types of differences have resulted in controversy over the precise name to 
describe these cells, and whether they fit the exact description of a ‘myofibroblast’ (Drake et 
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al., 2006).  A depiction of a typical lamina propria interstitial cell, with its characteristic 
shape, organelles and filaments is illustrated in Figure 1-8. 
 
The detrusor smooth muscle also contains interstitial cells, although they are morphologically 
different from those in the lamina propria.  Two types of these c-kit positive cells are found in 
this muscle layer: one that has a stellate shape, similar to those seen in the lamina propria; 
and another with an elongated shape containing a number of lateral branches (Drake et al., 
2003c, McCloskey, 2010, Brading and McCloskey, 2005). While the lamina propria 
interstitial cells form networks through gap junctions (Sui et al., 2002) and specific 
innervations (Wiseman et al., 2003), the detrusor interstitial cells are not networked with each 
other, yet appear to be present along the periphery of muscle bundles and close to 
innervations (McCloskey et al., 2009).  This location may present them with a role in 
modulating neuronal input to the muscle cells. 
 
It has been hypothesised that the detrusor interstitial cells might generate and modulate 
bladder spontaneous activity (Lagou et al., 2006, Brading, 2006). However, not all reviews 
agree with the minimal evidence that supports a pacemaking role (McHale et al., 2006b).  Of 
particular interest is the lack of pacemaking activity arising from these cells when carefully 
observed using microelectrodes and intracellular calcium imaging (Hashitani et al., 2004b).  
It is also possible that that the smooth muscle cells in the lower urinary tract have their own 
excitability, and as such may not be reliant upon pacemaking interstitial cells (Hashitani, 
2006).  Nonetheless, there is a clear lack of knowledge or research supporting a role for the 
interstitial cells in the detrusor, yet their lack of cell networks and close association with 
nerve fibres suggests that they are unlikely to be involved in the endogenous coordination and 
generation of spontaneous activity. 
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There is a rich network of capillaries and neuronal innervations to the lamina propria (Birder 
et al., 2010b), which may facilitate an important and active role for this region.  There is 
experimental evidence supporting the hypothesis that the interstitial cells in the lamina 
propria can regulate contractile activity.  For example, the interstitial cells respond to agonist 
activation, such as purinergic stimulation. This has been observed in intact guinea-pig bladder 
preparations where measurements of interstitial cell activity (isometric tension, intracellular 
calcium, and membrane current) has been increased in studies using the purinergic agonist 
UTP, which is known to excite interstitial cells in the lamina propria yet not the detrusor 
muscle itself (Fry et al., 2009, Sui et al., 2008).  This purinergic receptor (P2Y) activation is 
also thought to potentiate bladder activity through direct stimulation of receptors on the 
interstitial cells (Wu et al., 2004, Cheng et al., 2011a).  An individual receptor subtype 
(P2Y6) was also identified as the most likely receptor on these cells (Sui et al., 2006).  This is 
an important discovery as it demonstrates the potential to specifically modulate the interstitial 
cell activity within the lamina propria. 
 
The lamina propria interstitial cells respond to purinergic stimulation by generating calcium 
transients and activating chloride currents (Sui et al., 2004).  If two isolated interstitial cells 
are close together, each cell demonstrates an enhanced response to ATP.  This is thought to 
be through a mechanism involving membrane proteins, such as cadherin-11 (Smet et al., 
1996b) and investigations are still underway to ascertain the exact mechanism underlying this 
phenomenon (Fry et al., 2009).  Nonetheless, the fact that increased urothelial ATP can 
contribute to afferent sensitisation via interstitial cells is potential justification for the 
importance of researching clinical purinergic antagonists, in particular for the treatment of 
abnormal sensory activity in the bladder.  In addition, increased research into the activity of 
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the lamina propria interstitial cells may identify novel mechanisms of bladder modulation.  
The receptors which are expressed and functional on the interstitial cells may present new 
targets for therapeutic treatments in bladder diseases. 
 
 
Figure 1-7: A section of the wall from the dome of the bladder.  Image demonstrates the 
location of the network of interstitial cells within the lamina propria.  This layer is situated 
between the urothelial cells and the underlying detrusor smooth muscle. 
 
 
 
Figure 1-8: Image depicting a spindle-shaped bladder interstitial cell found in the lamina 
propria containing the characteristic histological and structural features. 
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1.3 NEUROPHYSIOLOGY OF THE LOWER URINARY TRACT 
 
The bladder stores and subsequently releases urine in a controlled manner, which is part 
voluntary and part involuntary.  Both the somatic and autonomic nervous systems innervate 
the lower urinary tract and neuronal control during filling and voiding requires coordination 
between the parasympathetic, sympathetic and somatic nerves. 
  
1.3.1  The micturition cycle 
 
The micturition cycle comprises the filling/storage phase followed by the subsequent voiding 
phase.  The process of transferring between these two phases involves both the somatic and 
autonomic nervous system and is co-ordinated and under voluntary control in the adult, but is 
involuntarily controlled by an entirely spinal reflex in infants (de Groat, 1997, de Groat, 
1993).  Bladder activity is regulated through an area in the brain stem called the pontine 
micturition centre (Figure 1-9).  The hypothalamus, frontal cortex and cingulated gyrex areas 
of the brain is also involved in bladder functions including the voluntary control of urination, 
awareness of bladder fullness and relaxation of the external sphincter (Blok et al., 1997b, 
Fowler et al., 2008). 
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Figure 1-9: Innervation of the bladder.  Diagram depicting the location of the supraspinal 
micturition centres (top right image) and the main neuronal innervations to the bladder (lower 
images).  The co-ordination of the micturition cycle is regulated within the pontine 
micturition centre and signals are transmitted from the spinal cord via sympathetic, 
parasympathetic and somatic nerves.  The parasympathetic innervation releases 
acetylcholine, ATP and nitric oxide.  The hypogastric nerves contain sympathetic afferent 
and efferent nerves.  Image collated from a range of sources including:  (de Groat, 2006, Ford 
et al., 2006, Yoshimura et al., 2008b, Blok et al., 1997a, Andersson and Arner, 2004). 
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1.3.2  Efferent innervation 
 
Bladder efferent nerves are known to be important in the normal regulation of the micturition 
cycle (De Groat, 1975, de Groat and Ryall, 1969, Iggo, 1955, Yoshimura et al., 2008b).  
Therefore, a clear knowledge of the mechanisms involved in neuronal control has greatly 
assisted in the understanding of bladder activity (Kanai and Andersson, 2010).  Bladder 
emptying can be induced through stimulation of the spinal cord roots, identifying the 
importance of these lower urinary tract innervations (Brindley, 1995, Brindley, 1977).  Both 
the sympathetic and parasympathetic nerves travel to the bladder via the pelvic plexus, and 
subsequently innervate the urethra, bladder dome and bladder neck (Fletcher and Bradley, 
1978, Ek et al., 1977b). 
 
There are three neuronal pathways from the spinal cord that innervate the lower urinary tract, 
the hypogastric, pelvic and pudendal pathways (de Groat and Ryall, 1969, de Groat et al., 
1981, Morgan et al., 1993, de Groat, 2006, Ford et al., 2006, Yoshimura et al., 2008b).  The 
pelvic nerve contains parasympathetic nerve fibres which release ATP, acetylcholine and 
nitric oxide, and extends from an area the spinal cord at the S2-S3 region (Thor et al., 1989).  
The pudendal is a somatic nerve which innervates the external urethral sphincter and pelvic 
floor muscles (de Groat et al., 2001, de Groat, 2006).  The hypogastric nerve is a sympathetic 
nerve which leaves the spinal cord from the T12-L2 region.  This nerve controls the tissue by 
releasing noradrenaline to act on the detrusor’s β-adrenoceptors causing relaxation, or on 
urethral α-adrenoceptors to cause contraction.  Ganglia in the bladder detrusor express 
enzymes for tyrosine hydroxylase (Smet et al., 1996a) as well a large proportion of neurons 
immunoreactive for human vesicular acetylcholine transporter (Dixon et al., 1999).  In 
addition, the sympathetic innervation and ganglia in the lamina propria are also 
 Page | 19 
immunoreactive for tyrosine hydroxylase (Dixon et al., 1999, Jen et al., 1995).  The presence 
of this enzyme may give these lamina propria neurons the ability to produce noradrenaline, 
which would act upon the α- or β-adrenoceptors expressed here.  However, the functional 
relevance for these receptors in the dome is still not clear. 
 
1.3.3  Afferent innervation 
  
Two types of afferent nerves are found in the bladder, the A-delta nerve fibres (Aδ-nerves) 
and the C-fibres.  The cell bodies of these afferent nerves are contained in the lower lumbar 
and sacral dorsal root ganglia (Kanai and Andersson, 2010) and transmit information to the 
brain as the bladder is stretched during the filling stage (de Groat et al., 1981).  Bladder 
afferent fibres contain a range of neuropeptides, including substance P, neurokinin A, 
neurokinin B, calcitonin gene related peptide, cholecystokinin and enkephalins (Donovan et 
al., 1983, Vizzard, 2000, Vizzard, 2001, Keast, 1991, Arms and Vizzard, 2011). 
 
The Aδ-fibers are located in the detrusor smooth muscle and contain relatively few peptide 
neurotransmitters.  They are thinly myelinated sensory fibres which can quickly transmit 
signals from the bladder to the spinal cord (Wyndaele, 2010). These Aδ-fibres are activated 
by relatively low thresholds, such as increases in bladder volume or detrusor contractile 
activity (Iggo, 1955, Birder et al., 2010a).  These fibres are therefore involved in the 
perception of bladder volume during the filling stage of the micturition cycle. 
 
C-fibre afferents also innervate the detrusor.  These nerve fibres, with their characteristic 
sensitivity to the agonist capsaicin, are unmyelinated nerve cells, less sensitive to distension 
than the Aδ-fibres (Kawatani et al., 1986, Maggi et al., 1989, Bahns et al., 1987, Mazieres et 
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al., 1998, Fowler et al., 1994, de Groat et al., 1990, de Groat et al., 2006, Andersson and 
Hedlund, 2002, Birder et al., 2010a, Habler et al., 1990).  There is little information on the 
role of these high-threshold C-fibre afferents in normal bladder function, although they 
appear to generate reflex contractions during the filling stage in some animal models (de 
Groat et al., 1990, Yoshimura and de Groat, 1997, Cheng et al., 1999).  However, this 
involvement is not clear and as such these nerves are not thought to be responsible for 
neuronal control of the normal micturition cycle. 
 
C-fibre afferents are activated in response to diseases of the bladder such as inflammation or 
overdistension (Wyndaele, 2010, Janig and Koltzenburg, 1990).  This suggests that the C-
fibre afferents may operate a mechanosensitive role, transmitting signals to the spinal cord 
during periods of inflammation or injury to the bladder.  They may also provide the 
additional neuronal sensitivity, such as increased urgency and pain, observed in inflammatory 
bladder diseases (Habler et al., 1990).  Additionally, abnormal regulation of this neuronal 
system may be functionally involved in stimulating the increased contractions seen in 
detrusor overactivity.  Both afferent and efferent nerves in the bladder dome not only 
innervate the detrusor muscle, but also extend into the lamina propria and come in close 
proximity to the interstitial cells, assumingly influencing their function (Wu et al., 2004, Sui 
et al., 2006, Ford et al., 2006, Kanai and Andersson, 2010, Gillespie et al., 2004, Hashitani, 
2006, Yoshimura, 2007).   
 
1.3.4  The filling and storage phase 
 
The empty bladder increases in size as it fills, allowing up to 1L of urine storage.  During the 
filling stage there is no significant increase in intravesical pressure due to a relaxation of 
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smooth muscle.  As the bladder enlarges, the internal rugae of the urothelium disappear and 
the umbrella cells alter their shape and position to accommodate the increasing size and 
length of the bladder wall (Lazzeri, 2006).  Low level firing of afferent nerve fibres results in 
the release of noradrenaline from the sympathetic nerves, which relaxes the smooth muscle in 
the bladder dome via activation of detrusor β-adrenoceptors (de Groat, 2006).  At the same 
time noradrenaline released in the urethra activates the nearby urethral α-adrenoceptors and 
causes contraction (Fry et al., 2010).  The release of noradrenaline is sensitive to stretch and 
as the bladder fills more noradrenaline is released, further stimulating detrusor relaxation.  
Other mediators are also involved in maintaining continence by facilitating the closure of the 
urethra and bladder outlet region, such as prostanoids, tachykinins (Andersson and Hedlund, 
2002) and ATP, which contracts smooth muscle and helps maintain urethral closure (de Groat 
and Yoshimura, 2001).  In males, sympathetic nerves also activate the α1-adrenoreceptors on 
the prostate smooth muscle which increases outlet resistance and assists in maintaining 
continence (Chapple et al., 1989). 
 
1.3.5  The voiding phase 
 
A neurogenic on-off circuit between the urinary bladder and urethral outlet causes the change 
from the filling/storage phase, to the voiding phase (Fowler et al., 2008).  The increased 
intravesical volume as the bladder fills enhances activity in afferent and sympathetic nerves 
up to a critical threshold at which the voiding reflex is initiated.  This afferent activity is 
relayed to the periaqueductal gray area in the pons which then transmits the signal to the 
pontine micturition centre and commences the voiding process (Sullivan and Yalla, 2002).  
When this occurs, the sympathetic and somatic pathways are inhibited and the 
parasympathetic innervation is activated (de Groat et al., 1997).  These parasympathetic 
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nerves release acetylcholine (Figure 1-9) which activates muscarinic receptors on the detrusor 
and initiates contraction (Nausch et al., 2010).  At the same time, ATP is released which acts 
upon detrusor muscle P2X1-receptors to enhance contraction (Burnstock, 2001b, Heppner et 
al., 2009, Layne et al., 2010).  Parasympathetic nerves also release nitric oxide to relax the 
urethra and bladder outlet region (Andersson and Arner, 2004).  These processes facilitate the 
voiding phase of the micturition cycle, causing relaxation of the urethra and bladder outlet, 
contraction of the detrusor and voiding (Chancellor and Yoshimura, 2002). 
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1.4 SPONTANEOUS ACTIVITY 
 
Many smooth muscle organs in the body exhibit some form of spontaneous rhythmic activity.  
These include the uterus, gastrointestinal tract, gallbladder, urethra, prostate and vas deferens.  
The common function of this spontaneous activity is to provide motility in these muscles, 
such as the ejection of fluids from the prostate or peristaltic contractions in the intestine.  As a 
result the mechanical consequences of the activity vary between tissues, from rapid phasic 
contractions to sustained contracture (McHale et al., 2006a). The contractions are not 
necessarily related to input from nerves innervating the smooth muscle, but appear mediated 
from specialised pacemaker cells (eg: interstitial cells), distinct from the smooth muscle cells 
themselves (Takaki et al., 2010). 
 
Spontaneous contractions in the bladder 
 
Urodynamically, the whole bladder develops spontaneous non-voiding contractions during 
filling.  Tonic contractions occur in the urethra while phasic contractions occur in the 
detrusor (Fry et al., 2010, Brading, 2006).  Traditionally, this activity was thought to be 
associated with abnormal bladder function, however, it is now understood that spontaneous 
contractions during filling are evident in healthy human bladders (van Waalwijk van Doorn et 
al., 1992, Robertson, 1999).   
 
However, the importance for the size of each bladder spontaneous contraction is uncertain 
and large amplitude spontaneous bladder activity may have a role in evoking afferent 
mechanisms; initiating sensations of bladder fullness or pain; maintaining muscular tone; or 
triggering voiding and urine storage reflexes (Fry et al., 2010, Brading, 2006). 
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The role of spontaneous activity in disease 
 
The normal role of spontaneous bladder contractions is unclear, however, they have been 
shown to change in frequency and magnitude during various disorders of the lower urinary 
tract. Patients suffering from overactive bladder may exhibit larger amplitude, higher 
frequency spontaneous contractions in isolated detrusor tissues in vitro (Fry et al., 2004b), or 
exhibit a higher bladder contractile index than healthy patients (Oh et al., 2011).  These 
increases in spontaneous activity during the filling stage are common identifying features 
used during urodynamic observations to diagnose patients with detrusor overactivity (Rovner 
and Goudelocke, 2010, Fan et al., 2011). 
 
Bladder outlet obstruction in mice causes the spontaneous contractions to decrease in 
frequency but increase in magnitude, simulating the symptoms of overactive bladder (Drake 
et al., 2003d).  Damage to the nervous system is also known to result in overactive bladder 
(Fowler et al., 2008), and this can be replicated in animal models through transection of the 
spinal cord, which increases the amplitude and frequency of spontaneous contractions in rat 
bladders (Ikeda et al., 2007).  The origins of the increases in spontaneous contractile activity 
during pathology are not known.  However, they may be related to changes in the properties 
of the smooth muscle; the inability of the detrusor muscle to correctly regulate intracellular 
calcium (Fry et al., 2002); increases in electrical conductivity with alterations of gap 
junctions (Wang et al., 2001, Haferkamp et al., 2003); changes in receptor or ion channel 
function (Turner and Brading, 1997); abnormal levels of muscle oxygenation (Vijaya et al., 
2012); chemical modulator release from the urothelium (Birder and de Groat, 2007); or an 
increased distribution of interstitial cells (Kubota et al., 2008).  
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Altering the frequency of the spontaneous contractile activity may be an action of 
antimuscarinic drugs prescribed to alleviate the symptoms of overactive bladder, although 
their precise mechanisms and sites of action have yet to be established (Sellers and Chess-
Williams, 2012). Nonetheless, such drugs are the preferred pharmacological treatment for 
urgency, frequency, and incontinence associated with bladder overactivity (Andersson, 
2004a, Chapple, 2000, Kumar et al., 2003, Nijman, 2004, Rovner and Wein, 2002, Yono et 
al., 2000).   
 
Detrusor spontaneous activity 
 
The spontaneous contractions of the bladder appear to arise from contractile activity within 
the detrusor smooth muscle.  This suggests that an increased rate or amplitude of detrusor 
contractions may result in an enhanced urge to urinate and thus be an underlying cause of 
overactive bladder (Coolsaet et al., 1993, Al-Ghazo et al., 2011, Kinder and Mundy, 1987, 
Mills et al., 2000).  The origin of these spontaneous contractions is not certain.  They do not 
arise from neuronal sources (Drake et al., 2003a), but are generated from within the detrusor 
smooth muscle itself (Drake et al., 2003b, Lagou et al., 2006), and possibly mediated by 
interstitial cells, identified within the detrusor (Davidson and McCloskey, 2005).  This 
spontaneous activity can be modulated through increased extracellular magnesium ions or by 
calcium agonists (Montgomery et al., 1992, Levin et al., 1991).  In addition, a range of other 
agonists, many of which are released endogenously from the urothelium/lamina propria, 
modulate detrusor activity.  For example, in animal models the contractions can be increased 
through exogenous ATP; nitric oxide; and acetylcholine.  Conversely, the contractions can be 
inhibited by noradrenaline; calcitonin gene-related peptide; and via the inhibition of 
phosphodiesterases (Gillespie et al., 2003, Drake et al., 2003d, Finney et al., 2008, Finney et 
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al., 2007, Streng et al., 2006, Gillespie, 2004c, Gillespie, 2004b).  It is still uncertain as to 
what extent the findings in animal models relate to human bladders.  Research in humans has 
measured only large contractions of the bladder through cystometry, whereas animal whole-
bladder models have been used to measure a wider range of pressure increases.  This method 
in animal bladders has identified a number of different variables in the spontaneous activity 
(Biallosterski et al., 2011, Streng et al., 2006).  As such, it is unknown whether isolated 
whole bladder preparations in humans have a similar range of contractile pressures during 
filling or if they respond in similar ways to receptor activation. 
 
1.4.1 Role of the urothelium and lamina propria in regulating detrusor spontaneous 
contractile activity 
 
As the bladder fills the urothelium/lamina propria is stretched and the cells within this layer 
change their shape to accommodate an increasing volume.  To accomplish this, sensors on the 
urothelium respond to stretch by releasing chemical transmitters.  These allow the bladder 
wall to relax, and thus facilitate increases in volume; or activate the sensory innervation to the 
area (Figure 1-10).  Upon stretching, acetylcholine is released endogenously from cells within 
the urothelium (Yoshida et al., 2006, Yoshida et al., 2004b, Hanna-Mitchell et al., 2007), 
along with ATP (Young et al., 2012, Ferguson et al., 1997, Cheng et al., 2011b).  Other 
chemicals released during stretch of the urothelium include nitric oxide which results in 
tissue relaxation (Ferguson et al., 1997, Birder et al., 1998), and prostaglandin E2 (Yoshida et 
al., 2004a) which can stimulate bladder contractions (de Jongh et al., 2007b, Kobayter et al., 
2012). 
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Many of the chemicals released from the urothelium and lamina propria during the filling 
stage may modulate the overall bladder spontaneous contractile activity. One main regulator 
of bladder spontaneous contractions in rats appears to be acetylcholine, which may enhance 
spontaneous activity in the intact bladder (Kanai et al., 2007).  Although acetylcholine is 
released by nerves in the detrusor, usually resulting in muscle contraction, it can also be 
released from the urothelium which shows positive immunohistochemical staining for choline 
acetyltransferase (Yoshida et al., 2008).  This urothelial-derived acetylcholine could act 
directly on the detrusor, or on the interstitial cells in the lamina propria, potentially 
influencing the spontaneous activity of the bladder (Gillespie et al., 2003, Fry et al., 2007).  
Furthermore, in experiments on human bladder strips this non-neuronal release of 
acetylcholine was increased in both aged rats and bladder stretching (Yoshida et al., 2008).  
There is also evidence to support the existence of purinergic receptors in the 
urothelium/lamina propria although their exact functional role is unclear.  ATP released from 
the urothelium/lamina propria in mice is thought to activate the afferent nerves adjacent to the 
urothelium (Rong et al., 2002).  This is via the P2X-purinergic receptors on both Aδ- and C-
fibre afferent nerves in the lamina propria (Kumar et al., 2004, Munoz et al., 2010, 
Yoshimura et al., 2008a, Du et al., 2007).  Additionally, in rats ATP also stimulates P2Y-
purinergic receptors on interstitial cells in the lamina propria which increases the frequency 
of calcium transient activity through the tissue (Fry et al., 2012).   
 
In addition to releasing chemical transmitters to directly influence detrusor contractile 
activity, another role for the urothelium/lamina propria may be the generation and modulation 
of bladder spontaneous activity (Kanai et al., 2007, Fry et al., 2012).  It has been identified 
that coordinated spontaneous activity in the rat bladder requires an up-regulation of gap 
junctions between cells within the urothelium and lamina propria (Ikeda et al., 2007).  
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Through using an optical mapping technique which traces the flow of charge through rat 
bladders, it was observed that the spontaneous activity, at least in regards to the calcium 
transients through the tissue, was generated from within the urothelium and modulated by 
structures within the lamina propria (Ikeda and Kanai, 2008).  A later study supported this in 
rat tissue, observing that calcium transients are initially generated in the lamina propria and 
then spread outwards to both the urothelium and detrusor (Fry et al., 2012).  Although the 
link between spontaneous calcium transients and the spontaneous contractile activity has not 
been established in many species, these finding still indicate the importance of the 
urothelium/lamina propria in generating, coordinating and modulating spontaneous activity 
within the detrusor.  Functional studies have also shown that the presence of the 
urothelium/lamina propria is associated with an increased bladder spontaneous activity (Sui 
et al., 2008, Akino et al., 2008).  Alternatively, a urothelial derived inhibitory factor (UDIF) 
is thought to be released from the urothelium/lamina propria and appears to depress responses 
to carbachol and histamine (Templeman et al., 2002a). Although the relationship between the 
urothelium/lamina propria and bladder spontaneous contractions is still uncertain, these 
recent studies have identified a clearly important role for the tissue, and the potential for a 
malfunctioning urothelium/lamina propria to be an underlying cause or contributor in bladder 
diseases. 
 
1.4.2 Spontaneous activity of the urothelium/lamina propria 
 
The urothelium/lamina propria has an ability to release various modulators of sensory 
neurons and smooth muscle which can influence detrusor spontaneous contractions (Birder 
and de Groat, 2007, Kumar et al., 2005, Buckner et al., 2002, Hawthorn et al., 2000, Kanai et 
al., 2007).  However, the isolated urothelium/lamina propria is capable of generating its own 
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spontaneous contractions (Sadananda et al., 2008) and these contractions may stimulate 
afferent nerves in the lamina propria; maintain bladder tone; assist the urothelium to fold into 
its rugae; or directly influence the detrusor to maintain normal continence during the filling 
stage. 
 
It is important to identify the possible cell types that may be responsible for the generation, 
propagation and pacemaking of the lamina propria contractile activity.  Interstitial cells are 
usually presented as the likely regulators of bladder spontaneous activity (Fry et al., 2004b, 
Montgomery and Fry, 1992).  Although the exact role for interstitial cells is unclear, they 
could facilitate the spontaneous activity by modulating the contractile amplitude and acting as 
pacemakers to regulate the frequency (Wiseman et al., 2003, Fry et al., 2004a, Gillespie et al., 
2006b).  This role for lamina propria interstitial cells would also relate to their morphological 
similarities with the ICC cells in the gut, which are responsible as pacemaking cells 
regulating contractions. 
 
The contractile activity of the urothelium/lamina propria may also be generated by muscle 
cells.  These are located between the basement layer of the urothelium and the muscularis of 
the detrusor, and termed the muscularis mucosae.  These muscle cells have been extensively 
studied, although usually in relation to their potential role in carcinomas of the bladder 
(Chaimuangraj et al., 2006, Paner et al., 2007, Weaver and Abdul-Karim, 1990).  There is a 
hypothesis that the muscularis mucosae is involved in the regulation of spontaneous 
contractile activity in the urothelium, and that the ability to contract with a cyclical frequency 
demonstrates its potential to work as a pacemaker or regulator (Heppner et al., 2011).  
However, this hypothesis is not widely accepted and in comparison to the detrusor, it is 
thought that sparse smooth muscle exists in the urothelium/lamina propria (Cheng et al., 
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2011b).  Furthermore, removal of the smooth muscle cells from the urothelium/lamina 
propria does not appear to affect contractile responses (Sadananda et al., 2008).  Smooth 
muscle actin is also present in the lamina propria interstitial cells which suggests that the 
observed spontaneous contractile activity may arise from these interstitial cells rather than a 
specialised muscle layer (Drake et al., 2006, McCloskey, 2010, Gevaert et al., 2011, Cheng et 
al., 2011b). 
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Figure 1-10:  Urothelial-derived transmitters acting on the detrusor smooth muscle and 
afferent innervation.  During the filling stage, transmitters are not only released by nerves 
within the bladder, but can be released from the urothelium and lamina propria.  Increased 
stretch and pressure leads to acetylcholine release from both nerves and the urothelium.  
ATP, urothelial derived inhibitory factor (UDIF), prostanoids, substance P, nitric oxide and 
nerve growth factor are also known to be released and may act on the lamina propria and 
afferent nerves.  Image collated from a range of references including: (Fry et al., 2010, Birder 
and de Groat, 2007, Hanna-Mitchell et al., 2007, Apodaca, 2004, Yoshida et al., 2006, 
Yoshida et al., 2004a, Ferguson et al., 1997). 
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1.5 RECEPTORS AND SYSTEMS IN THE URINARY BLADDER 
 
1.5.1 Cholinergic receptors 
 
1.5.1.1  Muscarinic receptors 
 
Muscarinic receptors are the main receptors mediating detrusor muscle contraction and as 
such, they are an important target in the pharmacological management of bladder diseases 
(Andersson, 2011, Yamaguchi, 2010).  Activation of the postjunctional muscarinic receptors 
was previously thought to be mediated exclusively by acetylcholine released from cholinergic 
nerves, which run throughout the detrusor muscle and into the lamina propria (Dixon et al., 
2000).  However, it is now understood that acetylcholine is also released from the urothelium, 
identifying a non-neuronal mechanism of receptor activation (Yoshida et al., 2006, Yoshida 
et al., 2008, de Groat, 2004). 
 
The muscarinics are 7-transmembrane receptors comprised of 5 subtypes, which have been 
classified as M1 – M5 via both pharmacological and molecular characterisation (Caulfield and 
Birdsall, 1998, van Koppen and Kaiser, 2003).  Of these, M1, M2 and M3 have been well 
characterised pharmacologically, primarily due to the availability of relatively selective 
antagonists.  Although there are similarities in their structure, the signal transduction system 
varies between the subtypes (Giglio and Tobin, 2009).  All five muscarinic receptors couple 
to G-proteins, with M1, M3 and M5 coupling to Gq/11 (Figure 1-11).  This leads to increased 
intracellular calcium release from the sarcoplasmic reticulum (SR) via inositol 1,4,5-
triphosphate (IP3), resulting in smooth muscle contraction (Wu et al., 2000).  In addition to 
the SR release, calcium also enters the cell through the membrane via the diacylglycerol 
(DAG)-mediated activation of protein kinase C and opening of L-type calcium channels 
 Page | 33 
(Berridge, 1984, Streb et al., 1983, Nishizuka, 1984, Schneider et al., 2004).  It is generally 
thought that the M2 and M4 muscarinic receptor subtypes act in an inhibitory role in bladder 
function (Andersson, 2011).  These receptors couple to Gi/o and affect the activity of 
adenylate cyclase (Hegde et al., 1997, Londos et al., 1981); inhibit potassium channels 
(Bonev and Nelson, 1993, Nakamura et al., 2002); and inhibit nonselective cation channels 
(Kotlikoff et al., 1999, Yamamoto et al., 2008).  The importance of the muscarinic receptors 
in the management of bladder function is highlighted by the fact that the main class of drugs 
used to treat overactive bladder are clinical muscarinic antagonists.  These include 
solifenacin, oxybutynin, tolterodine, darifenacin and trospium (Athanasopoulos and 
Giannitsas, 2011).  The mechanisms of action for these drugs is not fully understood; 
however, they likely target the muscarinic receptors expressed throughout the lower urinary 
tract and bladder (Hegde, 2006). 
 
Muscarinic receptors in the ureters 
 
The function of muscarinic receptors in the ureter is not clear.  Ureters from patients 
undergoing radical nephrectomy were examined in a study which observed mRNA 
expression for only the M2, M3 and M5 receptors, although the presence of all subtypes was 
demonstrated through immunohistochemistry (Sakamoto et al., 2006).  However, this study 
did not contain an adequate sample size (only 3 for RT-PCR and 4 for immunohistochemical 
analysis), and there was the confounding factor of the patient’s kidney diseases, which may 
affect the ureters.  In addition, this study heavily relied upon immunohistochemistry for the 
conclusion, yet did not present adequate controls to address the problems associated with the 
lack of specificity in current muscarinic and G-protein coupled receptor antibodies 
(Pradidarcheep et al., 2008, Pradidarcheep et al., 2009, Jositsch et al., 2009, Michel et al., 
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2009).  The functional role of the muscarinic receptors in the ureter is still uncertain, although 
they are suggested to be involved in stimulation of muscle contraction in human, canine, 
equine and porcine models (Canda et al., 2007, Long and Nergardh, 1978, Tomiyama et al., 
2004, Hernandez et al., 1993, Prieto et al., 1994). 
 
Muscarinic receptors in the urethra 
 
The urethra, where sympathetic nerves have the predominant role functionally, has also been 
found to receive a dense cholinergic innervation in both human and animal models (Ek et al., 
1977a, Persson et al., 1995, Arrighi et al., 2008).  The role of this neuronally released 
acetylcholine in the urethra is uncertain (Andersson, 2011) although it may act on M1, M2 or 
M3-muscarinic receptor subtypes, as identified through functional studies and radioligand 
binding in rabbit urethra (Mutoh et al., 1997, Nagahama et al., 1998).  Nonetheless, 
predominant research into receptor expression in the human urethra has focussed on the 
adrenoceptor system and there remains a paucity of research analysing the muscarinic 
receptor population and function. 
 
Muscarinic receptors in the prostate 
 
The exact function and expression of individual muscarinic receptor subtypes in the prostate 
is uncertain.  Molecular biological studies have demonstrated mRNA expression in human 
prostate cells for all muscarinic receptors (M1 - M5), with a strong expression of M2 in the 
stromal cells compared to the other receptors (Obara et al., 2000)  This was consistent with 
previous studies using radioligand binding (Yazawa et al., 1994).  Obara (2000) also 
concluded the expression of M1, M2, and M5-muscarinic receptors in prostatic epithelial cell 
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cultures, although the results and images presented in the paper did not display clear M1-
transcripts, with questions arising as to the validity of the conclusion.  Further radioligand 
binding assays in human and rat prostate has determined that only the M1 and M2-muscarinic 
receptor subtypes are present (Anisuzzaman et al., 2008), although this study relied on only 
one M3-selective antagonist, darifenacin, for this conclusion.  Functionally, recent research 
using electrical field stimulation and exogenously applied cholinergic agonists has identified 
the M3 muscarinic receptor as the subtype mediating the cholinergic component of 
contraction in mouse prostate (White et al., 2011).  It will be of interest to examine further 
roles for these receptors in the contractile function of human prostate, which may lead to 
additional targets for the pharmacological treatment of benign prostatic hyperplasia. 
 
Muscarinic receptors in the bladder 
 
Human detrusor muscle expresses all five muscarinic receptor subtypes at the mRNA level 
(Sigala et al., 2002), with a greater expression of the M2–muscarinic receptors relative to the 
M3-muscarinic receptors (Homma and Yamaguchi, 2009, Yamaguchi et al., 1996, Giglio and 
Tobin, 2009).  This was similar to that found in pig bladder (Maeda et al., 1988).  Rat urinary 
bladder also has a predominant expression of the M2 and M3 subtypes, and although these 
bladders were thought to express only the M1 – M4 muscarinic subtypes (Braverman et al., 
1998), recent studies have identified a low expression of the M5-receptor (Creed et al., 2010).  
At the protein level, human bladder contains ~70% M2 receptors, ~20% M3-receptors and 
~10% M1-receptors, as detected by competition radioligand binding (Mansfield et al., 2005) 
and immunoprecipitation (Wang et al., 1995, Goepel et al., 1998).  A higher proportion of the 
M2-muscarinic receptor subtype (~90%) is also seen in mice (Choppin and Eglen, 2001b), 
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rats (Choppin et al., 1998, Hegde et al., 1997, Longhurst et al., 1995, Longhurst and 
Levendusky, 2000, Tong et al., 1997), rabbit and guinea pig (Wang et al., 1995). 
  
Although the M2-subtype is the most prevalent in the bladder, it is the M3-subtype that is 
responsible for contraction in all species studied to date. During voiding, acetylcholine is 
released from the neuroeffector junctions of both ganglionic and postganglionic nerves 
(Persson et al., 1995, Smet et al., 1996a) where it then acts predominantly on receptors in the 
detrusor smooth muscle.  It has been ascertained that the M3-muscarinic receptor subtype is 
responsible for direct contraction in human (Chess-Williams et al., 2001, Fetscher et al., 
2002), porcine (Sellers et al., 2000b), dog (Choppin and Eglen, 2001a), mouse (Choppin and 
Eglen, 2001b) and rabbit (Tobin, 1995) bladders.  This is further supported by mice lacking 
the M3-receptor, through gene knockout, demonstrating a greatly reduced detrusor 
contractility (Matsui et al., 2002).  In addition, M3-receptor knock-out mice exhibit bladder 
distension and develop urinary retention, yet this does not occur in M2 knock-out mice 
(Matsui et al., 2000).  The mechanisms underlying this M3-receptor mediated contractile 
response in the detrusor are outlined in Figure 1-11.  The role of the M2-muscarinic receptors 
in the bladder appears slightly more complex. There is a small effect on cystometric 
parameters in mine lacking the M2-receptor via gene knockout (Igawa et al., 2004, Ehlert et 
al., 2005) and it is understood that the M2-receptors may oppose the sympathetically-
mediated detrusor relaxation through inhibition of adenylyl cyclase (Hegde et al., 1997).   
Alternatively, M2-receptors may have a function during periods of high sympathetic activity, 
or play a greater role when the M3-receptors are dysfunctional (Yamanishi et al., 2001).  
Nonetheless, the functional role of the M2-muscarinic receptor subtype in the bladder is still 
not clearly understood.   
 
 Page | 37 
 
Figure 1-11: Diagram representing the intracellular actions of acetylcholine acting on M2 
and M3 muscarinic receptor subtypes. The M3-receptor acts via the second messengers 
inositol triphosphate (IP3) and diacylglycerol (DAG) to result in smooth muscle contraction.  
Additionally, M2-receptors may inhibit cyclic AMP and reduce contraction.  In conjunction 
with the β-adrenoceptor mediated increase in cyclic AMP, may maintain smooth muscle tone. 
 
 
Muscarinic receptors in the urothelium/lamina propria 
 
In the urothelium/lamina propria of human bladders all muscarinic receptors are expressed at 
the mRNA level, with a high expression of the M2 and M3 subtypes (Mansfield et al., 2005, 
Bschleipfer et al., 2007, Ochodnicky et al., 2012).  Immunohistochemical studies have also 
identified a high prevalence of the M2 and M3 receptors in human urothelium/lamina propria 
(Mukerji et al., 2006b, Tyagi et al., 2006).  An interesting finding in porcine bladders, was 
that the density of muscarinic receptors was found to be higher in the urothelium/lamina 
propria than in the detrusor (Hawthorn et al., 2000), which is in direct contrast to rat tissue 
where the density is higher in the detrusor (Anisuzzaman et al., 2008).  However, these 
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differences may be due to experimental variations in exposure of the tissues to the 3H-QNB 
and carbachol.  Anisuzzaman et al (2008) found that receptor density, as measured using 3H-
QNB, was dependent upon the concentration and the time of incubation. 
 
The cell type distribution of the muscarinic subtypes in the urothelium and lamina propria is 
still uncertain.  Within human bladders the M1 receptors appear expressed exclusively on the 
urothelial basal cells, while the M2-receptor is most dense in the umbrella cell layer 
(Bschleipfer et al., 2007).  An immunohistochemical study has also identified both M2 and 
M3-receptors on nearby nerve fibres as well as the urothelium (Mukerji et al., 2006b).  An 
exciting prospect is the suggestion that the M3-muscarinic receptor subtype is located on the 
interstitial cells in the lamina propria, as demonstrated by immunohistochemical staining in 
the guinea pig (Grol et al., 2009).  These muscarinic receptors may present a potential 
mediator of bladder activity, and may influence the activity of the interstitial cells.  The 
urothelium and possibly the lamina propria can release non-neuronal acetylcholine, which 
may be a mechanism whereby the urothelium modulates detrusor contraction during filling or 
voiding via muscarinic receptors (Lips et al., 2007, Yoshida et al., 2006, Hanna-Mitchell et 
al., 2007, Kawashima and Fujii, 2008).  The urothelium and the lamina propria also responds 
to muscarinic agonists, demonstrating dose-dependent increases in intracellular calcium 
(Gupta et al., 2009).  Therefore, the expression and function of these muscarinic receptors on 
this tissue layer is important for the overall understanding of bladder activity. 
 
Presynaptic muscarinic receptors 
 
Prejunctionally, the M1-muscarinic receptor subtype appears to facilitate the release of 
acetylcholine in human (Somogyi and de Groat, 1999) and rat urinary bladders (Braverman et 
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al., 1998, Somogyi and de Groat, 1992).  There is also a role for the M4 receptor subtype as a 
prejunctional receptor which inhibits acetylcholine release in the bladders of rabbit (Tobin 
and Sjogren, 1995, Inadome et al., 1998), guinea pig (Alberts, 1995) and mouse (Takeuchi et 
al., 2008), and the prejunctional inhibitory muscarinic receptor also appears to be M4-subtype 
in humans (D'Agostino et al., 2000).  In the rat bladder the inhibitory prejunctional 
muscarinic receptor subtype has been argued to be the M4-receptor (D'Agostino et al., 1997, 
Shen and Mitchelson, 2001), or conversely the M2-muscarinic receptor subtype (Somogyi 
and de Groat, 1992, Braverman et al., 1998).  In studies by Somogyi and de Groat (1992) and 
Braverman et al (1998), the conclusions of M2-mediated inhibitory effects were highly reliant 
upon the relatively selective M2-antagonist methoctramine, and the M1-selective antagonist 
pirenzepine at a limited range of concentrations.  Both D’Agostino et al (1997) and Shen et al 
(2001) used a wider range of muscarinic receptor antagonists and concentrations to determine 
that the inhibition is mediated by the M4-muscarinic receptor subtype.  Although full 
concentration-response curves were not completed, and thus pA2 values not calculated, the 
latter conclusion, implicating the M4-receptor, appears to be better proven experimentally. 
 
The lack of highly selective antagonists for the M4 or M5 receptor subtypes has limited this 
research.  Studies using gene knock-mice show that the M4-receptor appears to be a 
promising prejunctional receptor as a regulator of normal bladder activity.  In M2-knockout 
mice, bladders that were pre-incubated with [3H]-choline and a muscarinic antagonist, could 
induce a tritium outflow signifying the release of acetylcholine, yet this did not occur in M4 
knock-out mice (Zhou et al., 2002).  These researchers suggested that the autoreceptors in the 
mouse bladders are exclusively M4.  However, a prior study had ruled out using the [
3H]-
choline as it does not tend to label all of the released acetylcholine (Shen and Mitchelson, 
2001). A later study using M4 knock-out mice confirmed that prejunctional inhibitory 
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muscarinic receptors were most likely the M4-receptor subtype (Takeuchi et al., 2008).  
Nonetheless, due to contradictory results and methods, it is clear that further controls need to 
be conducted in these knock-out studies prior to a clear confirmation of an M4-mediated 
effect, although the potential for these subtypes to induce functional effects does offer an 
exciting avenue of future research. 
 
Clinical antimuscarinics in bladder disease 
  
Antimuscarinics are the most common pharmacological treatment for bladder diseases such 
as overactive bladder.  The exact mechanisms by which these antimuscarinics alleviate the 
symptoms of pathologies such as overactive bladder are still uncertain.  The currently 
accepted hypothesis is that they act on muscarinic receptors in the detrusor, blocking the M3-
receptors and reducing the detrusor’s ability to contract (Abrams et al., 2006).  However, in 
relation to studies of muscarinic receptor antagonists in animal models, comparatively small 
doses of antimuscarinics are used in human patients, and at these doses they do not seem to 
significantly influence voiding contractions (Andersson, 2004a, Abrams et al., 2006).  
Therefore, it seems that the effect of these drugs is solely during the filling/storage phase, 
thus likely antagonising the acetylcholine released from the urothelium (Andersson and 
Yoshida, 2003).  They may also assist in minimising the responses due to an increased 
density of urothelial/lamina propria M2 and M3 muscarinic receptors, known to be associated 
with overactive bladder in humans (Mukerji et al., 2006b) and in models of bladder outlet 
obstruction in rats (Kim et al., 2008).  Based on results from animal studies, reviews have 
also suggested that the antimuscarinics act upon the urothelial afferent nerve activity 
(Yamaguchi, 2010, Finney et al., 2006).  This has been shown indirectly through the 
measurements of voiding intervals in rats which were administered muscarinic agonists and 
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antagonists (Kullmann et al., 2008, Finney et al., 2006), and also from directly measuring 
nerve afferent activity (Yu and de Groat, 2010). 
 
There is a further hypothesis that an increased release of acetylcholine might be responsible 
for the symptoms of bladder overactivity (Yoshida et al., 2008).  However, in mice, 
acetylcholine acting on muscarinic receptors appeared to depress sensory transduction (Daly 
et al., 2010a).  This is a controversial proposal in contrast to past studies which have 
suggested that increases in acetylcholine release contributes to bladder diseases such as 
overactive bladder through increasing afferent nerve activity (Yoshida et al., 2008).  
Subsequent discussions related to these findings have demonstrated a scientific interest in the 
bladder afferent function and the responses to acetylcholine (Daly et al., 2010b, Behr-Roussel 
and Giuliano, 2010). 
 
In overactive bladder and animal models of bladder dysfunction, the density of muscarinic 
receptors and detrusor sensitivity to acetylcholine is increased (Mukerji et al., 2006b, Stevens 
et al., 2007, Stevens et al., 2006).  This finding is not consistent across all models, and rats 
with benign prostatic hypertrophy, which is known to induce overactive bladder, have 
demonstrated a hyposensitivity to muscarinic agonists without signs of denervation (Lluel et 
al., 2002).  Studies have also attempted to associate the muscarinic receptors with interstitial 
cystitis (IC), providing a potential for antimuscarincs to be trialled as a treatment.  Bladder 
urothelial cells from patients suffering IC were found to have an increased sensitivity to the 
muscarinic agonist carbachol (Gupta et al., 2009).  However, IC is such a broad and 
undetermined pathology and the fact that only 4 patient samples were examined, means that 
this conclusion may not be representative.  Additionally, the increased sensitivity 
demonstrated in this study was only evident at 10 µM – 1 mM concentrations of carbachol, 
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which is not necessarily physiologically relevant.  Nonetheless, it is important to identify 
therapeutic targets in the bladder that may alleviate the symptoms of overactive bladder or 
interstitial cystitis.  The current use of antimuscarinics is the most common treatment for 
overactive bladder yet there has been no randomised placebo-controlled study identifying the 
effectiveness of muscarinic antagonists in alleviating the symptoms of interstitial cystitis. 
 
1.5.1.2  Nicotinic receptors in the bladder 
 
The bladder expresses mRNA for the α1-α7, β1-β4 nicotinic subunits, as identified using RT-
PCR in rat urothelial cells.  However, only α3- (excitatory) and α7- (inhibitory) subunits are 
translated into proteins, as detected by subsequent western blotting (Beckel et al., 2006, 
Yamamoto et al., 2011).  It has been suggested that there is an inhibitory nicotinic receptor on 
cholinergic nerve terminals of the rat urinary bladder (Somogyi and de Groat, 1992), 
although the physiological relevance of this is yet to be investigated. 
 
The possible role of nicotinic receptors in lower urinary tract dysfunction is not clearly 
understood.  The main response to acetylcholine in the bladder is mediated via cholinergic 
muscarinic receptors.  Therefore, it is not commonly thought that neuronally released 
acetylcholine acts upon nicotinic receptors to induce functional effects within the bladder.  
However, functional roles suggested for these urothelial nicotinic receptors may include 
stimulating calcium or ATP release from the tissue (Beckel and Birder, 2012).   
  
Application of intravesical nicotine affected bladder reflexes in rats in vivo, as well as 
increasing intracellular calcium concentrations in cultured urothelial cells (Beckel et al., 
2006).  The authors of that study were able to block the nicotinic response in cultured cells 
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with the antagonist hexamethonium, yet when applied intravesically this drug had no effect.  
This may either suggest that nicotine has a greater effect on cultured cells than on normal 
bladder function, or that nicotine’s effect is not localised to the urothelial layer but acts on 
other areas in the bladder.  In addition, other nicotinic agonists showed inconsistent results, 
such as epibatidine, which gave initial excitatory responses, then subsequently caused urinary 
retention (Beckel et al., 2006). DMPP, a nicotinic receptor agonist, can stimulate 
postganglionic action potentials in the rat bladder and cause the release of nonadrenergic 
noncholinergic neurotransmitters which stimulate contraction (Tong et al., 1996) although the 
released transmitters and targeted receptors are still unclear. 
 
There is the potential that therapeutic agents used to treat overactive bladder, such as 
distigmine, may also have an effect via its actions on the nicotinic receptors (Harada et al., 
2010).  These authors observed a clear distigmine binding to nicotinic receptors in the rat 
cerebral cortex, although the alterations in bladder activity appeared to be due solely to its 
effects on the muscarinic receptors.  A further hypothesis stems from the suggestion that 
activation of the nicotinic pathway is involved in the down regulation of inflammatory 
cytokine production in a number of human diseases including respiratory infections and 
inflammatory diseases (Ulloa and Wang, 2007, Lakhan and Kirchgessner, 2011).  This 
process may also have implications for bladder diseases, and researchers have identified that 
activation of nicotinic receptors leads to an attenuation of inflammatory mediator production 
in the bladder (Martinez-Ferrer et al., 2008, Starkman et al., 2008).  This conclusion was 
arrived at after histological (H&E staining), immunohistochemical and gene expression 
analyses of rat bladders that underwent chemical-induced inflammation.  These results 
identify the nicotinic receptors as potential therapeutic targets for bladder diseases, in 
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particular, those commonly associated with chronic inflammation and further research into 
these mechanisms is required. 
 
 
1.5.2  Adrenoceptors 
 
The adrenoceptors are activated by noradrenaline released from sympathetic nerves 
innervating the bladder (Figure 1-12).  Throughout the body, α-adrenoceptors and the β-
adrenoceptors mediate a variety of functions.  Generally, α-adrenoceptors play excitatory 
roles and can be divided into two characterised receptor subtypes, the α1 (consisting of α1A, 
α1B and α1D with a possible α1L conformation) and α2-adrenoceptors.  In contrast, activation of 
β-adrenoceptors tends to lead to inhibitory responses, and these receptors have been classified 
into the subtypes β1, β2 and β3 (Alexander et al., 2011). 
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Figure 1-12: Illustration of common neurotransmitters released from the bladder.  
Noradrenaline, acetylcholine and ATP are released from adrenergic and cholinergic nerves, 
and act on the nearby expressed and functionally active receptors.  
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1.5.2.1   β-adrenoceptors 
 
β-adrenoceptors in the lower urinary tract 
 
It is understood that the β-adrenoceptors have a clear role throughout the lower urinary tract, 
yet their distributions vary.  In the human ureters, although the mRNA for all three β-
adrenoceptor subtypes is expressed, only relatively low concentrations of β-adrenoceptor 
protein has been identified with radioligand binding (Park et al., 2000).  Functionally, the β-
adrenoceptors in the ureters appear to have no role, with noradrenaline-induced contraction 
mediated via the α1-adrenoceptors. However, there is evidence for a relaxation response to 
noradrenaline in the distal ends of the ureters, potentially mediated via β-adrenoceptors 
(Tindall, 1972).  In the prostate, β-adrenoceptors may have a role in inhibition of 
noradrenaline-invoked α1-adrenoceptor mediated contractions in animals and humans 
(Kalodimos and Ventura, 2001, Haynes and Hill, 1997, Normandin and Lodge, 1996, Garcia-
Sacristan et al., 1984, Tsujii et al., 1992, Drescher et al., 1994).  The presence of β-
adrenoceptors is also noted in the urethra, where there is evidence for a β-adrenoceptor 
mediated relaxation in humans (Thind et al., 1993), although the α-adrenoceptor contractile 
response also predominates in this tissue. 
 
β-adrenoceptors in the bladder 
 
All three β-adrenoceptor subtypes couple via G-proteins to adenylyl cyclase.  This leads to an 
increase in the levels of intracellular adenosine 3’:5’-cyclic adenosine monophosphate 
(cAMP) which subsequently activates protein kinase A.  During bladder filling there is no 
large elevation of intravesical pressure within the bladder lumen.  In order to accommodate 
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the increasing volume, the detrusor relaxes (Andersson and Arner, 2004), and it is thought 
that this may, at least partly, be facilitated via β-adrenoceptors  (Michel and Sand, 2009).  
Activation of β3-adrenoceptors causes the opening of large-conductance calcium-activated 
potassium channels in the urinary bladder smooth muscle, resulting in membrane 
hyperpolarisation and relaxation (Hristov et al., 2008).  β-adrenoceptors may also assist in 
reducing smaller spontaneous contractions which may allow a more stable detrusor during 
filling (Klausner et al., 2009), and a constant stimulation of these receptors would potentially 
alleviate the bladder from becoming overactive during pathological circumstances. 
 
The β-adrenoceptors in the bladder mediate responses to noradrenaline released from the 
sympathetic nervous system (Andersson and Arner, 2004).  For many years these β-
adrenoceptor responses were thought to arise specifically from the β1- and β2-receptor 
subtypes, although since then a third subtype has been identified and termed the β3-
adrenoceptor (Alexander et al., 2011, Bylund et al., 1994).  These three currently identified 
subtypes have been cloned and classified, yet much less appears to be known about the role 
of the β3-receptor in particular.  This is due to the range of pharmacological tools available to 
selectively target the β1- and β2-adrenoceptor subtypes, whereas the more recently developed 
agonists and antagonists that target the β3-receptor subtype have not yet been proven in a 
wide range of experimental studies.  However, some antagonists have shown promise in 
selectively targeting the β3-adrenoceptor, such as SR59230A (Manara et al., 1996) and 
L748337 (Candelore et al., 1999).  Alternatively, available agonists such as CL316,243 are 
claimed to be highly selective at the β3-adrenoceptors in some animals models (Clouse et al., 
2007, Bloom et al., 1992).  Although these are some of the current pharmacological tools for 
understanding the responses of the β3-adrenoceptor, there is controversy surrounding their 
selectivity.  For example, novel β3-antagonists such as SR59230A may lack selectivity in 
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humans, or even have a partial agonist affect accompanying the β3-antagonism (Sato et al., 
2007, Michel and Vrydag, 2006). 
 
At the molecular level it has been found that β3-adrenoceptors account for 97% of the mRNA 
expression in the human bladder, with 1.5% and 1.4% for the β1 and β2 respectively (Nomiya 
and Yamaguchi, 2003).  However, it is unwise to draw functional conclusions from this data, 
since β-adrenoceptor subtypes detected using reverse-transcription-PCR do not always 
correspond to those which mediate the smooth muscle relaxation.  In support of these 
findings, however, immunohistochemical studies have also detected the expression of all 
three β-adrenoceptor subtypes in the human urinary bladder (Otsuka et al., 2008).  Pig and 
human detrusor smooth muscle relaxation may be due to activation of both β2 and β3 with the 
latter predominating as the main functional receptor (Yamanishi et al., 2002b, Igawa et al., 
2001, Takeda et al., 1999).   
 
The distribution of β-adrenoceptors in the bladder and the corresponding β-adrenoceptor 
subtype responsible for bladder relaxation is still under investigation in many species.  
Studies utilising radioligand binding in the urinary bladder have reported the highest densities 
of the β2-subtype in pigs (Goepel et al., 1997) and rabbits (Latifpour et al., 1990).  However 
research into the range of radioligands used in these studies concluded that they have 
significantly lower affinities than previously thought, suggesting that more effective ligands 
and further studies utilising high-affinity β3-radioligands must be performed (Niclauss et al., 
2006, Hoffmann et al., 2004).   In addition, future research into the localisation of these 
subtypes may prove difficult as antibodies used to discriminate against the three β-
adrenoceptor subtypes appear to lack selectivity and their use has been criticised (Hamdani 
and van der Velden, 2009, Pradidarcheep et al., 2009).  This criticism is due to the low 
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specificity of primary antisera to the receptor of interest.  Standard controls, such as omitting 
the primary antisera or preabsorbing the primary antisera with an excess immunising antigen, 
may still not confirm a high selectivity for the antibody.  Current studies identifying the β-
adrenoceptors in the bladder through immunohistochemistry will therefore require more 
stringent controls, such as the observation that the antigens lack binding sites in gene 
knockout animals, prior to a valid conclusion being presented. 
 
Although β2-adrenoceptors appear to predominate the responses in rat and rabbit bladders 
(Morita et al., 1993), in guinea-pig detrusor the β1-adrenoceptor is the functionally active 
receptor subtype (Li et al., 1992, Yamamoto et al., 1998).  The β3-adrenoceptor is thought to 
mediate relaxation in the dog bladder (Yamazaki et al., 1998).  However, there have been 
conflicting results relating to the mouse bladder. One study published findings of an 
exclusively β2-mediated relaxation (Wuest et al., 2009), whereas another study found that 
relaxations occurred via the β3-adrenoceptor in this species (Deba et al., 2009).  The 
conditions, concentrations and measurements used in these studies varied widely, such as the 
use of potassium chloride to pre-contract male detrusor strips, and using lower concentrations 
of antagonists (Wuest et al., 2009) vs electrical field stimulation of female detrusor strips, and 
higher concentrations of antagonists (Deba et al., 2009).  However, the most notable 
difference was the age of the mice, with Deba et al. (2009) using mice that were 11 weeks 
old, where Wuest et al (2009) used mice that were 9-18 months old.  It is known that the 
expression of the β-adrenoceptors in humans is altered with age (Li et al., 2003), and a 
decreased response in the mature bladders may be related to the general decrease in β-
adrenoceptor response which is known to occur during aging (Scarpace et al., 1991).  Thus, 
although there were a range of differences in the methodology, the variations shown in the 
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two studies may infact be the first indication of a down-regulation of detrusor smooth muscle 
β-adrenoceptors in ageing mice. 
 
β-adrenoceptors in the urothelium/lamina propria 
 
The urothelial layer of the bladder expresses mRNA for all three β-adrenoceptor subtypes 
(Tyagi et al., 2009a, Otsuka et al., 2008, Ochodnicky et al., 2012, Kullmann et al., 2011).  
Although β-adrenoceptor activation results in detrusor muscle relaxation (Deba et al., 2009, 
Otsuka et al., 2008), current research is yet to conclude whether the urothelium has an 
involvement in the bladder’s overall responses to β-adrenoceptor stimulation.  Tyagi et al 
(2009a) reported that the urothelium was not involved in the relaxation responses to 
isoprenaline in pig bladder.  This was supported by another study on rat bladders, which did 
not find any difference to β3-adrenoceptor mediated detrusor relaxations with or without the 
urothelium/lamina propria (Kullmann et al., 2011).  In contrast, a past study had shown a 
conflicting result, identifying effects of the urothelium in changing the concentration 
response curve to isoprenaline (a parallel rightward shift) in intact human bladder strips (with 
urothelium) as opposed to denuded detrusor (Otsuka et al., 2008).  Although these studies 
varied in the use of different baselines (basal tension vs pre-contraction) prior to relaxation, 
and the obvious species differences, it still raises further questions as to the exact function of 
the urothelium in mediating these β-adrenoceptor relaxations. 
 
Activation of the β-adrenoceptors on the urothelium of rats stimulates the release of nitric 
oxide, which could further enhance the relaxing effect of β-adrenoceptor agonists (Birder et 
al., 1998, Birder et al., 2002c).  However, a study attempting to identify the role of the 
urothelium and lamina propria in mediating bladder responses to isoprenaline found that the 
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urothelium has a role in β-adrenoceptor stimulated inhibition of contraction, but not via the 
release of NO (Murakami et al., 2007).  These authors attempted to identify the effect of β-
adrenoceptor agonists on in vitro pig tissues that were pre-contracted with carbachol.  
However, this pre-contraction may not effectively represent normal conditions or functions of 
the bladder, where relaxation tends to occur during the filling stage, and contraction 
predominantly during the voiding phase.  This data did present a novel mechanism of β-
adrenoceptor mediated relaxation, as there are a range of similarities between human and pig 
β-adrenoceptor expression in the bladder (Goepel et al., 1997).  In human detrusor a similar 
result was identified, which also found that the relaxing agent was not NO, giving rise to the 
hypothesis that β-adrenoceptor activation in the bladder may lead to the release of an 
unidentified inhibitory factor from the urothelium (Otsuka et al., 2008, Masunaga et al., 
2010). 
 
β-adrenoceptors as therapeutic targets in bladder disease 
 
It is inconclusive as to whether the β-adrenoceptors are altered in pathological states of the 
bladder.  Bladder outlet obstruction does not appear to influence the β-adrenoceptor response 
(Nomiya and Yamaguchi, 2003).  Additionally, Igawa et al., (2001) found that the β3-
adrenoceptor was maintained as the predominant receptor involved in relaxation of both 
normal and neurogenic human bladders.  However, the reliability of this study is questioned 
not only due to the fact that only 7 patients exhibiting overactive bladders were analysed, but 
that they also exhibited a varied aetiology of the neurogenic conditions.  For example, 3 of 
the patients exhibited traumatic cervical cord injury, with 2 caused by hysterectomies and 1 
of an unknown cause.  This range of bladder pathologies may attest that each of these patients 
could have very different pathologies yet similar symptoms. 
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β3-adrenoceptor agonists are currently showing promise as clinical treatments for overactive 
bladder (Chapple et al., 2008).  Solabegron, a β3-adrenoceptor agonist has been claimed to 
suppress the spontaneous activity of the human bladder, and inhibit evoked contractions 
(Biers et al., 2006a).  Additionally another β3-agonist, mirabegron, has shown beneficial 
effects in animal studies where it decreases the frequency of spontaneous bladder 
contractions during the filling stage without affecting the amplitude during voiding (Takasu 
et al., 2007).  Mirabegron has shown significantly positive effects in humans in a range of 
studies and as such, has been approved for clinical use in Japan (and recently submitted for 
approval in the United States and Europe) for the treatment of urinary frequency, urgency and 
incontinence associated with overactive bladder (Tyagi and Tyagi, 2010, Gras, 2012).  
Currently, although muscarinic receptor antagonists are the standard treatment for overactive 
bladder, they are limited by low response rates and frequent side effects (Andersson, 2004b).  
It is therefore important to identify alternative therapies.  This current interest, focussed on 
the continued development and implementation of β-agonists for the treatment of overactive 
bladder, along with research into the effects of other β-agonists and antagonists on the 
urothelium/lamina propria, may provide a clearer understanding for the potential use of these 
drugs. 
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1.5.2.2   α-adrenoceptors 
 
Subtypes of the α-adrenoceptor 
 
Based on their anatomical position the adrenoceptors were originally divided into two 
subtypes, α and β (Ahlquist, 1948).  This theory of two “sympathins” for the adrenoceptors 
was not only a breakthrough, it was one of the forefront discoveries which paved the way for 
a formal system of pharmacological taxonomy (Black, 1976). For nearly 30 years these two 
groups remained the predominate classification of adrenoceptors until presynaptic regulation 
of catecholamine release was studied and a classification for pre-junctional (α2) and post-
junctional (α1) alpha-adrenoceptors was adopted (Langer, 1974).  As pharmacological drugs 
with greater affinities were produced in the 1980’s, the α1-subtype was further divided into 
the α1A, and α1B.  The onset of molecular cloning in the late 80’s and early 90’s allowed 
researchers to understand the genetic basis for these receptors, and an additional α1C-subtype 
was presented (Schwinn et al., 1990).  This finding, however, was later annulled, as the 
cloning, expression and tissue distribution of the rat homolog of the bovine α1C-adrenergic 
receptor provided evidence that it was precisely the same phenotype as the α1A subtype (Perez 
et al., 1994).  A study which proposed an additional mechanism of action of the α1A-subtype 
was later shown to be an independent receptor which was further labelled the α1D (Lomasney 
et al., 1991, Perez et al., 1991).  An additional subtype, labelled the α1L-adrenoceptor, arises 
from the same gene as the α1A, yet demonstrates functional differences, such as its low 
affinity for the antagonist prazosin, RS-17053 and WB4101, and its high affinity for 
tamsulosin (Gray and Ventura, 2006, Muramatsu et al., 2008, Daniels et al., 1999, 
Pennefather et al., 1999, Ford et al., 1996, Noble et al., 1997, Kava et al., 1998, Hiraoka et 
al., 1999).  The α1-adrenoceptors stimulate contraction of smooth muscle in the lower urinary 
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tract through the phospholipase C dependent activation of IP3 and diacylglycerol.  This leads 
to a calcium influx and subsequent activation of protein kinase C (Minneman, 1988). 
 
Presence of α-adrenoceptors in the lower urinary tract 
 
It is understood that although both α- and β-adrenoceptors are present in the ureters, 
noradrenaline acts predominantly through the α1-adrenoceptors, causing contractile responses 
across a range of animal models (Weiss et al., 1978, Morita and Suzuki, 1984, Labadia et al., 
1987, Hernandez et al., 1992, McLeod et al., 1973).  Adrenoceptors are also functionally 
active in the urethra where noradrenaline released from nearby nerves causes a contraction of 
the urethral muscle and is important for preventing urine leakage from the bladder.  In 
addition, prejunctional α2-receptors may have the potential to influence the release of 
neurotransmitters from sympathetic nerves, yet there is no evidence that they play a role in 
regulating bladder function.  In the prostate, the α1-adrenoceptors are known to mediate 
contractions, and are investigated due to their association in stimulating cell growth such as 
that seen in benign prostate hyperplasia (Kyprianou et al., 2000).  The functional subtype 
mediating prostatic contractions consistently appears to be the α1L-adrenoceptor, as seen in 
the mouse (Gray and Ventura, 2006), guinea pig (Pennefather et al., 1999), rat (Hiraoka et al., 
1999) and human prostate (Muramatsu et al., 1994). 
 
In the bladder, there have been some studies which have recognised the presence of α-
adrenoceptors.  mRNA analysis has identified the expression (yet not the translation) of α-
adrenoceptors in whole monkey bladder tissue (Walden et al., 1997) and the α1-receptor 
subtype has been found in whole rat bladder using western blotting and 
immunohistochemistry (Ishihama et al., 2006).  mRNA analysis has also identified their 
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presence in rat, mice and human bladders, and genetic analysis across species has found that 
the predominate subtype appears to be the α1A-subtype (Malloy et al., 1998, Hampel et al., 
2002, Lluel et al., 2003, Scofield et al., 1995).  Studies have also reported expression of the 
α1-adrenoceptor protein in the bladders of rats, pigs, guinea-pigs, rabbits, cats, monkeys and 
humans (Hampel et al., 2002, Monneron et al., 2000, Tsujimoto et al., 1986, Latifpour et al., 
1990, Walden et al., 1997, Malloy et al., 1998, Sigala et al., 2004).  Nonetheless, it is still 
unclear as to their exact function within the bladder and the fact that they are expressed does 
not directly indicate that they have any important physiological roles. The α-adrenoceptor 
expression on spinal cord nerves innervating the bladder and the urethral sphincter give these 
receptors potential as therapeutic targets for treating urinary tract symptoms (Yoshimura et 
al., 2008b).  The mRNA expression for the α1A, α1D and all subtypes of the α2-adrenoceptors 
have been located on human urothelium (Ochodnicky et al., 2012),  However, there is still a 
paucity of evidence for postjunctional α-adrenoceptors playing an important role in the 
function of normal bladder detrusor or urothelial/lamina propria activity.  
 
Noradrenaline released from the hypogastric nerve may act upon the α-adrenoceptors present 
in the bladder outlet and urethra in order to maintain normal continence.  A previous study 
found that α1-adrenoceptor agonists could enhance the release of acetylcholine and 
noradrenaline from bladder nerves (Somogyi et al., 1995).   However, this group found that 
their presumed α1-adrenoceptor mediated response was not blocked by an α1-adrenoceptor 
antagonist, indicating that the released noradrenaline might be acting on β-adrenoceptors. The 
lack of distinctive physiological functions for the α-adrenoceptors in the bladder has caused 
them to be overlooked as possible therapeutic targets for alleviating the symptoms of bladder 
pathologies.  A study using radioligand binding found that the α-adrenoceptor density on the 
bladder was not altered by age in rats (Kolta et al., 1984).  Nonetheless, there are definite 
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age-related differences in the contractile responses to noradrenaline (Lluel et al., 2003) which 
may warrant further investigation into the role of the α-adrenoceptors in bladder disease. 
 
α-adrenoceptors as a therapeutic target for lower urinary tract diseases 
 
Throughout the past 20 years α1-adrenoceptor antagonists have proven an effective therapy 
for treating men with benign prostate hyperplasia (Lepor et al., 2012).  A main target of this 
class of antagonists is the α1A-mediated contraction of the smooth muscle in the prostate, and 
preventing this contractile activity helps to reduce the symptoms of prostate enlargement 
which subsequently constricts the urethra (Ventura et al., 2011).  However, there is new 
clinical evidence that these α1-adrenoceptor antagonists may also act on other areas of the 
lower urinary tract, and alleviate other bladder malfunctions (Yoshida et al., 2012).  Two 
studies in Japan have both identified decreases in pressure flow during urodynamic analysis 
on patients taking silodosin, an α1A-selective adrenoceptor agonist (Yamanishi et al., 2010, 
Matsukawa et al., 2009).  Matsukawa et al. (2009) also demonstrated the loss of detrusor 
overactivity in patients taking silodosin.  These results indicate a potential additional role for 
the drugs, such as an influence on the detrusor smooth muscle or bladder dome.  The effect of 
these drugs has been further demonstrated in a rat model, where a similar antagonist, 
tamsulosin, increased urine flow and reduced bladder overactivity (Okutsu et al., 2011).  The 
potential for α1-adrenoceptor antagonists to reduce the symptoms of disorders such as 
overactive bladder is of considerable interest.. 
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1.5.3  Purinergic receptors 
 
Adenosine 5’-triphosphate (ATP) is a transmitter released throughout the body to evoke a 
broad spectrum of responses, including prejunctional modulation of neurotransmitter release 
and postjunctional receptor activation (Burnstock, 2011).  In addition to being released from 
parasympathetic nerves, ATP is also known to arise from non-neuronal endogenous sources.  
Within the bladder, ATP acts upon the P2-purinoceptors.  These have been subdivided into 
two groups, the P2X and the P2Y receptors based on pharmacological and molecular studies.  
P2X receptors are ionotropic ligand gated non-specific cation channels whereas the P2Y are 
G-protein coupled receptors (Burnstock, 2007). 
 
Presence of the purinergic receptors in the bladder 
 
There is evidence that a range of P2X and P2Y purinergic receptors are present in the lower 
urinary tract of both human and animal models.  mRNA analysis has identified the P2X1 as 
the predominant subtype (of the 7 characterised) within human detrusor muscle (O'Reilly et 
al., 2001b, O'Reilly et al., 2001a).  Using animal models, immunohistochemical studies have 
suggested a similar finding in cat, mice and rat bladders (Birder et al., 2004, Lee et al., 2000, 
Vial and Evans, 2000).  However, functional studies examining P2X3-receptor gene knockout 
mice found that this receptor was essential for the sensory pain responses and afferent 
neuronal pathways controlling the micturition reflex (Cockayne et al., 2000).  The sensory 
role may be mediated via the effect of ATP on the peripheral terminals of Aδ- and C bladder 
afferent nerve fibres, where it can convey mechanosensory information to the spinal cord 
(Ford et al., 2006). 
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A range of purinergic receptors are also present in the bladder urothelium (P2X1, P2X2, P2X3, 
P2X4, P2X5, P2X6, P2X7, P2Y1, P2Y2, P2Y4, P2Y6) (O'Reilly et al., 2001a, O'Reilly et al., 
2002, Sui et al., 2006).    The presence of the P2X and P2Y purinergic receptor subtypes in 
the urothelium as well as on the lamina propria interstitial cells (Fry et al., 2012) and bladder 
nerves suggests that ATP may play a number of roles in the bladder (Birder et al., 2004). 
 
Purinergic responses in the bladder 
 
Excitatory purinergic responses are found in the bladders of mammals such as rabbit (Dean & 
Dowie, 1978), guinea-pig (Burnstock et al., 1978), ferret, marmoset (Moss and Burnstock, 
1985), cat (Theobald, 1983), rat (Burnstock et al., 1972) and mouse (Acevado & Contreras, 
1985).  ATP is understood to play a role in neuroeffector mechanisms and the human bladder 
responds to ATP with concentration-dependent contractions (Husted et al., 1983). 
 
When applied intravesically into rat bladders, ATP causes an increase in the frequency of 
bladder contractions  (Pandita and Andersson, 2002) identifying its potential importance in 
the modulation of contractile activity.  ATP is released from the urothelium/lamina propria in 
response to stretch in strips of pig (Sadananda et al., 2009), rabbit (Ferguson et al., 1997), rat 
(Munoz et al., 2010, Sadananda et al., 2009), guinea pig (Young et al., 2012) and human 
tissues (Kumar et al., 2004).  Additionally, urothelial/lamina propria ATP can be released in 
response to other stimuli, such as acidic solutions in pig bladder (Sadananda et al., 2012), and 
acid and activation of TRPV1 receptors in strips of rat urothelium/lamina propria (Sadananda 
et al., 2009).  Urothelial cell cultures from samples of pig tissue have shown similar results, 
demonstrating a significant ATP release in response to acid and stretch (Cheng et al., 2011b).  
This has been further supported by studies on urothelial cell cultures from other animal 
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models, which also release ATP in response to stretch (Birder et al., 2003, Birder et al., 
2002a). 
 
Recent data from a guinea-pig model suggests that purinergic receptor mediated increases in 
bladder activity could occur through the P2Y6 purinergic receptor subtype located on the 
interstitial cells (Sui et al., 2006).  This conclusion resulted from observations of generated 
intracellular calcium transients.  Due to the limitations of antibodies for these receptors, not 
all purinergic P2Y receptors were examined by the authors, leaving potential for other 
receptors to be involved.  In addition, staining was also exhibited, albeit weakly, for the 
P2X3, P2Y2 and P2Y4 receptors on these cells, but their function is unknown.  Nonetheless, 
the data presented by Sui et al. (2006) has been supported by a more recent study with 
cultured interstitial cells from human lamina propria, where ATP was shown to significantly 
increase calcium activity, even at low concentrations (Cheng et al., 2011a).   
 
Purinergic receptors as a therapeutic target in bladder disease 
 
It has been predicted that the abnormal non-cholinergic bladder contractions associated with 
diseases such as overactive bladder demonstrate a degree of atropine resistance (Sjogren et 
al., 1982), and this may be mediated via ATP (Bayliss et al., 1999).  The exact effect of 
purinergic receptor stimulation or antagonism in human patients is currently being 
investigated; although a lack of safe clinical purinergic agents limits current research.  There 
is a possibility that patients with overactive bladder who do not respond to clinical 
antimuscarinics may have an increased sensitivity of the urothelium or detrusor to ATP; a 
heightened release of ATP from motor nerves or the urothelium; or reduced ATP hydrolysis 
within the neuromuscular junction.  Of particular interest is the increase in ATP release in 
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rats with chemically-stimulated detrusor overactivity (Munoz et al., 2011).  Bladder 
inflammation (Smith et al., 2005, Smith et al., 2008, Bodin and Burnstock, 1998), diabetes 
(Munoz et al., 2011) and spinal cord injury (Khera et al., 2004) have also been shown to 
enhance the release of ATP from bladders of rat models.  Studies have shown that augmented 
ATP release from the urothelium, due to damage or pathology, activates P2X receptors on 
sensory nerves, causing painful sensations (Burnstock, 2001a, Burnstock, 2006).  
Additionally, studies on models of interstitial cystitis have demonstrated increases in stretch-
invoked ATP release from urothelial cell cultures (Birder et al., 2003, Sun et al., 2001), as 
well as an alteration of the purinergic receptors in both the urothelium and detrusor smooth 
muscle (Birder et al., 2004, O'Reilly et al., 2002). This ATP release in response to noxious or 
mechanical stimuli may sensitise nociceptors in the urothelium, and be a contributing factor 
in diseases of the bladder.  As such, the future development of effective purinergic 
antagonists may play an important role in the pharmacological management of lower urinary 
tract dysfunction. 
 
1.5.4  Nitric oxide system of the bladder 
 
Nitric Oxide (NO) is a nonadrenergic noncholinergic (NANC) inhibitory neurotransmitter in 
various sites around the body (Artim et al., 2009) where it signals a range of responses in 
different tissues (Schlossmann et al., 2000, Casteel et al., 2005, Feil and Kemp-Harper, 2006, 
Hofmann et al., 2006, Nishikimi et al., 2006, Ãœckert et al., 2005).  NO is a highly reactive 
chemical that holds an unpaired electron within its valence orbital and is non-polar enough to 
diffuse freely across membranes in the uncharged state.  Due to its reactivity and toxicity, NO 
cannot be stored in the nerve terminals themselves but is synthesised from L-arginine by 
nitric oxide synthase. 
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Although the main neurotransmitter acting on detrusor smooth muscle appears to be 
acetylcholine (Sellers and Chess-Williams, 2012), the release of NO may also assist with 
normal bladder function.  In the bladder, nitric oxide acts via the cyclic 3’,5’-guanosine 
monophosphate (cGMP) pathway by activating soluble guanylate cyclase (Andersson and 
Persson, 1994, Caremel et al., 2010, Hernandez et al., 2008), which is similar to its effects in 
the nervous and cardiovascular systems (Moncada et al., 1991, Dinerman et al., 1993, Kerwin 
Jr et al., 1995).  The production of nitric oxide is catalysed by a family of enzymes termed the 
nitric oxide synthases.  Three isoforms of nitric oxide synthase (NOS) exist which are 
classified as inducible NOS (iNOS), endothelial NOS (eNOS) and neuronal NOS (nNOS) 
(Figure 1-13).  nNOS was previously considered to be the main isoform responsible 
synthesising nitric oxide in the bladder tissue.  However, it is now understood that endothelial 
nitric oxide synthase is also present in the bladder smooth muscle itself.  In addition to eNOS, 
there is also evidence for the existence of mitochondrial NOS (mtNOS) in urothelial cells, 
which are modified analogues of the nNOS neuronal form (Kanai et al., 2004).  The 
importance of each NOS isoform in bladder function is still under investigation (Zhang et al., 
2011).  Past studies have shown that mice lacking nNOS exhibited hypertrophy of their 
bladders (Burnett et al., 1997), while other similar studies have found no particular 
differences between those mice and wild-type controls (Sutherland et al., 1997).  High 
concentrations of nNOS positive nerves have been identified in the bladders of human (Ehren 
et al., 1994), rat (Orman et al., 2005), pig (Persson et al., 1993) and guinea pig (Gillespie et 
al., 2005).  These nerves may act directly on the detrusor, the urothelium/lamina propria, or 
the outflow region (trigone and urethra) of the lower urinary tract.  This outflow region 
demonstrates a particularly strong relaxation response to NO (Torimoto et al., 2004, Masuda 
et al., 2003, Takeda et al., 1995, Martinez-Saenz et al., 2011).  In the bladder neck, nitric 
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oxide is the main NANC mediator causing relaxation (Martinez-Saenz et al., 2011, 
Hernandez et al., 2008) and an open bladder neck is strongly correlated with the presence of 
stress urinary incontinence (English et al., 1999). 
  
Various studies have identified a role for NO in the relaxation of bladder detrusor (Chung et 
al., 1996, Moon, 2002).  Besides detrusor relaxation, NO may play an additional role in the 
regulation of blood flow within the bladder, as identified in canines (Pontari and Ruggieri, 
1999) and rabbits (Whitbeck et al., 2007).  Furthermore, in rat bladder smooth muscle cells 
the rate of protein and DNA synthesis was reduced after the addition of NO (Johansson et al., 
2002).  These authors utilised immunohistochemistry and western blot analysis, along with 
measuring the conversion of radiolabelled arginine, and suggested a role for nitric oxide as a 
growth inhibitory factor.  This suggests that NO may have an additional role in regulating the 
growth of bladder smooth muscle cells. 
  
Immunohistochemistry of the urothelium of the guinea pig bladder has detected the presence 
of nNOS (Gillespie et al., 2005), yet in the rat urothelium RT-PCR studies did not identify 
the expression of the nNOS gene (Birder et al., 2002c).  A number of factors are known to 
cause the release of NO in the urothelium including β-adrenoceptor agonists, TRPV1 
agonists, ATP and muscarinic receptor stimulation (Birder et al., 1998, Birder, 2011).  In past 
studies this NO release has been detected using different methods, including measurements of 
cAMP accumulation, or by the use of a NO-specific sensor (Birder et al., 2002c).  The effect 
of this urothelial-released NO on the bladder as a whole is currently under investigation.  NO 
appears to have direct effects on the detrusor muscle to inhibit tonic contractions induced by 
carbachol (Moon, 2002) and this is mediated by the activation of potassium channels via a 
pathway involving cGMP  (Deka and Brading, 2004).   
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Nitric oxide may also act on the interstitial cells in the lamina propria to increase cGMP 
levels within these cells (Gillespie et al., 2004).  Alternatively, there has been limited data 
suggesting an excitatory role for nitric oxide/cGMP in bladder contractions (Gillespie and 
Drake, 2004, Moon, 2002, Fujiwara et al., 2000), further complicating the potential role that 
it may have in regulating bladder activity.  In one study spontaneous phasic activity of the 
guinea-pig bladder was increased by the NO-donor nitroprusside and it was suggested that 
NO elevated cGMP in a subpopulation of interstitial cells within the lamina propria to induce 
microcontractions (Gillespie and Drake, 2004). 
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Figure 1-13: The synthesis of nitric oxide occurs within the urothelium and nerve cells 
innervating the bladder. In the muscle cell, NO activates the guanylate cyclase-mediated 
synthesis of cyclic guanosine monophosphate (cGMP) from guanosine-5'-triphosphate 
(GTP).  This molecule then interacts with a number of mediators including protein kinase G 
(PKG), ion channels, and a range of potential phosphodiesterases (PDE), which are most 
likely PDE 1 or 4 (Andersson et al., 2007, Uckert et al., 2006, Masuda, 2008). 
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1.5.5  Cannabinoid receptors 
 
A clear interest in cannabinoid receptor function in the bladder arose from studies where 
human patients found beneficial effects towards symptoms of bladder disorders following 
administration of cannabinoid agonists.  These benefits included alleviation of urgency, 
frequency, nocturia and incontinence episodes, while being administered cannabis extracts 
(Freeman et al., 2006, Russo and Guy, 2006, Kavia et al., 2010, Perez, 2006, Brady et al., 
2004).  A survey of multiple sclerosis patients who commenced the smoking of cannabis, 
found that over 59% of patients reported improvements in their urinary urgency, incontinence 
episodes or hesitancy in initiating micturition (Consroe et al., 1997).  In support of these 
studies, rats with partial urethral obstruction who were administered cannabinor, a selective 
cannabinoid-2 agonist, demonstrated an improved ability to empty the bladder (Gratzke et al., 
2011).  However, not all studies support this conclusion, such as the lack of beneficial effects 
observed on bladder activity after the administration of cannabis extracts to humans with 
bladder dysfunction as a result of multiple sclerosis (Wade et al., 2004).  Additionally, 
limited effects have been observed with cannabinoid agonists on normal human bladder 
function, contraction and urodynamics (Gratzke et al., 2010, Freeman et al., 2006, Kavia et 
al., 2010).  Nonetheless, cannabinoids may indicate an interesting avenue for future research 
into disorders of the urinary bladder, and their perceived successes in patients may designate 
them as a potential pharmacological target in future treatments. 
 
Cannabanoid-receptors are found on nerves throughout the body.  Both CB1 and CB2 
receptor subtypes have been identified in the bladder detrusor and urothelium/lamina propria 
of humans via mRNA analysis (Tyagi et al., 2009b) and in the mouse bladder via western-
blotting and mRNA analysis (Walczak et al., 2009).  Both CB1 and CB2 are present in all 
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layers of the bladder as identified using immunohistochemistry in rat (Hayn et al., 2008), 
human (Tyagi et al., 2009b), monkey (Gratzke et al., 2009) and mouse (Walczak et al., 2009).  
However, caution must be taken when analysing these conclusions.  In studies utilising 
immunohistochemistry, the specificity for antibodies used in the detection of the cannabinoid 
receptors have not been proven as selective for the individual subtypes (Ruggieri, 2011).  
These antibodies have come under the same scrutiny as those for other G-protein coupled 
receptors, and this lack of selectivity may explain why there is a discrepancy over which 
cannabinoid receptor is present in the neuronal cells of the bladder, with 
immunohistochemical reports identifying either a predominant CB1-receptor subtype (Hayn 
et al., 2008, Tyagi et al., 2009b, Walczak et al., 2009), or CB2-receptor (Gratzke et al., 2009).  
 
Cannabinoids activate the CB1 and CB2 receptors, which couple to Gi/o proteins, and result in 
an inhibition of adenylyl cyclase (Peters and Scott, 2009, Sade et al., 2006, Cabral, 2006, 
Mackie and Stella, 2006).  Activation of CB1 receptors opens potassium channels and 
inhibits calcium channels.  This activation presents a novel mechanism which may assist in 
the alleviation of lower urinary tract diseases (Ruggieri, 2011).  However, the findings from 
functional studies investigating cannabinoid agonists are further complicated by the ability of 
the cannabinoids to have additional functions and activate other receptors.  These include the 
TRPV1, which are present on the urothelial cells; and some effects that were originally 
attributed to CB2 receptor activation, and its related second messenger systems, may be due 
to one of these other systems (Gratzke et al., 2009). 
 
The cannabinoids may have a regulatory function in maintaining bladder spontaneous 
contractile activity.  Functionally active CB1-receptor subtypes (Tyagi et al., 2009b) might 
modulate the afferent activity of the bladder nerves (Walczak and Cervero, 2011, Walczak et 
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al., 2009).  Administration of the cannabinoid receptor agonist WIN 55,212-2 reduced 
bladder motility in the rat, which was investigated through cystometric measurements 
(Dmitrieva and Berkley, 2002).  In studies where neurotransmitter release was evoked by 
electrical field stimulation (EFS), cannabinoid antagonists have been shown to reduce the 
subsequent smooth muscle contraction in mouse, rat, pig, donkey, monkey and human 
bladders (Pertwee and Fernando, 1996, Martin et al., 2000).  However, Martin et al (2000) 
found variations in this response between species and suggested there may be 
pharmacological differences between orthologues of the CB1 receptor, or even a mixed 
population of CB1 and CB2 receptor subtypes in different species.  Although their roles are 
still unclear, cannabinoids warrant further research in their ability to alleviate the symptoms 
of bladder disease, and they are commonly identified as a potential therapeutic target for the 
management of lower urinary tract dysfunction (Apostolidis, 2012). 
 
1.5.6  Transient receptor potential (TRP) receptors 
 
Mammals have 28 genes encoding transient receptor potential ion channels (TRP receptors). 
The family includes canonical or classical (TRPC) vanilloid receptors (TRPV 1-6) and 
melastatin receptors (TRPM 1-8) (Hicks, 2006).  These receptors have a diverse range of 
physiological functions which includes temperature transduction and signalling of pain (Eid, 
2011).  In current bladder research, the receptors of most interest are the TRPV receptors 
(Birder, 2005, Birder, 2007), which appear to respond to a range of stimuli, including pH, 
capsaicin, resiniferotoxin, lipids, and thermal stimulation (Kullmann et al., 2009, Everaerts et 
al., 2010).  At the molecular level the genes for the TRPV1 receptors are expressed in the pig 
bladder urothelium/lamina propria as well as the detrusor in the dome, trigone and bladder 
neck (Sadananda et al., 2012).  Immunohistochemical staining has also identified TRPV1 
 Page | 68 
receptors expressed on the small diameter C-fibre afferent neurons which extend into the 
urothelium/lamina propria (Avelino et al., 2002, Yu et al., 2011a).  A study using TRPV1 
knockout mice have identified that these receptors play a clear role in the excitability of low 
threshold bladder afferent nerves (Daly et al., 2007).  Other TRP receptors (TRPV1, TRPV2, 
TRPV4, TRPM8) are also present in the urothelium of a range of animal models (Birder et 
al., 2002b, Stein et al., 2004, Birder, 2005, Xu et al., 2009).  However, not all studies have 
demonstrated clear expression of these receptors.  In mouse bladder urothelium the PCR 
products for TRPV1 were minimal, and there was no evident staining for its protein 
expression (Yamada et al., 2009, Everaerts et al., 2010). 
 
Upon activation, the TRPV channels may mediate bladder sensory responses (Mukerji et al., 
2006a).  Stimulation of the TRPV1 receptors on the urothelium/lamina propria can lead to 
release of transmitters such as ATP (Sadananda et al., 2009).  Of further interest, is the 
possibility that the TRPV receptors are involved in bladder disease (Birder, 2007).  For 
example, there is an increased expression of TRPV1 mRNA in human trigonal 
urothelium/lamina propria associated with sensory urgency (Liu et al., 2007).  Additionally, 
the TRPV2 transcripts may play a role in controlling cell growth and the progression of 
bladder cancer (Yamada et al., 2010, Caprodossi et al., 2008).  Furthermore capsaicin, a 
TRPV1-receptor agonist, can inhibit the growth of these tumor cells in the bladder by 
inducing apoptosis, identifying it as a possible chemotherapeutic agent for use in patients 
with bladder cancers (Yang et al., 2010, Lee et al., 2004).  Of further interest is the finding 
that urothelial cell cultures from mice lacking the TRPV1 gene exhibit a reduction in stretch-
induced ATP release (Birder et al., 2002b).  TRPV6 was also considered as a mediator in 
bladder function, and has been thought to increase in prostate tumours, although no studies so 
far have found an upregulation of this receptor in bladder urothelial cancer (Santoni et al., 
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2012).  For now, the important research focus should be to understand the clear mechanisms 
behind the TRPV1-mediated effects in the bladder.  There is a clear difficulty in interpreting 
results from this wide range of studies and although recent reviews have attempted to piece 
together the information (Yu and Hill, 2011), the roles for the functional TRP receptors will 
be an important area for future bladder research. 
 
1.5.7  Neurokinin receptors 
 
A range of neuropeptides are present in the bladder which may modulate or affect the activity 
of the urothelium and lamina propria.  These include neurokinin A, substance P, calcitonin 
gene-related peptide, vasoactive intestinal polypeptide and pituitary adenylate cyclase-
activating peptide (Yoshiyama and de Groat, 2008, Arms and Vizzard, 2011, Warner et al., 
2002, Smet et al., 1997).  Importantly, neurokinin A has been singled out as a known 
mediator of urothelial/lamina propria contraction (Sadananda et al., 2008) and it is thought 
that neurokinins play an important role in regulating normal bladder activity (Keast and De 
Groat, 1992).   Neurokinins are a class of peptide that bind to tachykinin receptors.  Three of 
these receptors are expressed in the bladder, the neurokinin 1 receptor (NK1R), neurokinin 2 
receptor (NK2R) and the neurokinin 3 receptor (NK3R) (Arms and Vizzard, 2011).  These 
receptors are functionally active in the lower urinary tract and are preferentially stimulated by 
substance P (NK1R), neurokinin A (NK2R) and neurokinin B (NK3R) respectively 
(Andersson, 2002).  Despite their selectivity, none of these agonists are specific for one 
receptor subtype and all neurokinins can act at each receptor, albeit at a slightly lower 
potency, giving them common mechanisms of action. 
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The neurokinin receptors contain 7 transmembrane spanning domains and each is coupled to 
the G-protein Gq/11, which activates the phosphoinositol pathway.  The neurokinins that 
activate these receptors are released from the peripheral terminals of bladder afferent nerves 
(Aδ-nerves).  Both NK1R and NK2R are located in the detrusor (Birder, 2010).  In the 
urothelium, low levels of the NK1-receptor can be seen at the mRNA level and by 
immunohistochemistry, yet the prevalence appears to be increased after capsaicin treatment 
(Heng et al., 2011).  NK2 is also known to be present in the urothelium and its activation in 
both the detrusor and urothelium/lamina propria results in tissue contraction (Sadananda et 
al., 2008, Ishizuka et al., 1995, Templeman et al., 2003).  The NK3R is expressed in only 
small amounts in the rat bladder (McCarson, 1999); although there is no functional evidence 
for its role in pig, human (Templeman et al., 2003), rat (Hall et al., 1992) or guinea pig 
(Longmore and Hill, 1992). 
 
Interest has developed in the role of the NK1R / substance P system in the bladder, since it 
may be an underlying cause of interstitial cystitis via initiating neurogenic inflammation 
(Marchand et al., 1998, Saban et al., 2007, Ruggieri, 1998).  The NK2R is also of particular 
interest, with its ability to elicit urothelium/lamina propria contractions (Sadananda et al., 
2008).  Abnormal expression or activation of the neurokinin receptors may be an underlying 
cause of bladder overactivity and other pathologies.  In isolated strips of human detrusor, the 
NKA-induced contractile responses were depressed in samples of idiopathic overactive 
bladder, although not in neurogenic overactive bladder (Sellers et al., 2006).  This further 
suggests a role in bladder disease, and further research into the neurokinin receptors of the 
bladder will provide a greater understanding of their significance. 
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1.5.8  Histamine receptors 
 
The histamine receptor subtypes H1, H2, H3 and H4 have been shown immunohistochemically 
in human detrusor (Neuhaus et al., 2006).  Functionally, histamine is known to cause 
contraction of the detrusor muscle in vitro (Poli et al., 1988, Rubinstein et al., 1987) where it 
may act directly on the muscle, or mediate the release of transmitters such as ATP or 
acetylcholine from nerves (Patra and Westfall, 1994).  The histamine H1-receptor subtype is 
recognised as the main subtype mediating contraction in the urinary bladder and when 
stimulated, is known to cause intracellular calcium release (Khanna et al., 1977, Neuhaus et 
al., 2006).  However, Neuhaus et al., (2006) also suggested a potential H3-receptor subtype 
mediated effect, and further research into this receptor subtype might contribute to the overall 
knowledge of these receptors in the bladder.  For now, the presence or functional role of the 
other histamine receptor subtypes in the bladder is not clearly understood. 
 
There is a possibility that histamine receptors may have a role in bladder pathology.  Release 
of histamine in the bladder can cause inflammatory responses as shown in guinea-pig tissues 
(Christensen et al., 1990), and abnormal concentrations of histamine release may occur in 
bladder diseases such as interstitial cystitis (French and Bhambore, 2011).  This release of 
histamine potentially mediates the pain associated with the IC syndrome (Rudick et al., 
2008).  In addition, there is also the possibility that the urothelium can release an amount of 
histamine which is greater than the underlying detrusor release (Saban et al., 1994).  These 
mechanisms of action for histamine in the lower urinary tract identify it as a potential 
therapeutic target for pathologies which induce sensory pain such as interstitial cystitis. 
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1.5.9  5-Hydroxytryptamine receptors 
 
5-hydroxytryptamine (5-HT, also termed serotonin) is released from nerves innervating the 
lower urinary tract, and is a potential regulator of the micturition cycle (Ramage, 2006).  This 
has led 5-HT modulators to be considered potential therapies for future treatments of lower 
urinary tract syndromes such as overactive bladder or stress incontinence (Tiwari and 
Naruganahalli, 2006, Vij et al., 2010).  Their importance is highlighted by duloxetine, a 5-HT 
reuptake inhibitor used clinically, which has been demonstrated to have favourable results in 
alleviating stress incontinence in women (Basu and Duckett, 2009).  Duloxetine was 
originally developed as an antidepressant, and it also affects the uptake of noradrenaline, yet 
it appears to increase bladder capacity and enhance urethral striated muscle activity in both 
animal models and human studies via the 5-HT system (Thor and Katofiasc, 1995, Duckett et 
al., 2008, Bump et al., 2008).  In addition, recent trials have found positive results, greater 
than the placebo, for the use of this drug in overactive bladder and mixed urinary 
incontinence (Bent et al., 2008, Steers et al., 2007). 
 
There are 14 structurally different 5-HT receptors, which have been classified into seven 
families (5-HT1-7) based on their pharmacological properties (Ramage, 2006, Andersson and 
Pehrson, 2003).  There is the potential for 5-HT to act both prejunctionally and 
postjunctionally within the bladder.   Nerves in the mouse and rabbit bladder respond to 5-HT 
via prejunctional excitatory 5-HT3 receptors (Chetty et al., 2007, Barras et al., 1996, Chen, 
1990).  Postjunctionally, the receptor mediating functional effects appears to be species 
dependent.  Preparations of detrusor smooth muscle contract in response to 5-HT2 receptor 
stimulation in human (Klarskov and Horby-Petersen, 1986), dog (Cohen, 1990), cat (Saxena 
et al., 1985) and rat (Kodama and Takimoto, 2000).  Furthermore, the addition of 5-HT 
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causes a potentiation of neurogenic contractile responses in the urinary bladders of human 
(Hindmarsh et al., 1977), mouse (Holt et al., 1986), guinea pig (Messori et al., 1995) and rat 
(Rekik et al., 2011, Palea et al., 2004).  The receptor mediating this potentiation response has 
been further identified as the 5HT4-histamine receptor subtype in the pig (Sellers et al., 
2000a) and human (Tonini et al., 1994, Chapple et al., 2004).  However, in the cat it appears 
to be partly mediated via the 5HT3-receptor subtype (Saxena et al., 1985).  These 
mechanisms and functional effects demonstrated for the range of 5-HT receptors may present 
an interesting target for future therapeutic treatments of bladder pathologies. 
 
1.5.10  Oestrogen receptors 
 
The extent to which oestrogen affects normal bladder activity is unknown.  Bladder diseases 
are thought to be more common in women and with age, which may relate to a correlation 
between their oestrogen levels and the mature onset of lower urinary tract disorders (Staskin, 
2005, Miodrag et al., 1988).  After menopause, for example, the lack of oestrogen appears to 
increase urethral tone (Rizk, 2005, Game et al., 2008).  The mechanism for this is not well 
understood, yet in a past study increased levels of oestrogen, through frequent injections in 
rabbits, resulted in increases to the immunohistochemical staining for the adrenergic 
innervation of the detrusor (Levin et al., 1981).  In addition, this study identified increases in 
the responses to both adrenoceptor and muscarinic receptor agonists.  This correlates with a 
more recent study suggesting that oestrogen may be responsible for reducing the release of 
acetylcholine from efferent nerves (Yoshida et al., 2007). 
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Oestrogen is a key modulator of pain and dysfunction and as such, it is generally thought that 
reduced levels of oestrogen would impact a range of mechanisms within the bladder wall.  
There is evidence that suggests both beneficial (Miodrag et al., 1988, Cody et al., 2009) and 
detrimental effects of oestrogen in lower urinary tract function (Jackson et al., 2002, Falconer 
et al., 1998, Keane et al., 1997, Palmer and Newman, 2007, DuBeau, 2005, Palmieri et al., 
2007).  Patients taking oestrogen in clinical trials of hormone-replacement therapy reported 
increases in both stress and urgency urinary incontinence (Hendrix et al., 2005, Townsend et 
al., 2009, Grady et al., 2001).  Alternatively, when applied locally it appears that there is a 
reduction in the symptoms related to urinary dysfunction (Cody et al., 2009).  In these 
studies, patient reports from those on hormone replacement therapy tend to contradict 
findings from the laboratory.  However, it does appear that there are a range of alterations 
occurring during systematic oestrogen treatment.  The potential benefits observed from local 
administration suggest a direct receptor-mediated effect on the lower urinary tract. 
 
Within the bladder, the concentration of oestrogen receptors appears to be higher in the 
urethra when compared to the dome or trigone (Iosif et al., 1981, Robinson and Cardozo, 
2011).  Nonetheless, immunohistochemistry has demonstrated the presence of these receptors 
on the urothelium and therefore a potential mechanism involved in tissue function (Miyamoto 
et al., 2012).  Oestrogen can regulate various visceral activities and influence a range of non-
genomic mechanisms in the bladder, such as activation of TRPV1 receptors (Kiasalari et al., 
2010).  β-estradiol, acting on the E2-receptor appears to modulate kinase activity in rat 
urothelial tissue (Birder et al., 2010c) and detrusor tissue (Valeri et al., 2009).  Oestrogen 
might even cause short term changes in bladder activity or increase the incidence of OAB in 
the female.  Tamoxifen, an oestrogen receptor antagonist, or modulators of protein kinase C 
(which is necessary in mediating the effects of oestrogen) have been suggested as 
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preventative agents for increases in the oestrogen levels that may contribute to bladder 
diseases such as OAB (Robinson and Cardozo, 2011).  Nonetheless, by itself oestrogen 
therapy does not appear to have a benefit to the management of bladder dysfunction.  
However, studies which have used oestrogen in conjunction with an α-adrenoceptor agonist 
have found that it may improve the leakage of urine in patients with stress incontinence 
(Robinson and Cardozo, 2003, Hilton et al., 1990). 
 
Clear beneficial evidence for the therapeutic use of oestrogen is still lacking and there is no 
experimental or clinical evidence to suggest exactly what mechanisms could be targeted for 
oestrogen treatment (Rechberger and Skorupski, 2007).  Although oestrogen levels may be a 
contributing factor towards stress incontinence in post-menopausal women, there is 
controversy regarding the effectiveness of oestrogen supplementation as an effective 
treatment (Koski and Chermansky, 2011, Robinson and Cardozo, 2011).  Additionally, in 
males a range of data indicates that exposure to oestrogen therapy may cause hyper-
proliferative or inflammatory responses in the prostate and obstructive voiding later in life (Li 
and Rahman, 2010).  This further identifies the caution required when examining or 
recommending oestrogen supplementation as a treatment for lower urinary tract dysfunction.  
Nonetheless, it may be important for further research to identify the effects of oestrogen on 
the functions of other receptors in the lower urinary tract, in an attempt to fully understand 
the mechanisms underlying its effects. 
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1.6 DISORDERS OF THE BLADDER 
 
1.6.1  Overactive bladder 
 
The overactive bladder syndrome is characterised by patients experiencing urinary urgency, 
with or without urge incontinence, and is usually coupled with frequency and nocturia 
(Abrams et al., 2002).  Studies in Western Europe and the USA have found that up to 17% of 
adults are affected by an overactive bladder (Stewart et al., 2003, Milsom et al., 2001).  
Patients experience a degree of urinary urgency and although it does not always result in 
urinary incontinence, 30% of sufferers experience involuntary leakage (Milsom et al., 2001, 
Milsom et al., 2000, Stewart et al., 2001, Stewart et al., 2003).  Frequency of greater than 8 
voids per day is usually required and nocturia is commonly present (Rovner and Wein, 2003).  
This inability to hold urine long enough to reach a restroom, including having intermittent 
strong desires to urinate causes a reduction in the quality of life in sufferers (Kelleher, 2002).  
 
A malfunctioning urinary bladder as a result of neurological dysfunction, injury or 
degeneration of the neural pathways controlling micturition is termed a neurogenic bladder 
(Ashok and Wang, 2010).  The symptoms of neurogenic bladder can involve detrusor 
underactivity or overactivity depending on the site of neurological insult.  Supraspinal lesions 
of the central nervous system above the pontine micturition centre, in the brainstem, leads to 
a loss of voluntary control of urination.  Studies on rats have demonstrated that cerebral 
damage can reduce central inhibition of the detrusor muscle, leading to potential bladder 
overactivity and a significantly smaller bladder capacity (Yokoyama et al., 1998b, Yokoyama 
et al., 2000).  From these studies on rats it appears that the dopaminergic and glutamatergic 
pathways contribute to bladder overactivity following brain lesions (Yokoyama et al., 1999, 
Yokoyama et al., 1998a), although research is yet to confirm this in humans.  The reduction 
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in bladder capacity and increased bladder overactivity is not limited to cerebral lesions as 
haemorrhages, tumours, dementia, and other cerebral diseases are also known to cause 
similar symptoms.  For example, the central nervous system in patients with Parkinson’s 
disease exhibits a degeneration of the basal ganglia, which often results in patients displaying 
signs of bladder overactivity during the filling stage (Uchiyama et al., 2011). 
 
Neuronal trauma below the brain, at the level of the spinal cord, is also associated with a loss 
of control in the urination reflex.  This is due to inhibited communication between the bladder 
and the pontine micturition centre.  Facilitation or inhibition of the detrusor contractions can 
occur after lesions in several areas of the central nervous system.  This has been supported 
historically through a range of animal studies and clinical evidence in humans (Andrew et al., 
1966, Andrew and Nathan, 1964, Barrington, 1927, Bors, 1952, Sherrington, 1892, Satoh et 
al., 1978, Nadelhaft and Booth, 1984).  In addition, changes in the activity of bladder afferent 
nerves have have been demonstrated following spinal cord injury in animal models (de Groat 
et al., 1990, de Groat et al., 1997).  However, it is still unclear as to exactly what changes 
occur after spinal cord injury that would specifically induce overactivity in humans.  Other 
neurogenic causes of overactive bladder may be associated with damage to the neurons 
innervating the bladder hence resulting in the loss of nervous control. 
 
Some patients have an overactive bladder as a result of detrusor overactivity. This is a 
clinical urodynamic observation characterised by involuntary detrusor contractions 
throughout the filling phase, which may be spontaneous or provoked (Abrams et al., 2002).  
There is a correlation between patients that have detrusor overactivity and overactive bladder 
symptoms (Al-Ghazo et al., 2011).  Urine can leak due to these abnormal spontaneous 
bladder contractions while the bladder is filling.  Animal models of neurogenic OAB, 
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obstructive  OAB and OAB associated with diabetes show some of the presentations 
commonly seen in patients with detrusor overactivity.  These models display a super-
sensitivity of the muscle to agonist stimulation suggesting that detrusor myocytes become 
more responsive to electrical signals (Vahabi et al., 2011, Vahabi et al., 2010, Stevens et al., 
2006, Brading, 1997). 
Although there are clear neurogenic origins for some sufferers of detrusor overactivity, 
idiopathic causes represent the largest population of patients.  The mechanisms underlying 
this form of overactivity are unclear but appear to involve both changes in neurogenic 
(neurological innervations to the bladder) and myogenic (smooth muscle) activity.  It is 
understood that dysfunction in either of these systems may give rise to overactive bladder. 
 
1.6.2  Interstitial cystitis 
 
Interstitial Cystitis (IC) is commonly termed painful bladder syndrome.  It is broadly 
described by an unpleasant sensation such as pain, pressure or discomfort perceived to be 
related to the urinary bladder and cannot be attributed to other causes (Hanno et al., 2011).  
Interstitial cystitis has not been linked to any known infection of the bladder.  It was 
traditionally diagnosed in patients suffering from lower urinary tract pain and dysfunction 
that cannot be classified under any of the normal bladder diseases (detrusor overactivity, 
bacterial cystitis, etc).  Along with the localised discomfort associated with having a painful 
bladder, many sufferers of IC report additional pain in the lower abdomen, lower back and 
urethra.  Diagnosis of IC in patients tends to occur after bladder pain or irritation has 
persisted for longer than 6 months (Hanno et al., 2011).  Following this initial diagnosis there 
is currently no universally successful treatment reported for this disease.  
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Interstitial cystitis is a multifactorial disease whose symptoms have similarities with those of 
the overactive bladder syndrome such as urinary urgency, frequency and dysuria.  The onset 
of chronic pelvic pain, however, is the symptom that separates it from other disorders.  Of 
these symptoms, it is the chronic pelvic pain that is the most difficult to control.  The current 
understanding of the aetiology of IC is incomplete and a variety of mechanisms may be 
involved at different stages of the disease.  With common misdiagnoses it is not known how 
many people suffer from IC, with reports ranging from less than 1% to as high as 11% of 
females (Berry et al., 2010).  However, the diagnoses for IC are broad and the prevalence of 
IC detected by urologists may simply depend on the definition used to identify it. The lack of 
clinical understanding for its management is evident from a study investigating the treatments 
prescribed to women with IC found 183 different types of therapies recommended by doctors 
(Rovner et al., 2000). 
 
Studies have suggested a range of bacterial infections (both gram-negative and gram-
positive) which can cause bladder inflammation (Echols et al., 1999).  However, cases of 
interstitial cystitis do not have any underlying infection, signifying that the inflammation is 
either due to infections which are difficult to test for, such as unknown pathogens or non-
infectious causes.  Known causes of inflammation in other areas of the body include exposure 
to radiation, medication side-effects, chemicals, autoimmune responses and cancer.  
However, the extent of how these may contribute to the chronic effects seen in IC patients is 
unknown.  It has been suggested that IC may relate to the activation of mast cells (Sant and 
Theoharides, 1994, Theoharides et al., 2001), increases in substance-P positive sensory nerve 
fibres (Pang et al., 1995), abnormal release of histamine (el-Mansoury et al., 1994) or 
dysfunction of the sympathetic innervation (Peeker et al., 2000).  Alternatively, a 
deterioration of the bladder’s protective GAG layer may lead to symptoms of IC (Chiang et 
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al., 2000, Metts, 2001, Ruggieri et al., 1994, French and Bhambore, 2011).  Treatments have 
attempted to replace this barrier with oral or intravesical pentosan polysulfate sodium or 
intravesical heparin or hyaluronic acid, which can assist with the repair of the GAG layer.  
Although there have been positive responses to this treatment in patients (Sand et al., 2008, 
Anderson and Perry, 2006), the broad spectrum of possible causes for IC means that patients 
who do not exhibit a reduction in symptoms from these treatments may have alternative 
aetiologies and this treatment may not be effective in a number of IC cases (Nordling, 2004, 
Sant et al., 2003).  Recent findings have also linked IC with recreational abuse of the drug 
ketamine (Nomiya et al., 2011, Chen et al., 2009, Chu et al., 2008) although no clear 
hypothesis was provided to suggest how this chemical causes damage to the bladder and 
induces chronic inflammation. 
 
Alternatively, the fact that pain is prevalent across areas such as the lower back and abdomen 
means that the symptoms shown from IC may not even arise from the bladder.  The pressure 
and burning sensations may indicate abnormal functioning of the myelinated C-fibres which 
connect to the colon as well as the bladder.  The wide range of symptoms makes the profile 
of IC difficult to target and correctly diagnose (Whitmore and Theoharides, 2011).  To 
advance the ability to treat IC a range of measures needs to be taken.  Rather than focussing 
solely on pharmaceutical or surgical treatments, research is required on behavioural, diet and 
lifestyle alterations which might alleviate the cause.  It has been shown that behavioural 
modifications, such as bladder training and monitoring of voiding intervals, demonstrate a 
50% reduction in IC symptoms (Parsons and Koprowski, 1991).  Further scientific studies on 
the benefits of diets and other common treatments in alleviating IC are required.  This 
research data would assist physicians to correctly diagnose and give evidence-based 
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prescriptions to patients rather than the current excessive range of widely ineffective 
treatments.   
 
1.6.3  Stress incontinence 
 
Stress incontinence is the most common form of incontinence in women.  It involves 
involuntary leakage of urine during activities that increase abdominal pressure, such as 
coughing, sneezing or jogging.  The symptoms of stress incontinence can be caused by a 
lowered bladder outlet resistance where urethral tone is reduced such as in old age, or by 
repositioning of the bladder due to a lack of pelvic floor support, as often found after 
pregnancy and childbirth.  Surgical treatments for stress incontinence include Burch 
colposuspension, where an incision is made in the abdomen and permanent stiches (Burch 
sutures) are placed around the bladder, anchoring it to the pubic bone.  The attachment to this 
bone at the lower part of the abdomen supports and assists the bladder to help prevent urinary 
leakage (Lapitan et al., 2009).  Newer procedures such as laparoscopic colposuspension are 
similar although a number of smaller incisions are used rather than one large incision in the 
abdomen.  Alternatively, a relatively new treatment involves insertion of a sub-urethral sling 
around the bladder neck which supports it during times of stress (Rehman et al., 2011).  
Nonetheless, these invasive surgery options are not practical for all patients and not always 
successful (Ogah et al., 2011, Sander and Lose, 2007).  Non-surgical procedures include 
initial treatments such as remedial exercises that increase the pelvic floor muscles.  This tends 
to be highly effective in reducing the prevalence of incontinence episodes (Dumoulin et al., 
2011, Bo, 2004).  In addition, lifestyle changes such as a reduction in weight; or lowering the 
intake of caffeine, alcohol or nicotine might also be effective in that they tend to alleviate the 
symptoms of stress incontinence in a number of patients (Jura et al., 2011, Townsend et al., 
2008). 
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1.6.4  Bladder infections 
  
Genitourinary infections are one of the leading causes of disease in humans, with urinary 
tract infections the most common complaint within this group (Schappert and Burt, 2006).  
These infections are usually associated with the bacterium E-coli often resulting in bladder 
inflammation (Nicolle et al., 2005, Hooton and Stamm, 1997, Kline et al., 2012).  In response 
to bladder inflammation, patients can experience pain, urgency and an increased frequency of 
urination. 
 
Attempts have been made to design effective animal models which can be used to simulate 
bladder inflammation (Bjorling et al., 2011, Hopkins et al., 1998, Bjorling et al., 2008).  
However, the relevance of these models is uncertain, due to the fact that responses to 
infection in human bladders are variable depending on the strain and severity of the invading 
bacteria and the individual’s immune response.  Animal models often use chemicals to irritate 
the bladder which result in chronic inflammation (Dinis et al., 2004, Krhut and Zvara, 2011, 
Cayan et al., 2003).  However, it is uncertain how relevant this “chemical cystitis” is to 
natural symptoms of bladder inflammation in humans.  Nonetheless, these models do present 
novel mechanisms underlying the disease which may shed more light on the onset of 
inflammation in human urogenital tracts. 
 
1.6.5  Overflow incontinence and bladder outlet obstruction 
 
Obstruction of the bladder outlet or a deficiency of the detrusor muscle to completely empty 
the bladder can cause symptoms of bladder outlet obstruction (BOO) (Drake et al., 2003d).  
This disorder can lead to the incomplete emptying of the bladder or over-distension resulting 
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in involuntary leakage due to the subsequent overflow (overflow incontinence).  This 
problem is common in male sufferers of prostate hyperplasia as the detrusor muscle is not 
strong enough to completely void the bladder whilst the prostate forces pressure on the 
urethra.  Catheterisation remains the predominate method for alleviating these symptoms.  
Other problems with bladder obstruction include the recurrence of urinary infections, weak 
urinary flow rates, terminal dribbling, difficulty in beginning the flow of urine (hesitancy), 
and an increase in the prevalence of overactive bladder.   
 
1.6.6  Bladder dysfunction in Australia 
 
Up to 15% of Australians and over 30% of elderly Australians are estimated to have some 
form of urinary incontinence (Pearson et al., 2002).  It is assumed that only 31% of these 
sufferers report having sought help from a health professional (Continence foundation of 
Australia, 2010).  The most common pharmacological treatments are clinical antimuscarinic 
drugs such as oxybutynin, tolterodine, darifenacin and solifenacin (Athanasopoulos and 
Giannitsas, 2011).  These drugs have consistently demonstrated small, yet statistically 
significant differences in their efficacy and tolerability (Robinson and Cardozo, 2010).  
However, the antimuscarinics are known to bind to muscarinic receptors in other organs such 
as the salivary glands where they cause dry-mouth, resulting in a constant discomfort to 
patients.  Additional actions on other areas in the body can produce further side effects 
including constipation, drowsiness, blurred vision, increased heart rate, dizziness and 
cognitive impairment (Saks and Arya, 2009). 
The most common forms of urinary incontinence are associated with a combination of 
urgency and stress and the three categories are not necessarily encountered independent of 
each other (Figure 1-14).  Australia already has 66% of nursing home residents requiring 
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some sort of bladder management (Pearson et al., 2002).  The cost to the health care system 
will continue to increase with the ageing population, who tend to have a higher prevalence of 
incontinence and bladder diseases (Kelleher, 2002).  Effective management of incontinence 
will assist in: 
  Reducing the cost of hospital treatments. The estimated cost of incontinence in 
Australia is $1.5 billion, and that cost is expected to rise over 200% by 2030. 
 Freeing up nurses and hospital staff from cleaning up incontinence-related spills.  Up 
to 60% of primary aid workers spend 40 hours a week or more managing patients 
with incontinence, and 44% of primary carers report a change in their physical or 
emotional wellbeing since taking on the caring role, compared to 27% of carers who 
did not usually assist in managing incontinence. 
 Greatly increasing the quality of life for the large numbers of patients suffering from 
involuntary leakage of urine, with over 117,700 healthy life years lost per annum due 
to incontinence. 
 
(Statistics supplied by the Continence foundation of Australia, 2010, the Commonwealth 
Department of Health and Ageing, 2011 and the Australian Institute of Health and Welfare, 
2012). 
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Figure 1-14: The prevalence of bladder disorders in Australia.  The chart incorporates stress 
incontinence, other forms of incontinence (including overflow), Mixed (OAB + Stress 
incontinence), and isolated OAB cases (Australia, 2009, Pearson et al., 2002). 
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1.7  GENERAL HYPOTHESIS AND AIMS 
 
The urothelium/lamina propria generates spontaneous contractions which are independent of 
any neuronal or detrusor activity and it is hypothesised that the receptors and transmitters, 
normally associated with the autonomic nervous system, regulates this activity. The 
objectives of this thesis were to investigate urothelial/lamina propria spontaneous activity 
and: 
 
1. Measure the frequency, amplitude and baseline tension of spontaneous contractions. 
2. Identify agonists and antagonists that modulate the spontaneous contractile activity. 
3. Determine the effect of the nitric oxide system, and the muscarinic and adrenergic 
receptor subtypes which influence contractile rate and tension in response to stretch or 
receptor stimulation. 
4. Determine the effect of nerve stimulation on contractile activity. 
5. Identify the role of the isolated urothelium in mediating spontaneous contractile 
activity of the urothelium/lamina propria. 
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Chapter 2  
 
 
MATERIALS AND METHODS 
 
  
 Page | 88 
2.1.1  Collection of bladders 
 
Pig bladders were used in this study as a suitable model to investigate human bladder 
function.  It has been previously shown that the porcine bladder is structurally similar to the 
human bladder and shares similar physiology and pharmacology (Sibley, 1984, Crowe and 
Burnstock, 1989, Templeman et al., 2003, Buckner et al., 2000, Kumar et al., 2004).  In 
addition, diseases prevalent in human bladders, such as detrusor overactivity have been 
exhibited in the pig (Jorgensen et al., 1983, Sibley, 1985, Speakman et al., 1987, Chapple and 
Smith, 1994).  Highchester abattoir (Gleneagle, QLD) supplied fresh tissues several times 
each week.   
 
Bladders were obtained from Large White-Landrace-Duroc crossbred pigs (Sus scrofa 
domestica), slaughtered for the provision of bacon. These bacon-pigs were chosen as they are 
consistent in their size, weight and age.  Pigs of both sexes were used since initial preliminary 
experiments demonstrated no differences in resting frequency, baseline tension or amplitude 
of spontaneous contractile activity. Sows, suckling pigs and other ages, sizes and breeds were 
not used.  The pigs were 6 months old and weighed ~100 Kg live weight, and ~80 Kg dead 
weight, after the removal of offal. 
 
2.1.2  Tissue preparation 
 
Following slaughter bladders were immediately immersed in cold Krebs-bicarbonate solution 
(composition in mM: NaCl 188.4, NaHCO3 24.9, CaCl2 1.9, MgSO4 1.2, KCl 4.7, KH2PO4 
1.2 and D-glucose 11.7) and transported to the Bond University laboratories on ice.  The 
urethras and ureters were removed and the bladders opened longitudinally (Figure 2-1).  Full 
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thickness strips of anterior wall from the dome region were removed.  From these tissues, 
strips of urothelium including the lamina propria were prepared (2cm x 5mm).  All serosa and 
surrounding tissue was removed from the strips.  For smooth muscle experiments detrusor 
strips were examined following removal of the urothelium and lamina propria.  
 
 
Figure 2-1: Whole pig bladder. The urothelial and lamina propria layers have been 
dissected away from the detrusor for inspection.  Note the clear colour and texture difference 
between the underlying white detrusor muscle and the pink lamina propria layer.  Through 
observation of this internal lamina propria layer, it is clear that the urothelium and lamina 
propria contains a rich network of capillaries and blood supply. 
 
2.1.3  Functional organ bath experiments 
 
Tissues were immersed in 10 mL organ baths in Krebs-bicarbonate solution (Labglass, 
Brisbane, Figure 2-3).  Throughout the experiments tissues were maintained at 37oC and 
gassed (95% O2, 5% CO2).  In each organ bath, tissues were attached to isometric force 
transducers (ADInstruments MCT050/D, Figure 2-2).  A small syringe was used to anchor 
the tissue to the base of the bath, and cotton twine was used to connect the tissue to the 
transducer longitudinally.  Developed tension was amplified using an octal-bridge amplifier 
(ADInstruments) and transmitted to the computer via a Powerlab analogue-to-digital recorder 
(ADInstruments, Castle Hill, Australia).  Developed tension was converted into a graphical 
trace using Labchart v7 software. 
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Figure 2-2: Custom-made organ baths (C. Moro, Labglass, Brisbane).  The tissue was 
connected to a MCT050/D isometric force transducer, and contractile activity recorded 
through an octal-bridge amplifier connected to a Powerlab 8/30 system. 
 
 
 
Figure 2-3: The experimental organ bath setup.  The organ baths were designed to 
maintain internal temperature of 37°C with a constant and steady stream of carbogen gas. 
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2.1.4 Measurements of spontaneous activity: 
 
Contractions were measured within a 2 - 5 minute period.  The frequency over the time frame 
was converted to cycles per minute. The amplitude of spontaneous activity was measured as 
absolute values (g, Figure 2-4).  Data was tabulated in Microsoft Excel 2010 and expressed as 
mean ± SEM. 
 
 
 
Figure 2-4: Calculation of the amplitude and the frequency of spontaneous activity. 
 
 
Responses to agonists: 
 
Measurements of frequency and amplitude of phasic contractions were taken at the peak 
response (Figure 2-5) after the addition of each drug or following stretching.  The frequency 
of contractions was expressed as the number of phasic waves per minute (cycles min-1) and 
the amplitude as grams tension.  The baseline tension was taken as the lowest point of the 
spontaneous phasic contractions.  After maintaining tissues under a baseline tension of 2g the 
tissues were allowed to equilibrate for 1 hour, with washes every 15 minutes with fresh 
warmed Krebs solution prior to the addition of any drugs.  All antagonists were left to 
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incubate for at least 30 minutes with the tissues.  In stretch experiments tissues were stretched 
in pairs (with or without the selective antagonist) by 1.5cm (75%) over 90 seconds and 
frequency was recorded before and after stretching.   
 
 
Figure 2-5: Demonstration of methods used to determine responses to agonists.  Initial 
calculations were made after 40 - 60 minutes of the tissue equilibrating and a steady rate of 
spontaneous activity, baseline tension, and amplitude was evident.  The average rate (in 
cycles second-1) was measured within 3 - 4 minutes prior to the stimulation, then measured 
again for 2 - 3 minutes at the peak response to the agonist.   
 
 
2.1.5  Urothelial contractile responses: concentration-response curves 
 
Concentration-response curves to selected agonists were obtained by the addition of the drug 
to the organ bath in increasing increments.  Most concentration-response experiments 
performed were within a range that did not exceed 0.05 - 300 µM.  Control experiments were 
performed with the addition of the vehicle alone and these experiments were used, if 
necessary, to correct for any time-dependent changes in tissue sensitivity or responsiveness 
during the course of the experiment.  Each increment of the drug was added at peak tension 
response (Figure 2-5), which was usually within 4 minutes of the previous dose. 
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After the initial curve to maximum response, the tissue was washed out several times and left 
to return to baseline tension for 30 minutes.  For studies involving agonists, the drug was 
added and the concentration-response curve completed from incremental drug additions.  For 
experiments involving antagonists, drugs were added 30 minutes prior to the commencement 
of the second concentration-response curve in the presence of the antagonist. A maximum of 
2 curves were completed for each tissue.  In experiments where a second curve was not 
possible due to desensitisation of the receptors, 4 cm strips of bladder tissue were dissected in 
half, and each tissue was set up in parallel.  Identical conditions were followed for the two 
strips, with one acting as control in the presence of the vehicle.  Specific drugs and 
concentrations are detailed in the results chapters. 
 
2.1.6  Electrical field stimulation 
 
Electrical Field Stimulation (EFS) was used to determine if urothelial contractions could be 
evoked from neuronal sources.  Tissues were prepared and placed in Krebs solution at 37°C 
and gassed with 95% O2 and 5% CO2.  In the organ bath, tissues were tied with cotton to a 
glass anchor, and the tissue was placed between two platinum-wire electrodes which ran 
alongside the length of the tissue.  The upper end of the tissue was anchored to an isometric 
force transducer connected to a Powerlab system.  After washing with warmed Krebs solution 
the tissues were allowed to equilibrate for an hour before commencing experiments. 
 
Electrical field stimulation of the tissues was obtained using a Grass S48 stimulator via a 
Med-Lab Stimu-Splitter II (Figure 2-6).  Measuring the electrical field stimulated 
contractions of the urothelium/lamina propria has the unique problem of the tissues 
displaying high rates of relatively strong spontaneous contractile activity.  Stimulation 
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frequencies for this tissue were optimised in order to obtain contractions that were 
significantly neurogenic in origin, while also above the spontaneous contractile activity 
(amplitude of ~0.6-1.0 g). 
 
The optimal stimulation parameters for urothelial/lamina propria strips were 5 second trains 
of pulses (0.1 - 0.5 ms pulse-width, 30 v) applied every 100 seconds.  Up to four stimulation 
frequencies (5, 10, 15 and 20 Hz) were examined for each experiment and at the end of 
selected experiments tetrodotoxin (1 µM) was used to confirm the contractions were 
neurogenic in origin.  Responses to electrical stimulation at set frequencies were recorded 
before and after the addition of selected drugs.  The amplitude of spontaneous contractions 
was calculated as the average amplitude for the contractions within 1 - 2 minutes prior to the 
electrical stimulation.  The response was measured as the contractile amplitude above the 
average spontaneous contractile activity (Figure 2-7).  Responses were compared in the 
absence and presence of various agonist and antagonists.  Contractions in the presence of 
agonists were recorded at maximum response, usually within the first 2 - 4 minutes of 
incubation with the drug.  Antagonists were left in the bath for 30 minutes to allow tissue 
equilibration tissues before contractions were measured. 
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Figure 2-6: The grass S48 Stimulator used to generate EFS signals.  Pulses are supplied to 
4 organ baths through the Med-Lab Stimu-Splitter II (above). 
 
 
 
Figure 2-7: Demonstration of the methods used to calculate EFS-mediated contraction of 
the urothelium/lamina propria.  This tissue exhibits spontaneous contractile activity.  Total 
contractile amplitude was taken as contractions above the normal spontaneous amplitude. 
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2.1.7  Analysis of data 
 
Data from each experiment were entered into Microsoft Excel 2010 (Microsoft, Redmond, 
WA, USA).  Measurements of frequency and amplitude for phasic activity were taken as an 
average value from 2 - 5 minutes prior to stimulation, and compared to measurements taken 
at the peak response after the addition of each drug unless otherwise stated.  At peak 
responses, frequencies were taken over at least 2 minutes. 
 
When possible, methods were developed so that tissues could be directly paired with the 
controls (ie: before and after drug in same tissue).  For these experiments, values in the 
absence and presence of drugs were compared using Student’s two-tailed paired t-test with P 
< 0.05 being taken as statistically significant, and the results presented as mean ± SEM.  Data 
from the experiment was exported to GraphPad Prism software v5 (GraphPad, San Diego, 
CA, USA) for statistical analysis.  If tissues could not be paired directly an unpaired 
Student’s t-test was applied for analysis of data.  For experiments involving more than one 
treatment per control, one way analysis of variance (ANOVA) tests were performed followed 
by an appropriate post hoc test. 
 
GraphPad Prism software v5 was used for the construction of concentration-response curves.  
After analysis of the individual curves, EC50 values were determined through a non-linear 
regression fit to a variable-slope concentration-response curve.  GraphPad Prism uses a four-
parameter logistic equation prism to calculate the curves. Each individual curve was 
designated a –logEC50 (pEC50) value, and a mean (± SEM) of each separate tissue calculated.  
Experiments were designed to give a minimum of 6 recordings (n ≥ 6) where possible prior to 
the calculations of these values. In some experiments a range of antagonist concentrations 
 Page | 97 
was used and dissociation constants for these antagonists were determined.  Schild regression 
analyses were constructed in Prism as detailed in past publications (Arunlakshana and Schild, 
1959). 
 
________________________ ܲܭ஻ ൌ logሺܥܴ െ ͳሻ െ logሾܤሿ 
________________________ 
Equation 1: pKB = Dissociation constant.  CR = Concentration ratio (ratio of the EC50 
values). [B] = Concentration of the antagonist. 
 
 
Data for some concentration-response curves were also calculated after normalising to 100%.  
The maximum contraction to an agonist was considered 100%, and GraphPad Prism software 
was used to extrapolate the interim values as a percentage of the maximum response.  
Concentration-response curves were constructed from this normalised data using a non-linear 
regression fitted with a sigmoidal variable slope function.  pEC50 values were calculated for 
each individual curve, and the group data combined and averaged in Microsoft Excel or 
GraphPad Prism. 
 
2.1.8  Drugs and solutions 
 
Sources of drugs: 
 
Carbamoylcholine chloride (carbachol), (R)- (-)-phenylephrine hydrochloride phenylephrine 
hydrochloride, α,β-methyleneadenosine 5’-triphosphate lithium (α,β-methylene ATP), 
tetrodotoxin (TTX), (±)-arterenol hydrochloride (noradrenaline), nifedipine, pyrilamine 
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maleate, guanethidine monosulphate, atropine sulphate, , protease inhibitor cocktail (P1860), 
phosphoramidon, histamine dihydrochloride, 1,1-dimethyl-4-phenylpiperazinium iodide 
(DMPP), Nw-Nitro-L-Arginine (L-NNA), capsaicin, diethylamine NONOate sodium salt 
hydrate (DEANO), 18-β-glycyrrhetinic acid, 4-diphenylacetoxy-N-methylpiperidine 
methiodide (4-DAMP), methoctramine hemihydrate, L-phenylephrinine hydrochloride,  
sodium nitroprusside, phentolamine hydrochloride, and  indomethacin, phosphoramidon, 
protease inhibitor cocktail (P1860), dimethyl sulfoxide, pirenzepine dichloride, , CL316243 
disodium salt, (±)-Noradrenaline hydrogen tartrate, CGP20712A methanesulfonate salt, 
oxybutynin chloride, and prazosin hydrochloride were purchased from Sigma (St Louis, 
Missouri, USA). 
Tamsulosin, mirabegron (YM-178), and solifenacin were gifted by Astellas, Leiderdorp, NL. 
 
A61603 hydrobromide, BMY7378 dihydrochloride, BRL37344 sodium salt, CL316243 
disodium salt, ICI118551 hydrochloride, (±)-propranolol hydrochloride, RS17053 
hydrochloride, RS100329 hydrochloride, SR59230A, salbutamol sulphate, Clonidine 
hydrochloride and UK14,304 were purchased from Tocris (Ellisville, Missouri, USA). 
 
The sources of other drugs, reagents and substances have been detailed where used. 
 
Preparation of drugs 
 
Indomethacin and nifedipine were dissolved in 100% ethanol.  Capsaicin and the protease 
inhibitor cocktail were dissolved in 100% dimethyl sulfoxide (DMSO).  The volume of drug 
added to the baths was kept to a minimum and the volume of ethanol and DMSO (>0.3% 
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dilution) used as vehicles exerted no effect in control experiments.  All other drugs were 
dissolved in distilled water and diluted in Krebs bicarbonate solution. 
 
Krebs was composed of the following (name, molecular formula, [mM]): sodium chloride, 
NaCl, 118.4; glucose, C6H12O6, 11.7; sodium hydrogen carbonate, NaHCO3, 24.9; potassium 
chloride KCl, 4.7; magnesium sulphate, MgSO4, 1.2; potassium dihydrogen 
monophosphate, KH2PO4, 1.2; and calcium chloride, CaCl2, 1.9.  Krebs solution was usually 
made up to 5 L solutions with distilled H2O and stored at 4°C.  Krebs was used within 24 
hours from the initial dilution of salts. 
 
2.1.9 Real-time quantitative PCR analysis 
 
Total RNA extraction 
 
Bladder tissues from 6 pigs were used to identify the transcriptonomic expression of 
adrenoceptor RNA in the bladder urothelium/lamina propria). Strips of porcine bladder were 
immediately dissected at the abattoir and immersed in RNALater solution (Ambion).  Within 
1 hour from extraction, the bladder samples were placed at room temperature, finely 
dissected with scissors (cleaned with RNAse away, Invitrogen) under magnification to 
remove all detrusor muscle fragments leaving ~0.25g of urothelium and lamina propria.  A 
Trizol plus RNA purification kit (Invitrogen Cat No. 12183-555) was used for the urothelial 
RNA extraction.  Dissected tissues were immediately immersed in Trizol and lysis of the 
tissue was achieved by passing the dissected fragments through a sterile pipette tip several 
times, then through sterile syringes of different gauges (19G and 23G).  Following this 
procedure, the homogenate was left to incubate for 5 min at room temperature.  
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In order to facilitate the recovery of the aqueous phase of the PCRs which have been overlaid 
with mineral oil, 0.2 ml chloroform was added to the mixture. This suspension was rolled 
swiftly by hand for approximately 15 seconds to combine the solutions.  Following 2 - 3 
minutes incubation (25°C), the sample was centrifuged at 12,000 x g for 15 minutes at 4°C in 
an Allegra-64 centrifuge (Beckman Coulter).  The colourless upper phase containing the 
RNA was collected and transferred into a sterile RNAse free tube containing an equal volume 
of 70% ethanol, prepared from ultrapure RNAse free water (Invitrogen) and pure ethanol.  
The sample was vortexed thoroughly for 30 seconds and placed in an RNA spin cartridge for 
further purification.  Binding of the RNA and washing steps were undertaken following the 
manufacturer’s instructions (Qiagen, 2010).  The total RNA was then treated with DNAse to 
digest any genomic DNA contamination.  A mix containing: diethylpyrocarbonate water 
(40μl); RQ1 buffer (RNase-Free DNase, 20 µL) which is a preparation of deoxyribonuclease 
1 that will degrade the single-stranded or double-stranded DNA in the mixture to produce 
oligonucleotides and thereby assist in maintaining high integrity RNA; and the redox reagent 
dithiothreitol (20μl of 0.1M) and deoxyribonuclease 1 (20μl of 2000 units/ml), which is a 
nuclease that cleaves DNA; was poured onto the RNA and left to incubate at 37°C for 15 
minutes.  RNA was eluted into 50 µl of RNAse free pure water and maintained at minus 
80°C to prevent decomposition.  All experiments were performed within 3 months of the 
initial extraction and procedures were designed so that there was no unnecessary thawing of 
samples. 
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Purity, integrity and quantitative analysis of the RNA sample 
 
A NanoDrop 1000 Spectrophotometer (Thermo Scientific) was used to measure the total 
RNA quantity and to assess the purity  The integrity of the RNA was also performed for all 
extractions by denaturing agarose gel electrophoresis and ethidium bromide staining 
(reagents from Qiagen, Hilden, Germany).  The protocol used was adapted from Qiagen and 
is designed to provide enhanced sensitivity when analysing RNA fragments, as per 
manufacturer’s recommendations (Qiagen, 2010). 
 
A key feature of this protocol is that the concentrated RNA loading buffer, allows for a 
higher volume of RNA sample to be loaded onto the gel than conventional protocols 
(Sambrook, 1989).  This procedure was performed with a 1.2% Formaldehyde Agarose (FA) 
Gel Electrophoresis prepared through 1.2g agarose, 10 mL 10x FA gel buffer (200 mM 3-[N-
morpholino]propanesulfonic acid (MOPS) (free acid), 50 mM sodium acetate, 10 mM EDTA, 
(PH stabilised at 7 using NaOH) which was then made up to 100 mL using RNAse-free 
water.  This mixture was then heated in order to melt the agarose and then cooled to 65°C in 
a water bath. 1.8mL of 37% (12.3 M) formaldehyde and 1 µL of 10 mg/mL ethidium bromide 
stock solution was added and mixed thoroughly.  The mixture was then transferred to a gel 
support.  Before running the gel the mixture was equilibrated in 1xFA gel running buffer 
consisting of 100 ml 10x FA gel buffer, 20 ml 37% formaldehyde, and 880ml RNase-free 
water, for 30 minutes. 
 
All trays and tanks were initially washed in 70% ethanol, rinsed with DEPC water, washed 
with RNaseAway (Invitrogen) and left until dry.  8 µL total RNA was diluted to 100 ng/µL 
and mixed with a 5× RNA loading dye (16 μl saturated aqueous bromophenol blue solution, 
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80 μl 500 mM EDTA, pH 8.0, 720 μl 37% (12.3 M) formaldehyde,  2 ml 100% glycerol, 
3.084 ml formamide, 4 ml 10 x FA gel buffer, RNase-free water to 10 ml).  The RNA 
samples were loaded onto the wells cut into the gel, and following 5 minutes of incubation at 
65°C they were electrophoresed at 90 Volts for 30 minutes. The gel was then visualised 
under an ultra violet transilluminator after ethidium bromide staining and photographed with 
a digital camera. 
 
cDNA synthesis: 
 
Synthesis of cDNA was performed using SuperScript III First-Strand Synthesis SuperMix 
from the qRT-PCR kit (Invitrogen). Initial incubation in a reaction mix [10 µL of 2X RT 
Enyme Mix] containing superscript III and RNaseOUT was performed.  Superscript III is a 
high-performance proprietary type of reverse transcriptase from Invitrogen Life Sciences, 
which has been optimised to synthesise first-strand cDNA from total RNA.  RNaseOUT is a 
potent non-competitive inhibitor of ribonucleases. To this mixture, 2 µL of Reverse 
Transcriptase Enzyme Mix was added, which contained oligo(dT)20 (2.5 μM), random 
hexamers (2.5 ng/μl), 10 mM MgCl2, and dNTPs; 8µL of Eluted RNA (2 µg), and maintained 
at 25°C for 10 minutes, followed by a second incubation at 50°C for 30 minutes.  The 
reaction was halted by bringing the mix to 85°C for 5 minutes.  The overall cDNA was stored 
at -20°C and used within 3 months of freezing. 
 
Quantitative real-time polymerase chain reaction: 
 
An iQTM SYBR Green Super Mix (BioRad) was used to amplify the cDNA targeted genes 
in the Quantitative Real-Time Polymerase Chain Reaction (Q-PCR) process.  This supermix 
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includes the SYBR green dye which binds to double stranded DNA as it is generated by PCR 
and allows the products to be quantified.  Real-time PCR was performed with a Research 
Rotor-Gene 6000 real time thermocycler (Corbett-Qiagen).  PCR volumes (containing 2 – 5 
µL cDNA) were placed in individual Corbett 100 µL tubes on -20°C pre-cool metal tube 
carriers. All PCR tubes were placed in a 72 well rotor and held in the machine with a locking 
ring.  Cyclic conditions were set which allowed specificity for each of the genes.  5µL of 
ADRB3 cDNA was used and amplified with the following conditions: 94°C 4 min (x1 cycle), 
cycle 2: 94°C 30 s, 51°C 15 s, 72°C 15 s (x40).  All other genes were expressed with the 
conditions: 94°C 4 min (x1), Cycle 2, 94°C 30 s, 60°C 30 s, 72°C 30 s (x45).  Prior to 
running the PCR, an amplification protocol was preset to obtain melt curve representations, 
ramping from 50 to 99°C with 1°C ramping every 5 seconds.  The number of cycles required 
to the point that the specific PCR product is amplified in a linear way is referred to as the 
cycle threshold (CT).  This can be used for quantitative analysis, where a single CT 
difference (Δ CT = 1) represents a two-fold difference in the amount of the specific target. 
Therefore, after each Q-PCR assay the CT value at linearity was determined for each gene.  
Realtime-PCR assays that demonstrated a non-specific product or primer-dimers at the end 
point were excluded from any further data collection.  Expression levels of each target gene 
were expressed relative to the housekeeping gene, β-actin. 
 
Primer selection: 
 
Oligonucleotide primers were designed from the characterised pig genome (Scrofa 
Domestica).  The primers (Table 1, Table 2) were designed specifically to bond to the 
targeted porcine genes and purchased from Geneworks (Thebarton, South Australia).  The 
following porcine genes were identified within genebank through their codes: 
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ADRA1A, adrenergic alpha-1A receptor; ADRA1B, adrenergic alpha-1B receptor; 
ADRA1D, adrenergic alpha-1D receptor; ADRB1, adrenergic beta-1 receptor; ADRB2, 
adrenergic beta-2 receptor; ADRB3, adrenergic beta-3 receptor, ACTB, beta actin. 
 Gene	 Forward	Primer	 Length	 Tm Amplicon	size	ȋbpȌ	 Position Number	of	exons	 Primer	Type	
ADRA1A	 CCATTGGGTCTTTCTTTCCT	 ʹͲ	 ͷͻ.ͻͲ ͳʹͶ ͺ͹͹ ʹ overlap	
ADRA1B	 GGTCATTCTGGTCATGTACTG	 ʹͳ	 ͸Ͳ.Ͷ͸ ͳ͵Ͷ ͸ͷͲ ͳ 	
ADRA1D	 TTTCTTCGTCCTACCACTG	 ͳͻ	 ͷͺ.ͻʹ ͻͲ ͳͲͻͳ ʹ span	ȋͳ͹,ͲͲͲbpȌ	
ADRB1	 CCAACCTCTTCATCATGTCC	 ʹͲ	 ͸Ͳ.Ͷʹ ͳͶͶ ʹ͹͹ ͳ 	
ADRB2	 GATCCATGACAACCTCATCC	 ʹͲ	 ͸Ͳ.ʹͲ ͳͳ͹ ͺͻͲ ͳ 	
ADRB3	 AGACTCCAGACCATGACC	 ͳͺ	 ͸Ͳ.ʹ͵ ͳ͵ʹ ͳͻͺ Ͷ span	ȋͳʹͷbpȌ	
ACTB	 ATGGGCCAGAAGGACTC	 ͳ͹	 ͸Ͳ.ͷͻ ͳͶͶ ͳ͵ͺ ͸ span	ȋͳ͵ʹbpȌ	
 
Table 1: Forward primers custom-designed for the identification of adrenoceptor genes 
  
 Gene	 Reverse	Primer	 Length	 Tm Amplicon	size	ȋbpȌ	 Position Number	of	exons	 Primer	Type	
ADRA1A	 TTTAAACTCTTGACTGGAGCAC	 ʹʹ	 ͸Ͳ.ͺ͵ ͳʹͶ ͳͲͲͳ ʹ Overlap	
ADRA1B	 TCGTGAAAGTTCTTGGAGTG	 ʹͲ	 ͸Ͳ.ʹͲ ͳ͵Ͷ ͹ͺͶ ͳ 	
ADRA1D	 GTTGAAGTAGCCCAGCC	 ͳ͹	 ͷͻ.ͻͳ ͻͲ ͳͳͺͳ ʹ span	ȋͳ͹,ͲͲͲbpȌ	
ADRB1	 CACAGTACGTCCACCGA	 ͳ͹	 ͸Ͳ.ͻͳ ͳͶͶ Ͷʹͳ ͳ 	
ADRB2	 GAAGGCCATCCTGAAATCTG	 ʹͲ	 ͸Ͳ.͹ͺ ͳͳ͹ ͳͲͲ͹ ͳ 	
ADRB3	 ACAGCTCGCAACAAGTG	 ͳ͹	 ͸Ͳ.Ͷͻ ͳ͵ʹ ͵͵Ͳ Ͷ span	ȋͳʹͷbpȌ	
ACTB	 GCAGCTCGTTGTAGAAGG	 ͳͺ	 ͸Ͳ.͵ͺ ͳͶͶ ʹͺʹ ͸ span	ȋͳ͵ʹbpȌ	
 
Table 2: Reverse primers custom-designed for the identification of adrenoceptor genes 
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Capillary electrophoresis: 
 
The QIAxcel capillary gel electrophoresis system (Qiagen, Hilden, Germany) was used to 
provide a further visual identification of the primer binding affinity and sample quality.  Post-
PCR products samples were analysed using a high resolution gel cartridge with 2 µL aliquots 
of the PCR product combined with a dilution buffer (Qiagen) to 10 μL total volume. The 
QIAxcel system produces a digital gel image and an electropherogram for primer binding 
analysis. 
 
Statistical analysis 
  
Graphpad version 5 (PC) was used to collate and analyse all data collected.  As each gene 
was performed with controls, a Student’s two-tailed t-test was used to initially determine 
whether the ct values of the adrenoceptors were statistically significant from the 
housekeeping gene β-actin for each cDNA sample (with P < 0.05 being significant, and 
groups with a SD < 0.8 being acceptable).  
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Chapter 3  
 
 
OPTIMISATION OF TECHNIQUES 
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3.1.1  Selection of an animal model 
 
Porcine bladder was used in this study as a suitable and effective model for research related 
to human bladders (Parsons et al., 2012).  This tissue is structurally similar to the human 
bladder, and shares similar physiology and pharmacology (Sibley, 1984, Crowe and 
Burnstock, 1989, Templeman et al., 2003, Buckner et al., 2000, Kumar et al., 2004).  In 
addition, diseases prevalent in human bladders, such as detrusor overactivity, have been 
demonstrated in pig models (Jorgensen et al., 1983, Sibley, 1985, Speakman et al., 1987, 
Chapple and Smith, 1994). 
 
Large White-Landrace-Duroc crossbred pig bladders from a local abattoir were used in this 
study.  It was important to identify a suitable size, age and health from this breed.  On 
request, the abattoir did not supply any tissues where the pigs were found to be infected with 
disease, and all pigs used in this study were fit for human consumption.  In addition, prior to 
the initial dissection of the tissue, each pig bladder used in this study was visually checked 
for pus, blood or infection.  Bladders were used within 24 hours of removal from the pigs.  
As an additional measure of pig health, an ABL 80 Flex Co-ox radiometer was transported to 
the abattoir where it was set up to receive the fresh blood immediately from the pig, and the 
analysis for each sample was commenced within 1-5 minutes of the blood being removed 
from the pig (n = 6).  Each pig’s blood analysis was consistent with healthy reference values. 
 
Some studies such as EFS and a range of organ-bath experiments required a single dose of an 
antagonist. The chosen concentration was selected as the highest possible concentration 
which remained selective for the individual receptor.  Tables of affinity values were compiled 
from the literature for the antagonists used in the study (Table 3, Table 4, Table 5). 
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Muscarinic receptor-selective antagonists 
Antagonist 
M1 
 
M2 M3 M4 M5 
mean range mean range mean range mean range mean range
4-DAMP 9.28 
9.24- 
9.40 
8.30 
8.14- 
8.40 
9.28 
9.10- 
10.60
8.93 
8.43- 
9.14 
8.98 
8.3– 
9.25 
Darifenacin 7.82 
7.50 
-8.15 
7.17 
6.94 
-7.40 
8.64 
8.01-
9.12 
7.65 
7.34 
-7.90 
7.99 
7.61– 
8.26 
Methoctramine 7.12 
6.55-
  7.50 
8.05 
7.56 
- 8.7 
6.67 
6.05 
-6.80 
7.31 
6.85 
- 7.6 
6.65 
6.3 – 
7.00 
Pirenzepine 8.15 
8.04-  
8.20 
6.47 
6.28-
6.65 
6.89 
6.40- 
7.44 
7.39 
6.98 
-7.76 
6.95 
6.40- 
7.20 
Tolterodine* 7.79 ±0.62 7.99 ±0.72 8.10 
 
 
8.58 ±0.90 8.62 ±0.57
Solifenacin* 
 
7.08 ±0.55 7.03 ±0.70 7.72 ±0.63 7.73 ±0.92 7.46 ±0.57
Oxybutynin* 
 
8.62 ±0.73 8.17 ±0.90 9.17 
8.2-
9.17 
8.90 ±0.93 7.96 ±0.11
 
Table 3: Published values of antagonist affinities for M1 – M5 subtypes.  Data presented 
as mean ± SEM (Chess-Williams et al., 2001; Dorje et al., 1991; Eglen et al., 2001; Eglen et 
al., 2000; Hegde et al., 1997; Moriya et al., 1999; Sellers et al., 2000b; Wallis et al., 1999; 
Wang et al., 1995; Watson et al., 1999). The mean affinity value given in the table was 
derived from the quoted affinity estimates (pKB or PKi), the range reflects both the lowest 
and highest affinity estimate at a given receptor subtype from the literature.  Functional data 
is limited for some drugs, and those denoted with an “*” are from radioligand binding data to 
human receptors expressed in CHO cells and are sourced from (Wuest et al., 2006, Mansfield 
et al., 2009, Mansfield et al., 2005, Nilvebrant et al., 1997, Ohtake et al., 2007). 
 
  
 Page | 109 
α-adrenoceptor antagonists 
 
Antagonist 
α1A α1B α1D 
mean range mean range mean range 
BMY7378 6.5 6.1- 7.1 6.9 6.2- 7.4 8.9 8.2- 10.5 
Prazosin 9.3 8.8– 9.9 9.6 9.0- 10.0 9.6 9.4- 10.2 
RS100329 9.6 9.6– 9.7 7.8 7.5- 8.0 7.9 7.9- 8.0 
RS17053 9.4 9.3- 9.5 7.6 7.2- 8.0 7.4 7.1- 7.8 
 
Table 4: Published values of antagonist affinities for α-adrenoceptor subtypes from 
both functional and binding studies (Michel & Insel, 1994; Burt, Chapple & Marshall, 1995; 
Goetz et al., 1995; Kenny, Chalmers, Philpott & Naylor, 1995; Buckner et al., 1996; 
Marshall, Burt, Green, Hussain & Chapple, 1996; Ford et al., 1997; Noble et al., 1997; 
Langer, 1999; Williams et al., 1999; Mackenzie, Daly, Pediani & McGrath, 2000, Bagot, K, 
Thesis 2005). Data presented as mean ± SEM. 
 
β-adrenoceptor antagonists 
 
Antagonist 
β1 β2 Β3 
mean range mean range mean range 
ICI118551 6.81 6.15-7.38 8.68 8.34-9.22 5.45 5.1-5.8 
CGP20712A 8.8 8.48-9.30 5.29 4.4-5.82 < 4 < 4 
SR59230A 6.39 (pIC50) 6.19 (pIC50) 8.7 8.6-8.8 
Propanolol 8.76 8.4-9.0 8.83 8.13-9.20 6.14 5.8-7.02 
 
Table 5: Published values of antagonist affinities for β1- β3 subtypes (Bylund and 
Larry, 2009, Bylund et al., 2007b, Bylund et al., 2007c, Bylund et al., 2007a, Louis et al., 
1999, Bylund et al., 1994, Yamanishi et al., 2002b, Candelore et al., 1999, Alexander et al., 
2011).  The mean affinity value given in the table was derived from the quoted affinity 
estimates (pKB or PKi), the range reflects both the lowest and highest affinity estimate at a 
given receptor subtype from the literature.  Data presented as mean ± SEM. 
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3.1.2  Real-time quantitative PCR analysis 
 
Polymerase Chain Reaction is the optimal method used in laboratories to amplify strands of 
actively transcribed DNA.  Current technologies utilise Real-Time PCR which allows 
accurate rates of DNA amplification.  The enzyme DNA polymerase commences 
amplification and replication of activated DNA strands in live cells.  In the laboratory, for 
PCR to replicate this process, the enzyme requires specific primers to be bound to the DNA.  
These are called the forward primers (5’).  Replication also occurs on the complimentary 
strand of DNA, where the reverse primer (3’) binds.  At suitable conditions, primers can be 
designed for specific genes and will bind effectively to DNA at the forward 5’ end and the 
reverse 3’ end of a targeted gene. 
 
Expressed genes in a tissue require encoding from messenger RNA (mRNA).  Rather than 
amplify an entire DNA strand, specific genes can be identified through extracting this mRNA 
from a tissue.  The mRNA is then used to synthesise a section of complementary DNA 
(cDNA), which can be amplified in the laboratory using PCR. Each PCR cycle exponentially 
amplifies a targeted region of cDNA.  This non-linear increase in the quantities of DNA after 
each cycle means that conventional methods of PCR are unable to quantify the relative 
expressions of each gene (Kainz, 2000, Sambrook, 1989).  New technologies have been 
developed which not only allow basic quantification, but which can also indicate the ratio of 
expression between genes in each cDNA sample (Klein, 2002). This contemporary method of 
Real-Time PCR allows the researcher to identify at which PCR cycle the targeted gene 
becomes amplified in a linear way, which is referred to as the Cycle Threshold (CT) value 
(Ginzinger, 2002).  On the logarithmic linear scale, each increase in the CT value is 
indicative of a doubling in the concentration of the targeted gene.  In processing this data, an 
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absolute PCR analysis is completed, which allows for the determination of the abundance of 
a particular gene in respect to others in the same sample of cDNA. 
 
The expression and relative abundance of the adrenoceptors in the pig urothelium is currently 
unknown.  Analysis of the porcine receptors through mRNA analysis was focussed on 
ascertaining which genes were present in this tissue, and detecting their abundance relative to 
the housekeeping gene β-actin using Real-Time Quantitative PCR (Q-PCR) analysis.  Special 
attention was drawn to select an appropriate housekeeping gene for porcine tissue, and to 
determine accordingly, the levels of expression of the alpha and beta adrenoceptors following 
the optimisation of all PCR parameters for each gene of interest. 
 
3.1.3  Optimal conditions for the extraction and assessment of total RNA from 
 porcine bladder tissue. 
 
Extraction of total RNA from bladder urothelium and lamina propria sections: 
 
The process outlined in the methods section of this thesis (Real-Time Quantitative PCR 
Analysis) was analysed to determine the quantity, purity, integrity and size distribution of the 
RNA samples extracted. 
 
NanoDrop 1000 Spectrophotometer (Thermo Scientific) was used to measure the total RNA 
quantity and to assess the purity. RNA concentrations and 260/280 ratios are tabulated in 
Table 6.  
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Table 6: Nanodrop recordings for each RNA sample 
RNA 
Sample 
A260 A280 Ratio 
260/280 
Ratio 
260/230 
ng/µL 
1 15.06 7.327 2.06 1.41 602.38 
2 17.479 8.316 2.10 2.18 699.17 
3 26.253 12.646 2.08 2.22 1050.11 
4 15.504 7.408 2.09 2.20 620.16 
5 20.577 9.818 2.10 2.21 823.10 
6 14.747 6.974 2.11 2.09 589.88 
 
To further demonstrate the quality of the extracted RNA, a gel electrophoresis was run.  
Across all samples of bladder urothelium and lamina propria (1 - 6), the 28s band was higher 
in intensity compared to the 18s band (Figure 3-1).  This demonstrates a good integrity of the 
large molecules of RNA with no significant degradation.  All bands appear sharp and none 
have significantly started to smear towards the smaller sized RNA.  This demonstrates that 
the procedure used to extract RNA from the bladder was effective in isolating high-integrity 
samples.  The RNA was taken from the vials stored at minus 80, and as a result, the bands in 
Figure 3-1 also demonstrate that the sample has not undergone any major degradation during 
the freeze-thaw processing prior to experimentation. 
 
 
Figure 3-1: RNA integrity shown in a 2% formaldehyde agarose gel.  Across all 6 samples 
the RNA extracted from the urothelium and lamina propria demonstrated high intensities of 
both the 28s band and the 18s band.  The clear visibility and clarity of both bands 
demonstrates a good integrity of the RNA, with minimal degradation. 
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Selection of a housekeeping gene for porcine adrenoceptors 
 
In order to determine the expression levels of adrenoceptors in porcine bladder 
urothelium/lamina propria, it is necessary for the QPCR analysis and interpretation of results 
to compare the real time PCR cycle thresholds of candidate genes with a common, known 
gene.  It is thus important to determine an optimum reference gene which can be used to 
normalise variations within individual adrenoceptor genes.  Quantification of the mRNA of 
the target and the housekeeping gene in a sample ensures that changes in transcript levels will 
influence both genes equally.  Identification of a viable reference gene was therefore carried 
out to ultimately obtain a stable, equivalent expression in all porcine bladder RNA samples.  
Two genes, 18S, and β-actin are commonly used for normalization purposes in many 
expression studies. However, transcript levels of these genes are known to vary between 
different types of animal, tissue (normal and pathological samples) and under different 
treatment conditions (drugs and chemicals).  Analysis of the PCR product of these genes has 
been undertaken to assist in identifying the correct gene for use in porcine bladder tissue. 
 
18S RNA primer analysis 
 
A common housekeeping gene for QPCR analysis is 18S ribosomal RNA  (Derks et al., 
2008).  This ribosomal subunit is consistently used as a standard when identifying levels of 
expression and the integrity of samples.  In comparison to other housekeeping genes, these 
ribosomal 18S subunits show the most consistent steady-state expression levels (Sturzenbaum 
and Kille, 2001).  Realtime PCR of 18S across all cDNA samples is shown in Figure 3-2 
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Figure 3-2: (a) PCR cycling graph showing evidence for a high expression of 18S RNA in 
urothelial tissues (n = 6 tissues, each run in duplicate).  (b) Melt curve analysis demonstrating 
homogenous PCR size amplification of the 18S gene. 
 
  
β-actin primer analysis 
 
β-actin is one of the major components in cytoplasmic microfilaments in eukaryotic cells, and 
plays important roles in a range of cell cytoskeleton functions.  Functional processes 
involving β-actin include phagocytosis, cytoplasmic streaming, cell division and alterations 
to cell shape (Romans et al., 1985, Kusakabe, 1997).  Every organism possesses a range 
(usually three to four) of actin isoforms and the total actin content can vary with cell 
conditions, pathologies and muscle type (Drew and Murphy, 1997).  Nonetheless, actin is 
widely used as a housekeeping gene, and β-actin has been used in a range of different QPCR  
studies where it has generally exhibited good housekeeping gene characteristics (Raff et al., 
1997).  Realtime PCR of β-actin across all cDNA samples is shown in Figure 3-3.  End-point 
PCR have been run through agarose gel electrophoresis and a QIAxcel to rule out the 
presence of any additional discrete extra bands (Figure 3-4, Figure 3-5). 
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Figure 3-3: (a) PCR cycling graph showing the exponential increases in fluorescence for 
the β-actin gene.  This gene was highly prevalent in all samples of urothelial tissues (n = 6 
tissues, each run in duplicate). (b) Melt curve analysis demonstrated specific amplicons of the 
same size. 
 
 
                       
 
Figure 3-4: Gel showing the fragment sizes of the 6 cDNA samples after binding with the 
β-actin gene (amplicon size: 144 bp). 
  
ladder cDNA:  1     2     3     4     5      6    ladder 
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Figure 3-5: Digital electropherograms from a QIAxcel system of the 6 PCR fragments of 
β-actin from urothelial/lamina propria cDNA. 
 
 
Comparison of suitable housekeeping genes between β-actin and 18s RNA genes for QPCR 
analysis of porcine samples: 
 
18S RNA is highly prevalent across all tissues as the average cycle threshold was 11.18.  β-
actin, however, appeared to commence an exponential increase later than the 18S gene, with 
its average cycle threshold at 21.15.  This value was a closer match to the targeted values.  In 
addition, the primers designed for β-actin showed a high affinity with the cDNA during PCR.  
As a result, β-actin was chosen as a suitable housekeeping gene with which to compare the 
adrenoceptor results. 
 
 
 
 
 
                    Ladder    1       2       3       4        5        6 
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3.1.4  Optimising conditions for real-time quantitative polymerase chain reaction of
  porcine adrenoceptors 
 
Preliminary experiments were performed on each targeted gene to identify the optimal 
conditions for the expression.  Table 7 identifies individual optimal PCR conditions for each 
gene expression. 
 
Table 7: Optimal PCR parameters found for each individual gene 
 
Gene Preheat Denaturing Annealing Extension Cycles 
ADRA1A 94°C 4min 95°C 30sec 60°C 30sec 72°C 30sec 45 
ADRA1B 94°C 4min 95°C 30sec 60°C 30sec 72°C 30sec 45 
ADRA1D 94°C 4min 95°C 30sec 60°C 30sec 72°C 30sec 45 
ADRB1 94°C 4min 95°C 30sec 60°C 30sec 72°C 30sec 45 
ADRB2 94°C 4min 95°C 30sec 60°C 15sec 72°C 15sec 45 
ADRB3 94°C 4min 95°C 30sec 51°C 15sec 72°C 15sec 40 
ACTB 94°C 4min 95°C 30sec 60°C 30sec 72°C 30sec 45 
18S RNA 94°C 4min 95°C 30sec 60°C 30sec 72°C 30sec 45 
 
 
3.1.5 Determination of an optimal β3-adrenoceptor primer set quantitative real time PCR 
using porcine cDNA 
 
Throughout initial PCR parameters, the custom designed β3-adrenoceptor primer sequence 
exhibited poor binding to the gene with unsatisfactory PCR results.  However, other sets of 
primers demonstrated the β3-adrenoceptor gene in porcine urothelium/lamina propria mRNA.  
Further optimisation was completed on this tissue such as altering the dilution factor of 
cDNA templates; the volume of cDNA in the PCR tubes; the annealing and extension PCR 
temperatures; and more specific sets of primers.  These methods contributed to obtaining the 
optimal real-time PCR parameters for each gene.  In addition, alternate primers were also 
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assessed on this gene.  Although the β3-adrenoceptor mRNA expression has not yet been 
successfully completed in the porcine urothelium and lamina propria, a recent publication has 
determined the levels of β-adrenoceptors in human bladders (Otsuka et al., 2008).  The β3 
oligonucleotide sequence in porcine is not fully known yet the sequence of the gene in human 
urinary bladder is roughly 98% similar.  It was hypothesised that the ADRB3 oligonucleotide 
primers designed through the ADRB3 human sequence (GeneBank accession Number 
NM_000025) may bind with similar affinity to the porcine gene and provide satisfactory PCR 
amplification (Table 8).  However, upon analysis of the PCR recordings, and the post-PCR 
products (Figure 3-6) the use of this primer was deemed unsuitable in porcine bladder 
analysis of β3-adrenoceptor gene expression by QPCR. 
 
The customised porcine β3-adrenoceptor primers, devised specifically using the porcine 
genome (Table 8), were able to provide a reliable PCR product following various 
optimisation procedures.  Agarose gel electrophoresis demonstrated an increased affinity for 
the primers at lower annealing temperatures and annealing time.  The final optimised settings 
of both time and annealing temperature were 51°C and 15 seconds annealing respectively.  
Extension was set at 72°C for 15 seconds. Optimised final PCR settings provided expected 
sized β3 gene amplification using β3-specific primers (Figure 3-7, nonselective binding is 
indicated with an arrow). 
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Figure 3-6: Melt curve and electropherograms: 
[Left]: Melt curve analysis of the human β3-adrenoceptor expression in porcine tissue. The 
graph shows unspecific melt curve profiling and demonstrates a very poor affinity for primers 
at end product PCR.  These primers were deemed unsuitable for the purpose of this study. 
[Right]: Digital electropherograms from QIAxcel system demonstrating non-specific 
expected size of β3-adrenoceptor amplicons post PCR, demonstrating a poor affinity of the 
human β3-primers screened (Otsuka et al., 2008) on porcine urothelial/lamina propria cDNA. 
 
 
 
Gene Forward Primer Reverse Primer 
ADRB3 
(Porcine) 
5’ AGACTCCAGACCATGACC  3’ 5’ ACAGCTCGCAACAAGTG 3’ 
ADRB3 
(Human) 
5’ GCTCCGTGGCCTCACGAGAA  3’ 5’ CCCAACGGCCAGTGGCCAGTCAGCG 3’ 
 
Table 8: Two types of primers used for analysis of the porcine β3-adrenoceptor.  
ADRB3 (Human, GeneBank accession number NM_000025) was ineffective at providing a 
consistent PCR product with a high affinity.   
  Ladder     1        2        3        5        6 
 Page | 120 
 
Figure 3-7: Melt curves for each β3 gene showing the affinity of primers for the gene 
product. Arrows point on the product of non-desired non-specific amplification. 
 
A: 94°C denat / 30 sec; 60°C annealing / 30 sec; 72°C extension / 30 sec. 
B: 94°C denat / 30 sec; 57°C annealing / 20 sec; 72°C extension / 30 sec. 
C: 94°C denat / 30 sec; 55°C annealing / 20 sec; 72°C extension / 30 sec. 
D: 94°C denat / 30 sec; 51°C annealing / 20 sec; 72°C extension / 30 sec. 
E: 94°C denat / 30 sec; 51°C annealing / 15 sec; 72°C extension / 15 sec. 
E represents the optimal conditions 
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Chapter 4  
 
 
 
 
 
 
 
 
Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic 
receptors in mediating rate responses to stretch and carbachol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The content in the following chapter is presented as the author’s copy of the published 
document, prior to the reviewer and publisher’s requested alterations. The final version of 
this manuscript can be accessed from the relevant peer-reviewed journal. Formatting and 
terminology changes have been made to maintain consistency throughout this thesis 
 
All data presented in this manuscript is the sole work of C. Moro.  
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4.1 ABSTRACT 
 
Objectives:  To investigate the effects of tissue stretch and muscarinic receptor stimulation 
on the spontaneous activity of the urothelium/lamina propria and identify the specific 
receptor subtype mediating these responses. 
Methods:  Isolated strips of porcine urothelium with lamina propria were set up for in vitro 
recording of contractile activity.  Muscarinic receptor subtype selective antagonists were used 
to identify the receptors influencing the contractile rate responses to stretch and stimulation 
with carbachol. 
Results:  Isolated strips of urothelium with lamina propria developed spontaneous 
contractions (3.72 cycles min-1) that were unaffected by tetrodotoxin, L-NNA or 
indomethacin. Carbachol (1 µM) increased the spontaneous contractile rate of these tissue 
strips by 122 ± 27% (P < 0.001).  These responses were significantly depressed in the 
presence of the M3-selective muscarinic antagonist 4-DAMP (10 - 30 nM), but not affected 
by the M1-selective antagonist pirenzepine (30 - 100 nM) or the M2-selective antagonist 
methoctramine (0.1 - 1 µM).  Stretching of the tissue also caused an increase in spontaneous 
contractile rate and these responses were abolished by atropine (1 µM) and low 
concentrations of 4-DAMP (10 nM).  Darifenacin, oxybutynin, tolterodine and solifenacin (1 
µM) all significantly depressed frequency responses to carbachol (1 µM). 
Conclusions:  The urothelium with the lamina propria exhibits a spontaneous contractile 
activity which is increased during stretch.  The mechanism appears to involve endogenous 
acetylcholine release acting on M3 muscarinic receptors.  Anticholinergic drugs used 
clinically depress responses of these tissues and this mechanism may represent an additional 
site of action for these drugs in the treatment of bladder overactivity. 
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4.2 INTRODUCTION 
 
Detrusor overactivity is a common condition affecting up to 17% of the population (Milsom 
et al., 2001).  In this condition spontaneous bladder contractions occur during the filling stage 
of the micturition cycle, but the mechanisms involved are unknown.  Local mechanisms 
appear to be involved since spontaneous contractile activity of isolated tissues has been 
observed (Jiang et al., 2005).  In recent years the urothelium and the underlying lamina 
propria have been recognized as important regulators of bladder activity, releasing factors 
that modulate detrusor contraction (Hawthorn et al., 2000, Templeman et al., 2002b) and 
sensory nerve activity (Cockayne et al., 2000).  Furthermore, these roles may be clinically 
relevant since the inhibitory effect these tissues have on detrusor contraction is depressed in 
the neurogenic overactive bladder (Chess-Williams, 2009), while non-neuronal ATP release 
from this tissue is enhanced in the bladders of patients with painful bladder (sensory) 
syndrome (Kumar et al., 2007).  Thus the urothelium and lamina propria are known to play 
important roles in maintaining normal bladder function and are associated with the 
development of pathological states. 
 
In addition to releasing ATP and other mediators, the urothelium/lamina propria of the pig 
bladder (Sadananda et al., 2008) and the lamina propria of the rabbit urethra (Mattiasson et 
al., 1985a, Zygmunt et al., 1993) display contractile properties and have been shown to 
contract in response to a number of agonists.  It is presently unclear which specific cell types 
mediate contraction, but it has been suggested that interstitial cells may be involved 
(Sadananda et al., 2008).  In addition, it has been reported that spontaneous contractions of 
intact bladder strips may be linked to the urothelium/lamina propria (Akino et al., 2008).  
Also, these tissues from the dome of the pig bladder have been shown to develop spontaneous 
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phasic contractile activity (Moro and Chess Williams, 2010).  Again it is unclear which cell 
types might act to initiate this spontaneous activity, but interstitial cells in the lamina propria 
have been shown to develop spontaneous depolarisations and calcium transients, which may 
suggest a possible pacemaker role (Kanai et al., 2007).  The present study has examined the 
contractile activity of isolated strips of urothelium/lamina propria with the aim of identifying 
the muscarinic receptor subtype responsible for regulating the frequency of spontaneous 
contractions and to investigate the effects of tissue stretch on the spontaneous rate of 
contraction. 
 
4.3 MATERIALS AND METHODS 
 
Fresh bladders from Large-White Landrace pigs (6 months old, 80 Kg) were obtained from a 
local abattoir and immediately immersed in cold Krebs-bicarbonate solution (composition in 
mM: NaCl 188.4, NaHCO3 24.9, CaCl2 1.9, MgSO4 1.15, KCl 4.7, KH2PO4 1.15 and D-
glucose 11.7).  The bladders were opened longitudinally and full thickness strips of anterior 
wall from the dome region were removed.  From these tissues, strips of urothelium including 
the lamina propria were prepared (2 cm x 5 mm).  For smooth muscle experiments detrusor 
strips were examined after removal of the urothelium and lamina propria.  All tissues were 
immersed in Krebs-bicarbonate solution, maintained at 37°C and gassed with 5% CO2 in 
oxygen. 
 
The tissues were attached to isometric force transducers (ADInstruments MCT050/D) and 
tension recorded with a Powerlab system (ADInstruments, Castle Hill, Australia) using 
Labchart v7 software.  After setting to a baseline tension of 2g the tissues were washed 
several times with fresh Krebs solution and allowed to equilibrate for 45 minutes before 
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starting drug additions.  All antagonists were left to incubate for at least 20 minutes in the 
organ baths prior to further agonist additions. In stretch experiments, tissues (with or without 
the selective antagonist) were stretched by increasing the length of the tissue by 75% and the 
spontaneous contractile frequency was recorded before and after stretching. 
 
Measurements of frequency, amplitude and baseline tension were taken at the peak response 
after the addition of each drug or stretching, as detailed in sections 2.1.1 - 2.1.4 of this thesis.  
The frequency of contractions was expressed as the number of phasic waves per minute and 
the amplitude as grams tension.  The baseline tension was taken as the lowest point of the 
spontaneous phasic contractions.  Mean (±SEM) values in the absence and presence of drugs 
were compared using Student’s two-tailed paired t-test with P < 0.05 being taken as 
statistically significant.  Prism software (GraphPad, San Diego, CA, USA) was used for 
statistical analysis of data. 
 
Acetylcholine chloride (Ach), carbamoylcholine chloride (carbachol), α,β-methyleneATP 
lithium (αβmATP), tetrodotoxin (TTX), atropine sulphate, Nw-nitro-L-arginine (L-NNA), 
pirenzepine dihydrochloride, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), 
1,1-Dimethyl-4-phenylpiperazinium iodide (DMPP), methoctramine hemihydrate, 
indomethacin and oxybutynin chloride were purchased from Sigma (St Louis, MO, USA). 
Darifenacin hydrobromide, solifenacin succinate and tolterodine tartrate were gifts from 
Astellas.  Indomethacin was dissolved in 100% ethanol and control experiments were 
performed using vehicle alone.  All other drugs were dissolved in distilled water and diluted 
in Krebs-bicarbonate solution. 
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4.4 RESULTS 
 
4.4.1 Spontaneous phasic contractions 
 
The preparations of urothelium and lamina propria exhibited spontaneous contractions within 
10 minutes of being placed in the organ bath.  This regular phasic activity occurred at a 
spontaneous contractile frequency of 3.72 ± 0.12 cycles min-1 with an amplitude of 0.71 ± 
0.05g (n = 53, Figure 4-1).  The frequency and amplitude of spontaneous contractions, and 
the baseline tension of tissues, were not affected by either tetrodotoxin (1 µM, n = 12), 
demonstrating a lack of neuronal input, indomethacin (5 µM, n = 7), indicating a lack of 
prostanoid activity, L-NNA (100 µM, n = 10) indicating no significant input from nitric 
oxide, or the nicotinic receptor agonist DMPP (100 µM, n = 8).  In contrast to the 
urothelial/lamina propria activity, only 25% of detrusor smooth muscle strips (n = 28) set up 
under identical conditions, developed spontaneous activity and the spontaneous rate of the 
active tissues (1.57 ± 0.20 cycles min-1) was significantly lower than that of the 
urothelium/lamina propria strips (P < 0.001).  
 
4.4.2 Muscarinic receptor stimulation  
 
The frequency of spontaneous urothelium/lamina propria contractions was not affected by 
atropine (1-30 µM, n = 16).  Addition of acetylcholine (1 µM) however, increased the 
frequency by 39 ± 14% (n = 8, P < 0.05).  Carbachol (1 µM) produced a greater increase in 
frequency than acetylcholine (1 µM), increasing the spontaneous rate by 122 ± 27% (Figure 
4-1).  Carbachol (1 µM) also increased the baseline tension by 152 ± 13% (P < 0.001, n = 27) 
and the amplitude of spontaneous phasic contractions was also reduced by 47 ± 4%, (P < 
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0.001, n = 27).  Increases in frequency induced by carbachol (1 µM) were not affected by the 
addition of indomethacin (5 µM) or L-NNA (100 µM). 
 
To identify which muscarinic receptor subtype mediated the increase in urothelium/lamina 
propria spontaneous rate, responses to carbachol (1 µM) were obtained in the presence of 
receptor-selective antagonists (Figure 4-2, Table 3 in Chapter 3 of this Thesis).  The M3-
selective antagonist 4-DAMP (10 nM) had the greatest effect on responses, more than halving 
the carbachol-induced (1 µM) increase in frequency from 83 ± 21% to 35 ± 8% (P < 0.01 n = 
12).  A higher concentration of 4-DAMP (30 nM) further depressed responses to carbachol (1 
µM, 18 ± 4%, n = 8).  The M1-receptor selective antagonist pirenzepine at concentrations up 
to 100 nM had no significant affect on the responses to carbachol (n = 12).  At a 
concentration of 100 nM (n = 9) the M2-receptor selective antagonist methoctramine had no 
effects on the frequency or tension responses to carbachol, but at a higher concentration (1 
µM, n = 8) it reduced the tension response without significantly affecting the 
urothelium/lamina propria frequency response (Figure 4-2). 
 
4.4.3 The effect of clinical anticholinergics on the muscarinic response to carbachol 
 
At a concentration of 100 nM darifenacin, oxybutynin, and tolterodine significantly reduced 
the frequency and tension responses of urothelium/lamina propria strips to carbachol (1 µM).  
Solifenacin (100 nM) slightly inhibited the response to carbachol, although this was not 
statistically significant at this concentration.  At a concentration of 1 µM all four antagonists 
significantly depressed the urothelium/lamina propria frequency and tension responses to 
carbachol (Figure 4-3). 
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4.4.4 Urothelium/lamina propria frequency responses to stretch  
 
In separate experiments, stretching the urothelium/lamina propria strips elicited an increase in 
the rate of spontaneous phasic contractions of 19 ± 3% (P < 0.001) and baseline tension also 
increased from 1.75 ± 0.12g to 9.58 ± 0.80g (P < 0.001, n = 42).  The increase in frequency 
of phasic contractions induced by stretch was not significantly altered after desensitisation of 
P2X receptors with αβmATP (10 µM, n = 12), the presence of the NOS inhibitor L-NNA (100 
µM, n = 7) or the cyclooxygenase inhibitor indomethacin (5 µM, n = 12).  However the 
stretch-induced increase in frequency was abolished by atropine (1 µM, n = 11, P < 0.01, 
Figure 4-4), indicating the involvement of muscarinic receptors.  To identify which receptor 
mediated this response, the frequency response to stretch was examined in the presence of 
selective antagonists (Figure 4-4).  In the presence of 4-DAMP (10 nM, n = 7) the increase in 
frequency observed during stretch was abolished.  In contrast, pirenzepine (100 nM, n = 7) 
and methoctramine (100 nM, n = 8) had no effect on the stretch-induced increase in phasic 
contractions. 
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Figure 4-1: Spontaneous activity of isolated urothelium/lamina propria strips; upper trace 
in the absence of any drug and lower trace in the presence of carbachol (1 µM).  Carbachol 
induced increases in baseline tension, but also increased the frequency of spontaneous 
contractions. 
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Figure 4-2: Increases in urothelium/lamina propria contractile frequency induced by 
carbachol (1 µM).  Responses were obtained to carbachol in the absence (open columns) and 
in the presence of antagonists (shaded columns).  Upper panels show changes in frequency 
(cycles min-1) and baseline tension (grams) to carbachol in the absence and presence of 30 
nM and 100 nM pirenzepine (M1 selective antagonist); middle panels show the effects of 100 
nM and 1 µM methoctramine (M2 selective antagonist) and lower panels show the effects of 
10 nM and 30 nM 4-DAMP (M3 selective antagonist). *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 4-3: Effects of clinically used anti-muscarinic drugs on frequency (left panels) and 
tension responses (right panels) of isolated urothelium/lamina propria strips to carbachol (1 
µM).  Increases in urothelial frequency (cycles min-1) and tension (grams) induced by 
carbachol are shown in the absence (open columns) and in the presence of antagonists 
(shaded columns) at concentrations of 100 nM (upper panels) and 1 µM (lower panels).  *P < 
0.05, **P < 0.01, ***P < 0.001. 
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Figure 4-4: Upper panels: Effects of muscarinic receptor subtype selective antagonists on 
the frequency responses of urothelium/lamina propria strips to stretch.  Lower panels: 
Increases in the frequency of spontaneous contractions of isolated strips of urothelium/lamina 
propria when stretched in the absence (open columns) and presence (shaded columns) of 
atropine (1 µM), α,β-methylene ATP (10 µM), L-NNA (100 µM) or indomethacin (5 µM).  
Responses are expressed as the percentage increase in frequency induced by stretch compared 
to those in the absence of any drug.  The spontaneous frequency before (open columns) and 
after stretching (solid columns) was obtained in the absence and then presence of either 
pirenzepine (M1-selective), methoctramine (M2-selective) or 4-DAMP (M3-selective).  
Stretching significantly increased the frequency of spontaneous urothelium/lamina propria 
contractions in all groups, except in the presence of 4-DAMP *P < 0.05, **P < 0.01. 
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4.5 DISCUSSION 
 
Contraction of the lamina propria was first reported for tissues from the urethra of the rabbit 
(Mattiasson et al., 1985a, Zygmunt et al., 1993) where a number of agonists and electrical 
field stimulation were shown to induce contractions.  In a recent study our laboratory showed 
that isolated strips of urothelium/lamina propria from the pig bladder dome can also contract 
in response to neurokinin-A and muscarinic receptor stimulation, the responses to neurokinin-
A being mediated via NK2 receptors (Sadananda et al., 2008).  These tissues from the dome 
of the bladder rarely develop spontaneous phasic contractions.  This spontaneous activity was 
observed in all urothelium/lamina propria preparations but was generally absent in detrusor 
muscle strips, with only 25% of detrusor strips demonstrating any spontaneous contractile 
activity.  Furthermore, in detrusor strips that did display this phenomenon, the rate of 
spontaneous contractions was significantly slower than that of the urothelium/lamina propria.  
The activity was insensitive to tetrodotoxin, which makes it unlikely to be neuronally 
mediated.  Whether the spontaneous activity originates in the smooth muscle or from another 
cell type is not clear.  A network of interstitial cells exists in the lamina propria and it has 
been suggested that these cells are similar to the Interstitial Cells of Cajal which act as 
pacemakers of electrical and contractile activity in the gastrointestinal system (Fry et al., 
2007, Ikeda et al., 2009, Ward and Sanders, 2001).  Electrophysiological studies have shown 
that the interstitial cells of the bladder lamina propria may develop spontaneous intracellular 
calcium and membrane potential transients and can function as a syncitium (Fry et al., 2007).  
The present results suggest that this cellular activity may be involved, and is potentially 
translated into contractile activity at an intact tissue level resulting in spontaneous phasic 
contractions, the frequency of which was increased by carbachol.  Of interest is the report 
that the frequency of transient calcium and membrane potential changes in bladder interstitial 
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cells is also increased during muscarinic receptor stimulation (Fry et al., 2007).  In some 
tissues activation of muscarinic receptors stimulates the production of prostaglandins (Hara et 
al., 2009) or nitric oxide (Andersson et al., 2008), however the urothelium/lamina propria 
contractile responses to carbachol were insensitive to indomethacin and L-NNA. 
 
The detrusor smooth muscle possesses a mixed population of M2 and M3 muscarinic 
receptors, with a M2:M3 ratio of about 3:1 in most species (Yamanishi et al., 2002a, Chess-
Williams, 2002a).  However the responses of isolated detrusor strips to muscarinic agonists 
are mediated via the minor population of M3 receptors (Sellers et al., 2000b, Chess-Williams 
et al., 2001, Fetscher et al., 2002).  A similar result was obtained in the urothelium and 
lamina propria.  Molecular biology and radioligand binding studies indicate that M2 receptors 
predominate at the mRNA and protein level in this tissue (Mansfield et al., 2005, Bschleipfer 
et al., 2007), but frequency responses to carbachol were significantly reduced by the M3 
selective antagonist 4-DAMP.  The M1 selective antagonist pirenzepine had no effect on 
responses, whilst the M2 selective antagonist methoctramine, had no effect at lower 
concentrations and even at 1 µM only had a minor effect on tension but not frequency 
responses.  This effect of methoctramine on tension responses to carbachol would be due to a 
lack of selectivity for this antagonist at the higher concentration resulting in M3 receptor 
antagonism with the 1 µM concentration.  In contrast, 4-DAMP significantly reduced 
frequency and tension responses to carbachol at a very low concentration (10 nM), indicating 
the increase in the rate of phasic spontaneous contractions of the urothelium/lamina propria to 
carbachol was mediated via the M3 receptor subtype. 
 
The relevance of the spontaneous contractile activity is unknown.  Detrusor overactivity 
results from involuntary contractions demonstrated by cystometry during the filling stage 
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where the bladder, including the urothelium, undergoes periods of stretch.  Thus it is possible 
that the contractile pacemaker activity in the urothelium/lamina propria may be activated 
during stretch and may possibly then drive contractions of the detrusor.  To investigate this 
possibility, we examined the effects of stretching the tissues and found that the frequency of 
the phasic contractile activity was increased.  This effect could be direct on the cells initiating 
the phasic contractions; whether smooth muscle, interstitial cells, or another cell type 
sensitive to stretch; or the activity might be driven by factors being released from the 
urothelium/lamina propria during stretch. 
 
To examine the latter hypothesis, a number of factors known to be released from the 
urothelium during stretch were investigated including ATP, acetylcholine (Ach) and nitric 
oxide (Birder et al., 2010b, Smith et al., 2008).  Although NO is usually inhibitory, there is 
evidence to suggest that it can exert excitatory effects in the bladder (Gillespie and Drake, 
2004).  Stretching tissues resulted in an increase in the frequency of phasic contractions, but 
this was not altered in the presence of L-NNA.  Furthermore, desensitising P2X purinergic 
receptors with α,β-methyleneATP had no effect on the stretch-induced responses, whereas 
atropine completely abolished the frequency response to stretch indicating that Ach released 
from the urothelium/lamina propria was responsible for the stretch-induced increases in 
spontaneous rate.  In support of this, 4-DAMP depressed these responses, whilst 
methoctramine and pirenzipine failed to affect frequency responses to stretch, again 
indicating that responses were mediated via the M3 receptor subtype.  Thus, stretch appears to 
induce the release of Ach from the urothelium/lamina propria which then activates M3 
receptors on the cells initiating the spontaneous contractile activity. 
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There is some evidence to suggest that this activity in the urothelium/lamina propria may be 
able to drive detrusor smooth muscle activity.  Firstly, electrophysiological studies in the rat 
have shown that the calcium and membrane potential transients produced by carbachol begin 
near the urothelial-lamina propria interface before spreading to the detrusor (Zygmunt et al., 
1993).  Secondly, when bladder sheets were examined, spontaneous contractions were greater 
in bladder tissue with an intact urothelium/lamina propria (Sui et al., 2008).  Finally, the 
increased contractions recorded in the bladders of cats with feline cystitis have been shown to 
be associated with enhanced calcium transients and supersensitivity to muscarinic stimulation 
in the urothelium/lamina propria (Ikeda et al., 2009).  Thus, it appears possible that 
spontaneously active cells in the lamina propria may be able to drive detrusor contractions, at 
least in the overactive bladder where gap junctions are increased (Roosen et al., 2009).  
Future studies will be required to test this hypothesis. 
 
Currently, the main treatments for overactive bladder are muscarinic antagonists.  The exact 
clinical mechanisms of action for these drugs is unclear, however this study has shown that 
these drugs will antagonise the muscarinic receptors on the cells regulating 
urothelium/lamina propria contractile activity, thus preventing these actions of acetylcholine 
released during stretch.  Tolterodine, solifenacin, darifenacin and oxybutynin all depressed 
the increases in urothelium/lamina propria frequency and tension induced by carbachol. Thus, 
the responses of the urothelium/lamina propria may represent another possible site of action 
for these clinically effective anti-muscarinic agents. 
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4.6 CONCLUSIONS 
 
The urothelium/lamina propria exhibits spontaneous phasic contractile activity which is 
increased during stretch.  The mechanism appears to involve acetylcholine and M3 
muscarinic receptors.  Anticholinergic drugs used clinically depressed these responses and 
this mechanism may represent an additional site of action for these drugs in the treatment of 
bladder overactivity. 
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Chapter 5  
 
 
 
 
 
Contractile activity of the bladder urothelium/lamina propria and its regulation 
by nitric oxide 
 
 
 
 
 
 
 
 
 
 
The manuscript in the following chapter is presented as a pre-publication copy, prior to the 
reviewer and publisher’s requested alterations. The final version of this manuscript can be 
accessed online from the journal. Formatting and terminology changes have been made to 
maintain consistency throughout this thesis. 
 
All data presented in this manuscript is the sole work of C. Moro  
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5.1 ABSTRACT 
 
In the bladder, nitric oxide (NO) is released from neuronal and non-neuronal sources, but its 
actions are unclear.  Strips of urothelium plus lamina propria contract in response to agonists 
and develop spontaneous phasic contractions, and the aim of this study was to investigate the 
influence of NO on this activity.  Isolated strips of urothelium/lamina propria from porcine 
bladder developed spontaneous contractions (3.54 ± 0.30 cycles min-1) and contracted in 
response to carbachol and electrical field stimulation (EFS).  The NO synthase inhibitor Nω-
nitro-L-arginine (L-NNA, 100 µM) had no effects on the tissues, but the NO donors 
diethylamine NONOate (DEANO, 100 µM) and nitroprusside (10 µM) caused relaxation, 
slowed the spontaneous rate of contractions and inhibited responses to carbachol.  Maximum 
tonic contractions to carbachol were reduced by 17 ± 4% (P < 0.001) and 35 ± 5% (P < 
0.001) by DEANO and nitroprusside respectively and the potency of carbachol was also 
reduced.  Carbachol also increased the spontaneous frequency of contraction and these rate 
responses were again inhibited by DEANO and nitroprusside, but unaffected by L-NNA.  
Similarly, responses to EFS were significantly depressed (52 - 70%) by DEANO (P < 0.05), 
but were unaffected by L-NNA.  These data demonstrate spontaneous contractile activity and 
also nerve and agonist-induced tonic contractile activity within the urothelium and lamina 
propria.  This activity is sensitive to depression by NO, but NO does not appear to be 
spontaneously released to influence this activity, nor does it appear to be released by 
muscarinic receptor stimulation.  However, the results suggest that in situations where NO 
production is increased, NO can influence the contractile activity of this tissue. 
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5.2 INTRODUCTION 
 
Nitric oxide (NO) plays a major role in the bladder outlet region during micturition, inducing 
relaxation and preventing large increases in intravesical pressure during bladder contraction 
(Bustamante et al., 2010).  Nitric oxide is also produced in the bladder body itself, although 
its role in this region of the bladder is less clear.  Neuronal NO synthase (nNOS) has been 
identified in the nitrergic nerves of the lamina propria in the human bladder and also between 
smooth muscle cells (Fathian-Sabet et al., 2001).  Along with acetylcholine, NO is released as 
a co-transmitter from parasympathetic nerves and exerts an inhibitory effect on contraction 
(Dokita et al., 1991).  Thus in electrical field stimulated (EFS) tissues, inhibition of NO 
synthase enhances contraction amplitude (Garcia-Pascual et al., 1991), while in precontracted 
tissues, NO donors induce relaxation (Hernandez et al., 2008).  However the influence of NO 
on detrusor contraction is relatively minor compared with its actions on the bladder outlet 
region (Kedia et al., 2009). 
 
Recently the urothelium and underlying lamina propria (urothelium/lamina propria) have 
been shown to be alternative sources of NO in the bladder.  Endothelial NO synthase (eNOS) 
has been identified using immunohistochemistry in the urothelium of the rat (Giglio et al., 
2005) and adrenergic stimulation has been shown to release NO from urothelial cells in 
culture (Birder et al., 1998).  Furthermore, extra-neuronal nNOS has been found in the 
urothelium and the interstitial cells of the lamina propria (De Ridder et al., 1999).  The 
function of this non-neuronal NO is uncertain, but it may play a role in modulating sensory 
nerve activity (Aizawa et al., 2011).  Other targets of NO action in the bladder have been 
identified using cGMP immunoreactivity and include detrusor, epithelial and interstitial cells 
(Fathian-Sabet et al., 2001, Gillespie et al., 2006a).  Although the vast majority of reports 
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concerning NO have indicated that it has an inhibitory effect on bladder smooth muscle, there 
is also some evidence to suggest that NO can exert excitatory effects.  In the isolated mouse 
bladder it has been shown that NO can increase phasic contractile activity (Gillespie and 
Drake, 2004) and in pre-contracted human detrusor strips both relaxation and contraction 
responses to NO donors have been observed (Moon, 2002).  Thus, NO is produced within the 
bladder wall, but its actions and role in bladder function remain unclear.   
 
In addition to contraction of the detrusor smooth muscle, isolated strips of urothelium (inner 
epithelial layer of the bladder) and underlying lamina propria from the dome of the pig 
bladder (Sadananda et al., 2008) and also strips of lamina propria from the rabbit urethra have 
previously been shown to contract to agonists (Mattiasson et al., 1985a).  These tissues, 
urothelium/lamina propria, from the dome of the pig bladder also spontaneously develop 
phasic contractile activity (Moro and Chess-Williams, 2010).  The aims of the present study 
were to investigate whether NO has inhibitory or excitatory effects on this tissue.  The effects 
of NO donors and a NO synthase inhibitor were examined on frequency and tension 
responses of strips of porcine urothelium/lamina propria. 
 
5.3 MATERIALS AND METHODS 
 
5.3.1  Tissue preparation 
 
Fresh pig bladders from pigs (5 - 6 months age, ~50 kg) were obtained from a local abattoir 
and immediately immersed in Krebs-bicarbonate solution composed of NaCl (188.4 mM), 
NaHCO3 (24.9 mM), CaCl2 (1.9 mM), MgSO4 (1.2 mM), KH2PO4 (1.2 mM) and glucose 
(11.7 mM).  The bladder was opened longitudinally and strips of urothelium plus lamina 
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propria (20 x 5 mm) were dissected from the anterior wall of the dome of the bladder.  The 
urothelium/lamina propria is easily recognised in the pig bladder, being pale in colour 
compared to the underlying detrusor smooth muscle.  The strips of tissue were set up under 
2g tension in baths containing Krebs-bicarbonate solution at 37°C and gassed with 5% CO2 
in oxygen.  Isometric tension developed by tissues was recorded to PC via a Powerlab 
recording system and Labchart software (AdInstruments, Castle Hill, Australia).   
 
5.3.2  Contractile responses to electrical field stimulation 
 
Preliminary experiments indicated that the optimal stimulation parameters for tissue strips 
was 5 second trains of pulses (0.5 ms duration, 30v) applied every 100 seconds.  Two 
stimulation frequencies (10 and 20 Hz) were examined and the neurotoxin tetrodotoxin (1 
µM) was used to confirm the neurogenic origin of contractions.  Responses to electrical 
stimulation at both frequencies were recorded before and after the addition of either Nω-nitro-
L-arginine (L-NNA, 100 µM), diethylamine NONOate (DEANO, 100 µM) or sodium 
nitroprusside (10 µM). 
 
5.3.3 Frequency responses to carbachol 
 
To investigate the influence of NO on muscarinic receptor mediated rate responses, separate 
groups of tissues were stimulated with a single concentration of carbachol (1 µM) and 
responses re-examined in the presence of either L-NNA (100 µM), DEANO (100 µM) or 
sodium nitroprusside (10 µM). 
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5.3.4 Contractile responses to carbachol 
 
Complete cumulative concentration-response curves to carbachol were obtained for tonic 
contractile responses.  After washout of the drug, concentration-response curves to carbachol 
were repeated in the presence of either L-NNA (100 µM), DEANO (100 µM) or sodium 
nitroprusside (10 µM).  Control experiments were performed without the addition of NO 
synthase inhibitor or NO donor and these experiments were used to correct for any time-
dependent changes in tissue sensitivity or responsiveness during the course of the experiment. 
 
5.3.5 Drugs 
 
Carbamoylcholine chloride (carbachol), diethylamine NONOate (DEANO), Nω-nitro-L-
arginine (L-NNA), sodium nitroprusside and tetrodotoxin were purchased from Sigma-
Aldrich Co. (St. Louis, MO). 
 
5.3.6 Data analysis 
 
Graphpad PRISM software was used for statistical analyses. Mean (±S.E.M.) increases in 
tension in grams and increases in spontaneous phasic contractions in cycles min-1were 
calculated.  Where complete concentration-response curves were obtained, mean (±S.E.M.) 
maximum responses and -logEC50 (pEC50) values were calculated.  Student’s paired t-tests 
were used to compare responses obtained in the absence and presence of NO synthase 
inhibitor or NO donors.  
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5.4 RESULTS 
 
5.4.1 Spontaneous tissue activity 
 
Within 10 min of being set up in the baths, the isolated strips of urothelium/lamina propria 
spontaneously developed phasic contractile activity.  The contractions occurred with a 
frequency of 3.54 ± 0.26 cycles min-1, a baseline tension of 1.99 ± 0.09g and an amplitude of 
0.73 ± 0.07g (n = 59).  The addition of the NO synthase inhibitor L-NNA (100 µM) alone had 
no effect on these resting values.  In contrast, both the NO donors, DEANO (Figure 5-1) and 
nitroprusside, exerted significant inhibitory effects on the tissues. When applied to 
unstimulated tissues, DEANO (100 µM, n = 17) caused relaxation of the urothelial strips by 
40 ± 6% (P < 0.001) and slowed spontaneous phasic contractions by 58 ± 11% (P < 0.001).  
The amplitude of phasic contractions was also reduced by 39 ± 10% (P < 0.01).   
Nitroprusside (10 µM, n = 9) had a similar effect, relaxing the tissues by 32 ± 5% (P < 0.001) 
and slowing the rate of spontaneous contractions by 35 ± 14% (P < 0.05), but without 
significantly reducing the amplitude of spontaneous contraction (Figure 5-2). 
 
5.4.2 Responses to carbachol 
 
Carbachol (1 µM) induced tonic contractions with the basal tension increasing by 4.49 ± 
0.86g (n = 23).  The frequency of spontaneous phasic contractions was also increased by 3.41 
± 0.29 cycles min-1 (P < 0.001).  The addition of L-NNA alone had no effect on resting 
values and the NO synthase inhibitor also failed to influence subsequent responses to 
carbachol.  Increases in basal tension and spontaneous rate induced by carbachol (1 µM) in 
the presence of L-NNA (100 µM, n = 7) were similar to paired controls (Figure 5-3). The 
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addition of DEANO significantly inhibited responses to carbachol.  In the presence of 
DEANO (100 µM) both the frequency responses and the baseline tension responses to 
carbachol (1 µM) were significantly reduced (both P < 0.001, n = 20).  Similarly, 
nitroprusside inhibited the increases in frequency and tension induced by carbachol (Figure 5-
3). 
 
5.4.3 Carbachol concentration-contraction curves 
 
For contractile responses it was possible to obtain complete concentration-response curves to 
carbachol and the effects of L-NNA (100 µM), DEANO (100 µM) and nitroprusside (10 µM) 
could be investigated (Figure 5-4).  As with the experiments using a single concentration of 
carbachol, L-NNA (100 µM) was without effect and concentration-response curves in the 
absence and presence of L-NNA were identical.  Again, both DEANO and nitroprusside 
exerted significant inhibitory effects.  The potency (pEC50 value) of carbachol was reduced 
from 6.18 ± 0.08 to 4.95 ± 0.06 in the presence of DEANO (100 µM, n = 8, P < 0.001) and 
from 5.91 ± 0.04 to 5.11 ± 0.03 by nitroprusside (10 µM, n = 8, P < 0.001).   Both drugs 
significantly reduced the maximum contractile responses to carbachol, DEANO by 17 ± 4% 
(n = 8, P < 0.001), and nitroprusside by 35 ± 5% (n = 8, P < 0.001) 
 
5.4.4 Responses to electrical field stimulation 
 
When stimulated electrically at 10 Hz, urothelium/lamina propria strips contracted by 0.79 ± 
1.51g (n = 6) above the baseline spontaneous contractions.  Increasing the frequency of 
stimulation to 20 Hz further increased the contractions to 1.12 ± 0.16g (P < 0.001).  In the 
presence of tetrodotoxin (1 µM), responses were reduced by 79 ± 12% at 10 Hz (n = 6, P < 
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0.001) and by 80 ± 26% at 20 Hz (P < 0.01), indicating that they were significantly 
neurogenic in nature. 
 
The addition of L-NNA (100 µM, n = 8) had no effect on the responses of urothelium/lamina 
propria tissues to electrical field stimulation (Figure 5-3).  In contrast, when detrusor smooth 
muscle strips were stimulated using identical stimulation parameters, L-NNA caused an 
increase in contraction magnitude by 65 ± 27% at 10 Hz and 56 ± 27% at 20 Hz (n = 8, both 
P < 0.05).  Also, the time taken to relax back to the baseline tension was increased by L-NNA 
in the detrusor smooth muscle, but not the urothelium/lamina propria.  Relaxation time for 
detrusor muscle was increased by 34 ± 9% at 10 Hz (P < 0.01) and 10 ± 4% at 20 Hz (n = 8, 
P < 0.05). 
 
In urothelium/lamina propria tissues, baseline tension was reduced on the addition of the NO 
donors; DEANO reducing tension by 64 ± 4% (n = 6, P < 0.001) and nitroprusside by 24 ± 
2% (n = 6, P < 0.001).  DEANO (100 µM, n = 6), but not nitroprusside (10 µM, n = 6), also 
significantly inhibited contractile responses of urothelium/lamina propria strips to electrical 
field stimulation (Figure 5-5).  DEANO (100 µM) reduced responses by 70 ± 33% when 
tissues were electrically stimulated at 10 Hz (P < 0.05) and by 52 ± 9% when tissues were 
stimulated at 20 Hz (P < 0.01). 
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Figure 5-1: Experimental trace showing the effects of DEANO (100 µM) on the 
contractile activity of unstimulated strips of urothelium and lamina propria. 
 
 
 
 
Figure 5-2: Effects of DEANO (top row, 100 µM, n = 17) and sodium nitroprusside (SNP, 
bottom row, 10 µM, n = 9) on the spontaneous frequency (cycles min-1), baseline tension (g) 
and amplitude of phasic contractions (g) of strips of urothelium/lamina propria. *P < 0.01, 
**P < 0.01, ***P < 0.001. 
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Figure 5-3: Frequency and baseline tension responses of strips of urothelium/lamina 
propria to carbachol (1 µM, n = 23) in the absence (open column) and in the presence of L-
NNA (100 µM, n = 7), DEANO (100 µM, n = 20) and sodium nitroprusside (SNP, 10 µM, n 
= 12).  ***P < 0.001 compared with control responses. 
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Figure 5-4: Cumulative concentration-response curves to carbachol of urothelial/lamina 
propria strips in the absence and presence of L-NNA (100 µM, upper panel), DEANO (100 
µM, centre panel) and sodium nitroprusside (SNP, 10 µM, lower panel).  Responses are 
expressed as a percentage of the maximum response in individual experiments. (n = 8 for all 
groups). 
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Stimulation at 10 Hz Stimulation at 20 Hz 
Tissue n Control L-NNA Control L-NNA 
Urothelium 12 1.92±0.27g 2.00±0.25g 2.37±0.41g 2.33±0.33g 
Detrusor 8 4.17±1.12g 6.20±1.37ga 10.99±2.97g 14.83±3.14ga 
Table 9: Contractile responses of urothelium/lamina propria and detrusor strips to 
electrical field stimulation at 10 Hz and 20 Hz in the absence and presence of L-NNA (100 
µM). aP < 0.05 
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Figure 5-5: Contractile responses to electrical field stimulation (10 Hz and 20 Hz) in the 
absence and presence of DEANO (100 µM, n = 6) and tetrodotoxin (1 µM, n = 6). *P < 0.01, 
**P < 0.01, ***P < 0.001 
  
 Page | 154 
5.5 DISCUSSION 
 
The tissue strips of urothelium and lamina propria developed spontaneous contractile activity.  
Whether these contractions are developed by smooth muscle within the lamina propria or 
whether they are elicited by another cell type is uncertain.  It has previously been suggested 
that the tonic contractions of these tissues induced by NKA involve interstitial cells, since 
tissues were able to contract in response to NKA even after removal of smooth muscle by 
microscopic dissection (Sadananda et al., 2008).  In the present study, full thickness strips of 
urothelium and lamina propria were investigated and contractions may represent the activity 
of some remaining detrusor muscle, interstitial cells or a muscularis mucosa in the lamina 
propria.  Of particular interest however, was the finding that these tissues developed 
spontaneous contractions and the frequency of contractions was increased by carbachol.  The 
interstitial cells of the bladder resemble the Interstitial Cells of Cajal of the gastrointestinal 
system, where they act as pacemakers of electrical and contractile activity.  Interstitial cells 
have been identified in the bladder lamina propria of several species where they 
spontaneously generate transient membrane potentials and calcium transients (Kanai et al., 
2007).  The results of the present study suggest that these cellular transients are transduced 
into whole tissue contractile activity resulting in spontaneous phasic activity.  Interstitial cells 
are also found distributed amongst the detrusor muscle fibres, but in the urothelium they are 
arranged in an organised network.  It is interesting that the spontaneous contractile activity 
was observed in all the urothelial strips, but it only occurred in a minority (25%) of detrusor 
muscle strips.  This urothelial phasic activity persisted after the addition of tetrodotoxin (1 
µM) and atropine (1 µM) indicating that neuronal inputs were not necessary for its 
generation. 
 
 Page | 155 
Both NO donors caused a reduction in basal tone and simultaneously slowed the rate of 
spontaneous contractions.  This indicates that the cells responsible for eliciting contraction 
and the pacemaker cells initiating the spontaneous activity, have the intracellular machinery 
to respond to NO.  Gillespie et al (2006) have identified cells in the lamina propria that stain 
for cGMP following the addition of NO donors and these cells also stained for markers of 
interstitial cells.  These cells therefore have the intracellular mechanisms to respond to NO 
and the current study demonstrates that NO can inhibit contraction and pacemaker activity in 
this tissue.  Interestingly the NO synthase inhibitor L-NNA did not affect contractile activity 
suggesting that there was no basal release of NO in these tissues.  This would appear to apply 
to both the contractile cells and those initiating the spontaneous activity. 
 
Since several studies have shown that NO release in the bladder can be due to muscarinic 
receptor stimulation (Munoz et al., 2010, Kullmann et al., 2008), the role of NO in 
modulating tissue responses to carbachol was also examined.  Carbachol increased the rate of 
phasic contractions, which agrees with reports of interstitial cells also responding to 
carbachol with increases in the frequency of intracellular calcium transients (Kanai et al., 
2007).  Radioligand binding studies have shown that the urothelium/lamina propria of the pig 
possesses a greater density of muscarinic receptors than the detrusor muscle (Hawthorn et al., 
2000), and the predominant receptor subtype is the M2 receptor (Yamanishi et al., 2000).  
Despite this finding, the tonic contractions of this tissue appear to be mediated via M3 
receptors and this receptor also mediates the carbachol induced increases in the rate of 
spontaneous phasic contractions (Moro and Chess-Williams, 2010)).  This is not unusual, 
since responses of the detrusor smooth muscle have also been shown to be mediated via the 
minor population of M3 receptors (Sellers et al., 2000b). 
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In urothelium/lamina propria tissues the inhibition of NO synthase did not affect contractile 
or frequency responses to carbachol.  However the NO donors inhibited both these responses 
to carbachol and also inhibited the contractile responses to electrical field stimulation.  The 
results again suggest that these tissues respond to NO, but there was no basal release or 
muscarinic receptor-stimulated release of NO.  This contrasts with the detrusor strips where 
L-NNA potentiated responses to electrical field stimulation, suggesting that NO was released 
and acted in the detrusor during nerve stimulation. It has been suggested that in the rat, 
urothelial muscarinic receptors induce NO release but this only occurs after the induction of 
inducible NO synthase in conditions such as bladder inflammation (Giglio et al., 2005).  
Situations where the expression of this enzyme in the urothelium is increased include 
interstitial cystitis (Koskela et al., 2008) and bladder outlet obstruction (Romih et al., 2003).  
In these conditions NO may be released and would exert the NO effects observed in the 
present study. 
 
It seems likely that NO is synthesized predominantly in the lamina propria since there is only 
sparse NOS distribution in the urothelium (Fathian-Sabet et al., 2001, Persson et al., 1999).  
Munoz et al. (2010) also reported that NO release induced by electrical field stimulation in 
the rat, was not affected by removal of the urothelium.  The targets of NO action have also 
been identified in immunohistochemical studies.  In the presence of NO donors, cGMP 
staining cells have been demonstrated in the detrusor and nerves of the bladder but also in the 
urothelium and the interstitial cells of the lamina propria (Fathian-Sabet et al., 2001, Gillespie 
et al., 2006a).  These cells may possibly be the target of NO in the present experiments. 
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5.6 CONCLUSIONS 
 
The urothelium and lamina propria develops spontaneous contractile activity that is inhibited 
by NO donors.  The tissues contract in response to electrical field stimulation and respond to 
carbachol with an increase in tonic baseline tension and an increase in spontaneous 
contractile rate, and all of these responses are sensitive to inhibition by NO donors.  
However, inhibition of NO synthase had no effect on responses suggesting that there is no 
basal release of NO nor any muscarinic receptor mediated release of NO in these tissues.  
However the potency of NO in these tissues suggests that in conditions where NO release is 
enhanced it will have significant effects on urothelial function. 
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Chapter 6  
 
 
 
 
 
 
Adrenoceptor function and expression in the bladder 
urothelium and lamina propria 
 
 
 
 
 
The manuscript in the following chapter is presented as a pre-publication copy, prior to the 
reviewer and publisher’s requested alterations. The final version of this manuscript can be 
accessed online from the journal. Formatting and terminology changes have been made to 
maintain consistency throughout this thesis. 
 
All data presented in this manuscript is the sole work of C. Moro  
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6.1 ABSTRACT 
 
The inner lining of the urinary bladder (urothelium/lamina propria) develops spontaneous 
phasic contractile activity and the aims of this study were to investigate the role of 
adrenoceptor subtypes in regulating this activity. The responses of isolated strips of porcine 
urothelium/lamina propria to noradrenaline, phenylephrine and isoprenaline were obtained in 
the absence and presence of receptor subtype selective antagonists. Quantitative real-time 
PCR was undertaken to assess the expression of adrenoceptor genes. The tissues expressed all 
α1- and β-adrenoceptor subtypes with the α1A-, α1B- and β2-adrenoceptors being the 
predominant receptors at the mRNA level.  In functional experiments, the rate of phasic 
contractions and the basal tension were increased by the α1-adrenoceptor agonists 
phenylephrine (100 µM) and A61603 (10 µM).  Rate and tension responses to phenylephrine 
were reduced by low concentrations of tamsulosin (3 nM) and RS100329 (10 nM), but were 
unaffected by BMY7378 (100 nM), prazosin (10 nM) and RS17053 (1 µM).  In contrast, 
isoprenaline and salbutamol (both 1 µM) induced a relaxation of tissues and slowing of 
phasic contractions.  Rate and tension responses to isoprenaline were inhibited by propranolol 
(100 nM) or a combination of CGP20712A (30 nM) and ICI118551 (70 nM), while the rate 
responses were also significantly inhibited by ICI118551 alone (70 nM). All α1- and β-
adrenoceptor subtypes are expressed in the pig urothelium/lamina propria, but the α1A/L-
adrenoceptor appears to mediate increases in contractile rate and tension.  The β-adrenoceptor 
induced inhibition of spontaneous contractile activity appears to be predominately mediated 
by β2-adrenoceptors with possibly β1- and β2-adrenoceptors involved in the tension responses. 
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6.2  INTRODUCTION 
 
The functions of the bladder include both relaxation, which occurs during bladder filling, and 
contraction which occurs during the emptying phase of the micturition cycle.  Detrusor 
smooth muscle contraction to muscarinic agonists is mediated via M3 muscarinic receptors 
(Chess-Williams, 2002a), while noradrenaline relaxes the tissue via β-adrenoceptors, 
although the subtype involved appears to be species dependent (reviewed by Michel et al., 
2006).  α-adrenoceptors are also present on the detrusor muscle, but receptor density is low 
and responses to α-adrenoceptor agonists are small or non-existent (Michel and Vrydag, 
2006). 
 
Over recent years the importance of the inner epithelial lining of the bladder, the urothelium, 
and the underlying lamina propria in regulating bladder function has been increasingly 
recognised.  The lamina propria, is the layer of tissue between the inner epithelial layer of the 
bladder wall and the underlying detrusor smooth muscle. This inner region of the bladder 
wall has a barrier function, but also when stretched it releases a number of factors that 
influence detrusor contraction and afferent nerve sensitivity (Birder, 2010).  In addition, the 
urothelium with lamina propria from the dome of the pig bladder (Moro et al., 2012; 
Sadananda et al., 2008) and also strips of lamina propria from the rabbit urethra (Mattiasson 
et al., 1985b, Zygmunt et al., 1993) have been shown to contract to agonists such as 
carbachol, neurokinin-A and noradrenaline.  Isolated strips of urothelium with lamina propria 
also develop spontaneous contractile activity, with carbachol and also stretch-induced release 
of acetylcholine mediating increases in spontaneous contractile frequency via M3 receptors 
(Moro et al., 2011). 
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The lamina propria of the human bladder has been shown to be immunoreactive for tyrosine 
hydroxylase (Dixon et al., 1999, Jen et al., 1995) indicating a sympathetic innervations, and 
the lamina propria of the rabbit urethra contracts in response to phenylephrine demonstrating 
that α1-adrenoceptors are present (Mattiasson et al., 1985).  Three α1-adrenoceptor subtypes 
have been identified at the molecular and functional level (α1A, α1B, α1D; Alexander et al., 
2011) and another, termed the α1L-adrenoceptor because of its low affinity for prazosin, has 
been recognised in functional experiments (Flavahan and Vanhoutte, 1986).  Which α1-
adrenoceptor subtypes are present in porcine urothelium and lamina propria and their 
functional role has not been investigated.  Similarly, all three β-adrenoceptor subtypes are 
expressed in the human lamina propria at the mRNA and protein level (Otsuka et al., 2008), 
but their influence on contractile activity is unknown.  Many studies have identified the pig 
bladder as a suitable model for human bladder pharmacology (Crowe and Burnstock, 1989, 
Goepel et al., 1997, Sibley, 1984).  The present study examines which α- and β-adrenoceptors 
are expressed in the pig urinary bladder urothelium and lamina propria, and identifies the 
adrenoceptor subtypes responsible for mediating the frequency and tension responses of this 
tissue. 
 
6.3 MATERIALS AND METHODS 
 
6.3.1 Functional organ bath studies 
 
Fresh bladders from Large White-Landrace pigs (6 months old, ~80 kg) were obtained from a 
local abattoir and immediately immersed in cold Krebs-bicarbonate solution (composition in 
mM: NaCl 188.4, NaHCO3 24.9, CaCl2 1.9, MgSO4 1.15, KCL 4.7, KH2PO4 1.15 and D-
glucose 11.7).  The bladders were opened longitudinally and full thickness strips of anterior 
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wall from the dome region were removed.  From these tissues, strips of urothelium with 
lamina propria were prepared (20 x 5 mm) and immersed in Krebs-bicarbonate solution, 
maintained at 37°C and gassed with 5% CO2 in oxygen.  The tissues were attached to 
isometric force transducers (ADInstruments MCT050/D) and tensions recorded with a 
Powerlab system using Labchart v7 software (ADInstruments, Castle Hill, Australia).  After 
washing with fresh Krebs solution the tissues were allowed to equilibrate for 45 minutes 
under a baseline tension of ~2g before starting drug additions.  For studies with antagonists, 
adjacent pieces of tissue were dissected, set up in pairs under identical conditions and 
allowed to equilibrate. One tissue was incubated with the antagonist for 30 minutes, and the 
other remained as a control in the absence of any antagonist.  Where antagonists selective for 
a particular receptor subtype have been used, affinity values were obtained from the literature 
and the concentration carefully selected to give a maximum antagonism of the receptor 
without an action on the other receptor subtypes. 
 
6.3.2 RT-PCR studies 
 
Strips of urothelium with lamina propria (n = 6) were finely dissected with scissors under 
magnification and immediately immersed in RNALater solution (Ambion Inc.).  The 
urothelium and lamina propria (~0.2g each) was then homogenised and RNA extracted with a 
Trizol plus RNA purification kit (Invitrogen Cat No. 12183-555) as per manufacturer’s 
instructions.  All storage of RNA was maintained at -80°C and experiments performed within 
3 months of the initial extraction.  A NanoDrop 1000 Spectrophotometer (Thermo Scientific) 
was used to measure the total RNA quantity (ng/µL) and to assess the purity (260/280 ratio).  
The integrity of the RNA was also performed for all extractions with formaldehyde agarose 
gel electrophoresis in ethidium bromide staining for 28s and 18s RNA band visualisation.  
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cDNA synthesis was then performed using SuperScript III First-Strand Synthesis SuperMix 
from the qRT-PCR kit (Invitrogen).  Initial incubation was in a reaction mix (10 µL of 2X RT 
reaction mix; 2µL of reverse transcriptase enzyme mix; 8 µL of eluted RNA) and performed 
at 25°C for 10 minutes. 
 
An iQTM SYBR Green Super Mix (BioRad) was used to amplify the cDNA targeted genes.  
Real-time PCR was performed with a Research Rotor-Gene 3000 (Corbett).  5 µL of cDNA 
was used to amplify the genes.  PCR for ADRB3 was undertaken in triplicate with the 
following conditions: 94°C: 10 min (x1), Cycle 2, 94°C: 30s, 51°C: 15sec, 72°C: 15sec 
(x40). All other genes (Table 10) were investigated with the following conditions: cycle 1, 
94°C 10 min (x1), Cycle 2, 94°C: 30s, 60°C: 30s, 72°C: 30s (x45).  A post-PCR 
amplification protocol was preset before the run to obtain melt curve representations, 
ramping from 50 to 99°C with 1°C increases every 5 seconds.  The expression levels of each 
target gene were expressed relative to the PCR amplification of the housekeeping gene β-
actin. 
 
Gene Forward Reverse 
Amplicon 
Size 
α1A CCATTGGGTCTTTCTTTCCT TTTAAACTCTTGACTGGAGCAC 124 
α1B GGTCATTCTGGTCATGTACTG TCGTGAAAGTTCTTGGAGTG 134 
α1D TTTCTTCGTCCTACCACTG GTTGAAGTAGCCCAGCC 90 
β1 CCAACCTCTTCATCATGTCC CACAGTACGTCCACCGA 144 
β2 GATCCATGACAACCTCATCC GAAGGCCATCCTGAAATCTG 117 
β3 AGACTCCAGACCATGACC ACAGCTCGCAACAAGTG 132 
β-actin ATGGGCCAGAAGGACTC GCAGCTCGTTGTAGAAGG 144 
Table 10: Porcine receptor-specific PCR primer sequence and PCR amplicon sizes. 
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6.3.3 Data analysis and statistical procedures 
 
Measurements of frequency and baseline tension were taken at the peak response after the 
addition of each agonist.  The frequency of contractions was expressed as the number of 
phasic waves per minute (cycles min-1) and the baseline tension as grams (g).  The baseline 
tension was taken as the lowest point of the spontaneous phasic contractions.  Mean ± 
standard error of mean (SEM) values in the absence and presence of drugs were compared 
using a Student’s two-tailed t-test with P < 0.05 being taken as statistically significant.  Prism 
software (GraphPad v4, San Diego, CA, USA) was used for statistical analysis of data. A 
one-way analysis of variance (ANOVA) with a Dunnett post test was applied for analysis of 
more than one sample (Table 11).  n represents the number of different porcine tissues used 
in the study.  Real-time PCR data were calculated using the cycle threshold determination 
method (Corbett rotor gene 6000 series software v1.7). 
 
6.3.4 Drugs, chemical reagents and other materials 
 
(±)-Noradrenaline hydrogen tartrate, CGP20712A methanesulfonate salt, clonidine 
hydrochloride, isoprenaline hydrochloride, phentolamine hydrochloride, (R)-(−)-
phenylephrine hydrochloride, and prazosin hydrochloride were purchased from Sigma (St 
Louis, Missouri, USA). Tamsulosin was a gift provided by Astellas Pharma (Leiderdorp, 
NL).  A61603 hydrobromide, BMY7378 dihydrochloride, BRL37344 sodium salt, CL316243 
disodium salt, ICI118551 hydrochloride, (±)-propranolol hydrochloride, RS17053 
hydrochloride, RS100329 hydrochloride, SR59230A, salbutamol sulphate, and UK14,304 
were purchased from Tocris (Ellisville, Missouri, USA).  Oligonucleotide primers (Table 10) 
were obtained from Geneworks (Thebarton, South Australia). 
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6.4 RESULTS 
 
6.4.1 Spontaneous phasic contractions 
 
The urothelium and lamina propria exhibited spontaneous contractions within 10 minutes of 
being placed in the organ bath (Figure 6-1).  This regular phasic activity of the urothelium 
was present throughout the course of the experiment and occurred at a spontaneous 
contractile frequency of 3.48 ± 0.07 cycles min-1 and an amplitude of 0.68 ± 0.03g (n = 211). 
 
6.4.2 Responses to noradrenaline 
 
Noradrenaline (10 µM, n = 8) significantly reduced the frequency of spontaneous 
contractions by 15.2 ± 6.5% and baseline tension by 22 ± 4% (Table 11).  The frequency 
responses were significantly enhanced in the presence of phentolamine (10 µM), 
noradrenaline then reducing the frequency of contractions by 39 ± 7%, while relaxation of the 
tissues to noradrenaline was not significantly affected (Table 11).  In contrast, in the presence 
of propranolol (1 µM), responses to noradrenaline (10 µM, n = 8) were converted to increases 
in the rate of spontaneous contractions (41 ± 7% increase) and the baseline tension increased 
by 52 ± 10% (Table 11). 
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Table 11: Frequency and tension responses of urothelium/lamina propria to 
noradrenaline. 
 
Drug Change in 
frequency 
(cycles min
-1
) 
Change in 
tension 
(grams) 
n 
Noradrenaline (10 µM) -0.57 ± 0.24 -0.64 ± 0.16 8 
Noradrenaline (10 µM) + 
Phentolamine (10 µM) 
-1.40 ± 0.25a -0.82 ± 0.06 8 
Noradrenaline (10 µM) + 
Propanolol (1 µM) 
1.34 ± 0.20b 0.76 ± 0.13b 8 
Values are mean ± SEM. 
aSignificantly different from noradrenaline alone, P < 0.05 (ANOVA) 
bSignificantly different from noradrenaline alone, P < 0.01 (ANOVA) 
 
 
6.4.3 α-adrenoceptor responses 
 
The α2-adrenoceptor agonists clonidine and UK14,304 are highly potent agonists at α2-
adrenoceptors and produce responses at nano-molar concentrations if these receptors are 
present in a tissue.  However at concentrations up to 1µM, neither agonist had any effect on 
either the spontaneous contractile frequency or the basal tension developed by tissues (n=8).  
Higher concentration of these drugs will activate α1-adrenoceptors and thus were not 
examined. In contrast, the α1-adrenoceptor selective agonist phenylephrine (100 µM) 
increased the spontaneous activity by 41 ± 8% and the baseline tension by 22 ± 5% (n = 21, P 
< 0.001 for both).  At a 10-fold lower concentration, the α1A-adrenoceptor selective agonist 
A61603 (10 µM) produced a similar increase in spontaneous contractile frequency 31 ± 4% 
and also increased baseline tension by 31 ± 4% (n = 26, P < 0.001 for both; Figure 6-1).  
Lower concentrations of phenylephrine (1 – 10 µM, n = 8) did not cause any significant 
responses for frequency or tension, yet lower concentrations of A61603 (3 µM, n = 8, data 
not shown) resulted in significant increases for frequency by 27 ± 9% (P < 0.05) and baseline 
tension by 18 ± 5% (P < 0.01). 
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The increase in the frequency of contractions produced by phenylephrine was significantly 
reduced by low concentrations of the α1A-adrenoceptor antagonists, RS100329 (10 nM, n = 8) 
and tamsulosin (3 nM, n = 8), but not by the α1D-adrenoceptor selective antagonist BMY7378 
(100 nM, n = 8; Figure 6-2).  Increases in basal tension induced by phenylephrine (100 µM) 
were similarly reduced by RS100329 (10 nM, n = 8, P < 0.05) and tamsulosin (3 nM, n = 8, P 
< 0.05), but not BMY7378 (100 nM, n = 8, Figure 6-2).  Two antagonists that discriminate 
between α1A- and α1L-adrenoceptors, prazosin and RS17053 were also examined.  Neither 
prazosin (10 nM, n = 10) nor RS17053 (1 µM, n = 8) had any significant effect on either 
frequency or tension responses to phenylephrine (Figure 6-2). 
 
6.4.4 β-adrenoceptor responses 
 
Isoprenaline (1 µM, n = 62) reduced the spontaneous contractile frequency of tissue strips by 
34 ± 2% (1.21 ± 0.08 cycles min-1, P < 0.001) and the baseline tension by 37 ± 2% (0.66 ± 
0.44g, P < 0.001, Figure 6.-1).  A higher concentration of isoprenaline (10 µM, n = 16) 
produced a greater inhibition of the contractile frequency (49 ± 1%, P < 0.01), but the 
depression of baseline tension was similar to that obtained with the lower concentration of 
isoprenaline (40 ± 3%).  Salbutamol (1 µM, n = 7) reduced the frequency of spontaneous 
contractions by 33 ± 6% and the baseline tension by 22 ± 2% (P < 0.001 for both responses, 
Figure 6-1).  A higher concentration of salbutamol (10 µM) did not induce greater inhibition 
of the tissues.  The β3-adrenoceptor selective agonist, BRL37344, at concentrations up to 10 
µM (n = 8, data not shown), did not affect the frequency of spontaneous contractions or 
baseline tension.  Another β3-adrenoceptor selective agonist, CL316243, was similarly 
without effect over a range of concentrations up to 1 µM. 
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Isoprenaline (1 µM; Figure 6-3) induced relaxation and a slowing of spontaneous phasic 
contractions and both these responses were significantly reduced in the presence of 
propranolol (100 nM, n = 8) or a combination of the β1-adrenoceptor antagonist CGP20712A 
(30 nM, n = 8) and β2-adrenoceptor antagonist ICI118551 (70 nM, n = 11). However the 
responses were unaffected by CGP20712A (β1-adrenoceptor antagonist, n = 8), or SR59230A 
(β3-adrenoceptor antagonist, n = 8).  The β2-adrenoceptor antagonist ICI118551 (70 nM, n = 
12) significantly reduced frequency responses to isoprenaline (P < 0.05), but not relaxation 
responses to this agonist (Figure 6-3). 
 
6.4.5 Real-Time Polymerase Chain Reaction 
 
RNA was extracted from isolated urothelium and lamina propria samples (n = 6, run in 
triplicate) and tested for integrity prior to being converted into cDNA.  RNA concentrations 
and 260/280 ratios were as follows: Sample 1: 602 ng/µL, 2.06; Sample 2: 699ng/µL, 2.10; 
Sample 3: 1050 ng/µL, 2.08; Sample 4: 620 ng/µL 2.09, Sample 5: 823 ng/µL; 2.10, Sample 
6: 590 ng/µL, 2.11.  The real-time PCR products for all six adrenoceptor genes and the 
housekeeping gene β-actin were run in triplicate and the end product visualised on 2% 
agarose gels to identify that all genes demonstrated the correct fragment sizes (Figure 6-4).  
For α1–adrenoceptors, the greatest expression was observed for the α1A- and α1B-
adrenoceptor subtypes, while that for the α1D-adrenoceptor was only half that obtained for 
α1A- and α1B-adrenoceptors (Figure 6-4).  All three β-adrenoceptor subtypes were expressed 
in these tissues.  The expression was highest for β2-adrenoceptors; which was nearly double 
that for either β1- or β3-adrenoceptors (Figure 6 4). 
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Figure 6-1: Typical experimental traces showing the effects of adrenoceptor agonists on 
urothelium and lamina propria contractile activity. [A] Noradrenaline (10 µM) in the 
presence of phentolamine (10 µM), [B] noradrenaline (10 µM) in the presence of propanolol 
(1 µM), [C] isoprenaline (1 µM), [D] phenylephrine (100 µM), [E] salbutamol (1 µM) and 
[F] A61603 (10 µM). 
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Figure 6-2: Frequency and tension responses of urothelium/lamina propria strips induced 
by phenylephrine (100µM), in the absence (shaded columns) and in the presence (open 
columns) of antagonists: RS100329 (10nM, n=8), tamsulosin (3nM, n=8), BMY7378 
(100nM, n=8), prazosin (10nM, n=10) and RS17053 (1µM, n=8). Columns represent the 
mean ± SEM. Student’s two-tailed t-test: *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 6-3: Frequency and tension inhibitions induced by isoprenaline in the absence 
(shaded columns) and presence (open columns) of antagonists: propanolol (100nM, n=8), 
CGP20712A (30nM, n=8), ICI118551 (70nM, n=8), SR59230A (30nM, n=8), and a 
combination of ICI118551 (70nM) & CGP20721A (30nM, n=11, CGP & ICI).  Responses 
are expressed as the percentage increase (upper figure) or inhibition (lower figure) of rate and 
tension. Columns represent the mean ± SEM. Student’s two-tailed t-test: *P < 0.05, **P < 
0.01, ***P < 0.001. 
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Figure 6-4: Relative expression of each adrenoceptor gene. Expression values are based 
relative to β-actin expression for the α-adrenoceptors (upper panel) and β-adrenoceptors 
(middle panel) and expressed as the mean ± SEM (n=8 for each). 
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6.5 DISCUSSION 
 
In the absence of any exogenous agonist, the urothelium with lamina propria samples 
developed spontaneous phasic contractions.  Initial data obtained with noradrenaline suggests 
that both α- and β-adrenoceptors are present and functional in this tissue: α-adrenoceptors 
mediating contraction and increases in frequency, whilst β-adrenoceptor activation relaxes 
the tissue and slows the frequency of phasic contractions. The dominant response to the 
physiological agonist noradrenaline is β-adrenoceptor mediated relaxation and slowing, since 
these were the responses obtained to noradrenaline in the absence of antagonists.  However, 
these inhibitory responses to noradrenaline were enhanced in the presence of phentolamine, 
indicating that α-adrenoceptors were reducing these inhibitory responses to noradrenaline in 
the absence of any antagonists.  Thus both α- and β-adrenoceptors are involved in mediating 
responses to the endogenous agonist noradrenaline. 
 
6.5.1 α-adrenoceptors 
 
The α-adrenoceptor mediated responses of the urothelium and lamina propria appear to 
involve the α1-adrenoceptor subtype since both phenylephrine and A61603 increased phasic 
frequency, whilst the agonists with predominantly α2-adrenoceptor agonist selectivity, 
clonidine and UK14304, had no effect.  The tissue expresses mRNA for all three cloned α1-
adrenoceptors, but the levels of α1A and α1B-adrenoceptor mRNA are greater than that for the 
α1D-adrenoceptor subtype. On isolated tissues, both phenylephrine and the α1A-adrenoceptor 
selective agonist A61603 (Knepper et al., 1995) induced increases in baseline tension and the 
rate of phasic contractions.  The tension and rate responses for A61603 (10 µM) were 
significantly greater than those to the same concentration of phenylephrine, due to the higher 
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affinity of A61603 at the α1A-adrenoceptor subtype.  Higher concentrations of phenylephrine 
(100 µM) produced a greater response almost identical to that produced by the 10-fold lower 
concentration of A61603. These agonist data suggest that responses were mediated via the 
α1A-adrenoceptor subtype.   
 
The antagonist data support these findings.  Responses to phenylephrine were reduced by a 
low concentration of tamsulosin (3 nM), an antagonist possessing high affinity for α1A- and 
α1D-adrenoceptors (Noble et al., 1997).  Thus responses were not mediated via α1B-
adrenoceptors.  In addition, rate and tension responses to phenylephrine were potently 
inhibited by RS100329, a selective antagonist for the α1A-adrenoceptor subtype.  RS100329 
has a pKi at α1A-adrenoceptors of 9.6 and demonstrates a 126- and 50-fold selectivity over 
α1B and α1D-adrenoceptor subtypes (Conley et al., 2001; Williams et al., 1999), thus at the 
concentration used in the present study (10 nM) it would only have an action at α1A-
adrenoceptors.  The lack of involvement of α1D-adrenoceptors was confirmed using 
BMY7378, an antagonist with a greater than 100-fold high affinity for the α1D-adrenoceptor 
subtype over α1A and α1B-adrenoceptors (Piascik et al., 1995, Yang and Endoh, 1997).  The 
lack of effect at a concentration of 100 nM with BMY7378 supports the conclusion that α1D-
adrenoceptors are not involved in mediating responses of the urothelium and lamina propria, 
and that the α1A-adrenoceptor is the functional α1-adrenoceptor in this tissue. 
 
A number of studies have demonstrated that contractions of the bladder neck and prostate are 
mediated via α1-adrenoceptors that, unlike the cloned receptors, have a low affinity for the 
antagonist prazosin and this putative receptor subtype has been termed the α1L-adrenoceptor 
or α1A/L-adrenoceptor (Alexander et al., 2011).  It is generally accepted that this functional 
receptor exists as a conformational state of the α1A-adrenoceptor, but the mechanisms 
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involved are unclear and it has been suggested that experimental conditions (Ford et al., 
1996, Ford et al., 1997) or specific intracellular proteins (Nishimune et al., 2010) may be 
involved.  Both prazosin and RS17053 have a low affinity for this form of the receptor 
compared to the α1A-adrenoceptor, and the lack of effect for these antagonists in the present 
study suggests that it is this conformational state (αA/L-adrenoceptor) that mediates 
contraction of this tissue. 
 
6.5.2  β-adrenoceptors 
 
Noradrenaline, isoprenaline and salbutamol all induced relaxation of tissues and a slowing of 
the frequency of phasic contractions.  Propranolol antagonised the inhibitory effects of 
isoprenaline and abolished those to noradrenaline, converting them to a small contraction and 
an increase in phasic rate of contractions to noradrenaline.  All three subtypes of β-
adrenoceptor (β1, β2 and β3) were present at the mRNA level, with the expression of β2-
adrenoceptors being double that of either the β1- or β3.-adrenoceptor subtypes.  Isoprenaline 
reduced the rate of phasic contractions and these inhibitory responses were reduced when β2-
adrenoceptors were antagonised with either propranolol (β1- and β2- antagonist), ICI118551 
(β2-antagonist) or a combination of ICI118551 and CGP20712A (β1- antagonist).   The 
responses were insensitive to CGP20712A alone or SR59230A (β3- antagonist) indicating β2-
adrenoceptors are the predominant functional β-adrenoceptor subtype inhibiting spontaneous 
contractile frequency in these tissues.  For relaxation responses, combined β1- and β2-
adrenoceptor antagonism appeared to be required to significantly inhibit responses to 
isoprenaline and CGP20712A alone, ICI118551 alone or SR59230A alone failed to influence 
responses.   In some species, the responses of detrusor smooth muscle to isoprenaline are 
mediated via β3-adrenoceptors, but for porcine urothelium and lamina propria, selective 
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concentrations of SR59230A did not affect frequency or tension responses to isoprenaline, 
and also CL316243 and BRL37344, two selective β3-adenoceptor agonists did not influence 
either response.  Thus inhibitory responses of the urothelium and lamina propria to 
isoprenaline appear to be mediated predominantly by β2-adrenoceptors with a possible 
contribution from β1-adrenoceptors for tension responses. 
 
The mechanisms involved in these responses of the urothelium and lamina propria are not 
clear.  Tension responses to neurokinin-A and carbachol are present after fine dissection and 
removal of smooth muscle from the preparations and it has been suggested that myfibroblasts 
may be involved (Moro et al., 2011; Sadananda et al., 2009).  In addition, spontaneously 
generated electrophysiological events have been observed in interstitial cells located within 
the lamina propria (Fry et al., 2007).   The function of this contractile activity is also 
uncertain.  It may act to ensure folding of the urothelium in the empty bladder or alternatively 
it may act to enhance sensory nerve function (Kanai et al., 2011).  It has been reported that 
spontaneous calcium and electrical activity arise in the urothelium-lamina propria interface 
and pass into the detrusor regions (Kanai et al., 2007) and this is increased in tissues from 
cats with interstitial cystitis (Ikeda et al., 2009).  Therefore, in situations where electrical 
coupling is enhanced, it may be possible that the lamina propria may drive larger spontaneous 
contractions of the detrusor smooth muscle.  
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6.6 CONCLUSIONS 
 
In conclusion, the urothelium and lamina propria of the pig bladder develops spontaneous 
contractile activity that can be regulated by the sympathetic nervous system.  The force of 
contraction and the frequency of spontaneous contractions are increased by α1-adrenoceptor 
stimulation and depressed by β-adrenoceptor stimulation.  The predominant α1-adrenoceptor 
subtype has the pharmacological characteristics of the α1A/L-adrenoceptor subtype, while β2-
adrenoceptors (with possibly a β1- contribution for tension) appear to be the predominant 
receptors mediating inhibitory responses. 
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Chapter 7  
 
 
 
 
 
Non-adrenergic, non-cholinergic, non-purinergic contractions of the 
urothelium/lamina propria of the pig bladder 
 
 
 
 
 
 
 
 
The manuscript in the following chapter is presented as a pre-publication copy, prior to the 
reviewer and publisher’s requested alterations. The final version of this manuscript can be 
accessed online from the journal. Formatting and terminology changes have been made to 
maintain consistency throughout this thesis. 
 
All data presented in this manuscript is the sole work of C. Moro  
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7.1 ABSTRACT 
 
Objectives: Acetylcholine, and to a lesser extent ATP, mediate neurogenic contractions of 
bladder smooth muscle.  Recently, the urothelium and lamina propria has also been shown to 
have contractile properties, but the neurotransmitters involved in mediating responses to 
nerve stimulation have not been investigated. 
Methods: Isolated strips of porcine urothelium with lamina propria were electrically 
field stimulated and contractions recorded. Drugs interfering with neurotransmission were 
then employed to identify which neurotransmitters mediated responses. 
Results: Strips of urothelium/lamina propria developed spontaneous contractions with a 
frequency of 3.50 ± 0.10 cycles min-1 and amplitude of 0.84 ± 0.06g.  Electrical field 
stimulation at 5, 10, and 20 Hz resulted in frequency-related contractions (1.13 ± 0.36g, 1.59 
± 0.46g and 2.20 ± 0.53g respectively, n = 13) and these were reduced in the presence of 
tetrodotoxin (1 µM) by 77 ± 20% at 5 Hz, 79 ± 7% at 10 Hz and 74 ± 12% at 20 Hz (all P < 
0.01) indicating they were predominantly neurogenic in nature. Neither the muscarinic 
antagonist atropine (10 µM), the adrenergic neurone blocker guanethidine (10 µM), nor 
desensitisation of the purinergic receptors with α,β-methylene ATP (10 µM) affected the 
contractile amplitude.  Similarly, responses were not affected by the nitric oxide synthase 
inhibitor L-NNA (100 µM) or drugs that interfere with peptide neurotransmission (capsaicin, 
NK2 antagonist GR159897, protease inhibitors). 
Conclusions: Electrical depolarisation of the nerves present in the porcine 
urothelium/lamina propria results in frequency-dependent contractions which are 
predominantly neurogenic in nature.  These contractions are resistant to drugs which inhibit 
the adrenergic, cholinergic and purinergic systems.  The neurotransmitter involved in the 
responses of this tissue is therefore unknown but does not appear to be a peptide. 
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7.2 INTRODUCTION 
 
The detrusor smooth muscle of the urinary bladder receives both sympathetic and 
parasympathetic innervation.  During bladder filling, activity in the sympathetic nerves 
results in detrusor relaxation via stimulation of β-adrenoceptors, thus allowing an increase in 
bladder volume without increases in intravesical pressure.  The β-adrenoceptor subtype 
involved is species dependent but responses are mediated via the β3-adrenoceptor subtype in 
pig (Yamanishi et al., 2002b) and human (Igawa et al., 1999, Yamaguchi, 2002, Badawi et 
al., 2007) detrusor muscle. During bladder emptying, activity in the parasympathetic nerves 
results in detrusor contraction which is mediated via M3 muscarinic receptors (Sellers et al., 
2000b, Chess-Williams et al., 2001). 
 
Detrusor responses to nerve stimulation during electrical field stimulation (EFS) may also 
involve a non-cholinergic, non-adrenergic (NANC) neurotransmitter that was first identified 
as ATP by Burnstock et al. (1972).  NANC responses have been observed in the bladders of 
several species (Sibley, 1984, Somogyi et al., 1998), although in human this component is 
usually only observed in the diseased bladder (Sjogren et al., 1982). 
 
It has been reported that the inner lining of the bladder and urethra, the urothelium and 
lamina propria, exhibits contractile properties (Sadananda et al., 2008, Moro et al., 2011, 
Mattiasson et al., 1985a). The porcine tissue also exhibits spontaneous phasic contractile 
activity and contracts in response to neurokinin (Sadananda et al., 2008) and muscarinic 
(Moro et al., 2011) receptor stimulation.  Nitric oxide (NO) donors relax this tissue, although 
there does not appear to be endogenous release of nitric oxide (Moro et al., 2012). 
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The responses of this tissue to electrical field stimulation have never been investigated and 
the aim of this study was to assess the relative involvement of the neurotransmitters 
acetylcholine, noradrenaline, ATP and nitric oxide in mediating neurogenic responses of the 
urothelium and lamina propria. 
 
7.3 MATERIALS AND METHODS 
 
Bladders from pigs (6 months age, ~70 Kg) were obtained from a local abattoir and 
immediately immersed in Krebs-bicarbonate solution composed of NaCl (188.4 mM), 
NaHCO3 (24.9 mM), CaCl2 (1.9 mM), MgSO4 (1.2 mM), KH2PO4 (1.2 mM) and glucose 
(11.7 mM).  The bladder was opened longitudinally and strips of urothelium plus lamina 
propria (20 x 5 mm) were dissected from the anterior wall of the dome of the bladder. These 
were set up under 2g tension in 10 mL baths containing warmed Krebs-bicarbonate solution 
at 37°C and gassed with 5% CO2 in oxygen.  Isometric tension developed by tissues was 
recorded via a Powerlab system using Labchart software (AdInstruments, Castle Hill, 
Australia). 
 
Preliminary experiments indicated that the optimal stimulation parameters for tissue strips 
was 5 second trains of pulses (0.5 ms duration, 20 V) applied every 100 seconds.  Three 
stimulation frequencies (5, 10 and 20 Hz) were examined and the neurotoxin tetrodotoxin (1 
µM) was used to confirm the neurogenic origin of contractions.   Responses to electrical field 
stimulation (EFS) were measured as the increase in developed tension above the baseline 
spontaneous contractions.  Control experiments were performed without the addition of any 
drugs and these established that responses to EFS were stable and reproducible over the time 
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course of the experiment.  Data obtained at each stimulation frequency in the absence and 
presence of drugs were analysed using paired Student’s t-tests. 
 
7.3.1 Drugs and solutions 
 
Tetrodotoxin, atropine sulfate, α,β-methyleneadenosine 5’-triphosphate lithium salt, Nω-
nitro-L-arginine (L-NNA), guanethidine monosulfate, protease inhibitor cocktail (P1860, 
containing a mixture of protease inhibitors with broad specificity for the inhibition of serine, 
cysteine, aspartic and aminopeptidases), phosphoramidon disodium and capsaicin, were 
purchased from Sigma-Aldrich Co. (St. Louis, MO). GR159897 and neurokinin-A was 
purchased from Tocris Bioscience (Minneapolis, MN). 
 
7.4 RESULTS 
 
Strips of urothelium with lamina propria exhibited spontaneous contractile activity within 15 
minutes of being set up in the organ baths.  These contractions occurred with a mean 
amplitude of 0.84 ± 0.06g and a frequency of 3.50 ± 0.10 cycles min-1 (n = 146).  When 
stimulated electrically at 5 Hz, strips contracted by 1.13 ± 0.36g above the baseline 
spontaneous contractions (n = 13, P < 0.01).  Increasing the frequency of stimulation to 10 Hz 
increased the contractions to 1.59 ± 0.46g (P < 0.01), while stimulation at 20 Hz resulted in 
contractions of 2.20 ± 0.53g (P < 0.001).  In the presence of tetrodotoxin (1 µM, Figure 7-1), 
responses were reduced by 77 ± 20% at 5 Hz, 79 ± 7% at 10 Hz, and 74 ± 12% at 20 Hz (n = 
13, P < 0.01 for all frequencies) indicating that they were predominantly neurogenic in 
nature.  The EFS contractions did not have a significant effect on the rate of spontaneous 
contractile activity over 20 minutes.  Control experiments without the addition of any drugs 
demonstrated that responses to electrical field stimulation were stable over the duration of the 
experiment. 
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Atropine at concentrations up to 10 µM (n = 8) had no significant effect on responses of the 
urothelium/lamina propria strips to electrical field stimulation at any of the frequencies 
examined (Figure 7-2).  As a positive control the effects of atropine on contractile responses 
of urothelium/lamina propria strips to carbachol were examined and atropine (1 µM) 
abolished responses to carbachol (1µM, Figure 7-3).   In further control experiments, EFS at 
5 Hz induced contractions of detrusor smooth muscle strips and these were reduced by 68 ± 
8% (P < 0.05) by atropine at a concentration of 1µM ( n = 8). 
  
Similarly, neither the presence of the adrenergic neurone blocker guanethidine (10 µM, n = 
12) nor the NO synthase inhibitor L-NNA (100 µM, n = 15) had any effect on the responses 
of the urothelium/lamina propria to field stimulation (Figure 7-2).  As a positive control the 
actions of guanethidine (10 µM) were examined on the pig urethra stimulated at 5 Hz under 
identical conditions.  In these control experiments guanethidine depressed contractions to 
field stimulation of the pig urethra by 95 ± 3% (n = 6).   
 
To investigate the involvement of ATP in mediating neurogenic contractions, α,β-methylene 
ATP (10 µM) was used to desensitise the purinergic receptors.  This agent caused a transient 
contraction of the tissue and subsequent responses to this agonist were reduced by 85 ± 2% (n 
= 8, P < 0.001, Fig 3) indicating a desensitisation of purinergic receptors.  However, 
following this procedure, responses to field stimulation were similar to controls (n = 8, Fig. 
2) indicating a lack of input from purinergic nerves.  To further investigate a role for these 
classical transmitters, a cocktail of all these drugs (atropine, guanethidine and α,β-methylene 
ATP) was examined, but again these agents in combination failed to alter responses to 
electrical field stimulation of the urothelium/lamina propria tissue (Figure 7-4).  
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To investigate the possible involvement of peptide neurotransmitters in mediating responses, 
the effects of phosphoramidon (10 µM, n = 8), and also a cocktail of protease inhibitors 
(Sigma P1860, 50 µL, n = 8) were examined.  None of these compounds had any effect on 
tissue contractions to EFS (Table 12).  Similarly the addition of capsaicin (100 µM) had no 
immediate effect on tissue tension or on the subsequent responses of the urothelium/lamina 
propria to field stimulation (n = 14, Table 12).  The effect of the neurokinin-2 receptor 
antagonist was also examined on the contractile responses of the urothelium/lamina propria 
induced by EFS.  Both frequency and tension were increased following administration of 
neurokinin-A (10 - 100 nM, P < 0.05, n = 8), yet at a concentration of (1 µM, n = 6) 
GR159897 abolished responses to neurokinin-A (100 nM, Figure 3) but failed to have any 
effect on responses of these tissues to EFS. 
 
 
 
 
 
 
Figure 7-1: Responses of urothelium/lamina propria strips (mean ± SEM, n = 13) to EFS 
at different stimulation frequencies in the absence (open columns) and presence (filled 
columns) of the neurotoxin tetrodotoxin (1 µM). 
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Figure 7-2: Experimental traces and histograms showing urothelium/lamina propria 
contractile responses to electrical field stimulation.  For histograms, mean responses (± SEM) 
are shown in the absence (open columns) and presence (shaded columns) of [A] atropine (1 
µM, n = 15), [B] α,β-methylene ATP (10 µM, n = 8), [C] guanethidine (10 µM, n = 12), and 
[D] L-NNA (100 µM, n = 15).  There were no significant differences between pairs of data (P 
> 0.05, Student’s paired t-test).  
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Figure 7-3:  Typical experimental traces of urothelial/lamina propria contractile activity 
showing the effects of GR159897 on responses to neurokinin-A (top trace), atropine on 
responses to carbachol (middle trace) and the effects of P2X purinergic receptor 
desensitisation on responses to α,β-methylene ATP (lower trace). 
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Figure 7-4: Experimental trace (left) and histogram (right) demonstrating the responses to 
electrical field stimulation of the urothelium/lamina propria in the absence (open columns) 
and in the presence (shaded columns) of a combination of atropine (1 µM), α,β-methylene 
ATP (10 µM), guanethidine (10 µM), and L-NNA (100 µM). This cocktail of drugs had no 
effect on responses (n = 16). 
 
 
 
Table 12: Drugs influencing peptidergic neurotransmission 
Urothelium  5 Hz 10 Hz 20 Hz 
Drug: 
n absence 
(g) 
presence 
(g) 
absence 
(g) 
presence 
(g) 
absence 
 (g) 
presence 
(g) 
Phosphoramidon 
(10 µM) 
8 0.88 ±0.4 0.97 ±0.5 1.84 ±0.7 1.75 ±0.7 2.91 ±0.9 2.60 ±0.9 
Protease Inhibitor 
Cocktail (50 µL) 
8 1.69 ±0.3 1.64 ±0.4 2.76 ±0.6 2.83 ±0.6 4.54 ±0.7 4.78 ±0.9 
Capsaicin 
(100 µM) 
14 0.83 ±0.2 1.01 ±0.2 1.80 ±0.2 1.63 ±0.2 3.00 ±0.4 2.60 ±0.4 
GR159897 
(1 µM) 
6 0.65 ±0.2 0.62 ±0.2 0.92 ±0.1 0.96 ±0.1 1.16 ±0.1 1.22 ±0.2 
 
Mean ± SEM contractile responses to EFS (5, 10, 20 Hz) of urothelial/lamina propria strips in 
the absence and presence of drugs interfering with peptide neurotransmission: protease 
inhibitors (phosphoramidon & cocktail of inhibitors), depletory of sensory neuropeptides 
(capsaicin) and NK antagonist (GR159897).  There were no significant differences between 
pairs of data (P > 0.05, Student’s paired t-test). 
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7.5 DISCUSSION 
 
Isolated strips of urothelium and lamina propria developed spontaneous phasic contractions 
that have been reported previously (2012, Moro et al., 2011).  Whether this contractile 
activity originates in smooth muscle cells or in interstitial cells within the lamina propria is 
unclear (Sadananda et al., 2008, Heppner et al., 2011).  Electrical field stimulation of the 
tissues induced contractions significantly greater than the background phasic contractions.  
These responses were frequency-dependent and predominantly (70 - 80%) neurogenic in 
origin as demonstrated by their sensitivity to the neurotoxin tetrodotoxin. Similar neurogenic 
responses can be observed in the detrusor smooth muscle where the majority of the 
contraction is mediated via acetylcholine acting on M3 muscarinic receptors (Sellers et al., 
2000b, Chess-Williams et al., 2001).  However, in the urothelial/lamina propria tissue, 
responses were insensitive to antagonism by atropine even at concentrations up to 10 µM. As 
a positive control, the actions of atropine at the lower concentration of 1 µM were examined 
on isolated strips of pig detrusor muscle (stimulated under identical conditions), and in these 
tissues, atropine reduced contractions to electrical stimulation at 5, 10 and 20 Hz by 68 ± 8%, 
80 ± 7% and 88 ± 4% respectively (all P < 0.01, n = 8).  Both the pig detrusor (Sellers et al., 
2000b) and the urothelium/lamina propria (Moro et al., 2011) contract strongly to muscarinic 
agonists and these data therefore suggest that the detrusor, but not the urothelium/lamina 
propria, has a dominant efferent cholinergic innervation capable of inducing contraction. 
 
Another neurotransmitter often co-released with acetylcholine is ATP and detrusor muscle 
expresses P2X1 receptors that mediate a contractile response to electrical field stimulation 
(Somogyi et al., 1998, O'Reilly et al., 2001a, Vial and Evans, 2000). On strips of 
urothelium/lamina propria the potent P2X receptor agonist α,β-methylene ATP induced a 
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transient contraction and abolished subsequent responses to purinergic agonists, indicating 
desensitisation of the P2X receptors. However, responses to electrical field stimulation were 
not altered by this procedure suggesting that ATP does not contribute to the contractions 
induced by field stimulation. It has been suggested that lamina propria interstitial cells may 
possess P2Y receptors for ATP and respond with a rise in intracellular calcium to the P2Y 
receptor agonist UTP (Wu et al., 2004).  However the changes in intracellular calcium were 
not accompanied by contractile responses in that study and in the present studies strips of 
urothelium/lamina propria failed to contract to UTP or UDP (100 µM, n = 8).  These results 
suggest that the tissue is similar to the detrusor muscle in possessing purinergic receptors 
(probably P2X) that can cause contraction, but unlike the detrusor, ATP does not appear to be 
an important neurotransmitter in the urothelium/lamina propria.  
 
The detrusor muscle also receives a sympathetic innervation which induces relaxation via β3-
adrenoceptors in the porcine and human bladder (Yamanishi et al., 2002b, Igawa et al., 1999, 
Yamaguchi, 2002, Badawi et al., 2007).  In the detrusor of the bladder dome, α1-adrenoceptor 
density is low and responses to α-adrenoceptor agonists are small or non-existent (Michel and 
Vrydag, 2006).  Similarly in the urothelium/lamina propria, α1-adrenoceptor stimulation has 
only minor effects on contraction, although it has been found to increase the frequency of 
spontaneous contractions of this tissue (Moro et al., 2010).  The responses of this tissue to 
noradrenaline support this conclusion, the predominant response being a β-adrenoceptor 
mediated relaxation and an inhibition of spontaneous phasic contractions (Moro et al., 2010).  
Responses to electrical stimulation in the present study were not affected by the adrenergic 
neurone blocker guanethidine at a concentration that almost abolished the neurogenic, 
sympathetic responses of the pig urethra. 
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Immunohistochemical studies of the bladder have identified the presence of a number of 
neuropeptides including tachykinins, enkephalin, calcitonin gene related peptide (CGRP), 
vasoactive intestinal peptide (VIP) and neuropeptide Y (Arms and Vizzard, 2011).  Some of 
these have been associated with efferent nerves, while others are found in the afferent nerves 
within the lamina propria.  Some of these neurotransmitters (eg. VIP) have relaxant effects on 
smooth muscle and are unlikely to be responsible for mediating urothelial/lamina propria 
contraction. It is interesting to note that neurokinin-A potently induces large contractions of 
this tissue which are mediated via the NK2 receptor (Sadananda et al., 2008).  However, the 
NK2 antagonist GR159897, at concentrations that significantly antagonises contractions to 
exogenous neurokinin-A (Sadananda et al., 2008), had no effect on the responses to electrical 
field simulation.  A possible role for neuropeptide neurotransmitters was also investigated 
using inhibitors of endopeptidases.  Peptidase enzymes located in the urothelium/lamina 
propria are important in terminating the effects of endogenous peptides, and inhibition of 
these enzymes will potentiate responses to peptides (Saban et al., 1997).  Neither the neutral 
endopeptidase inhibitor phosphoramidon nor a commercially available cocktail of protease 
inhibitor with broad specificity for serine, cysteine, aspartic and aminopeptidases had any 
effect on responses to field stimulation.  Pre-treatment of tissues with capsaicin to deplete 
neuronal stores of sensory neuropeptides also had no effect on responses of the 
urothelium/lamina propria to field stimulation.  Furthermore, when capsaicin was added to 
the bath no contraction was observed suggesting that no contractile sensory neuropeptides 
were present, or at least no significant release occurs in these tissues.  
 
In the detrusor muscle, NO is released as a co-transmitter with acetylcholine and inhibits 
smooth muscle contraction (Dokita et al., 1991).  Thus NO synthase inhibition enhances 
responses to electrical field stimulation (Garcia-Pascual et al., 1991).  In the 
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urothelium/lamina propria, NO donors relax the tissue and inhibit contractions to carbachol.  
However, the NO synthase inhibitor L-NNA has no effect on basal phasic contractions or 
those elicited by carbachol suggesting that the tissue is responsive to NO but that there is no 
basal release or muscarinic receptor stimulated release of NO in these tissues (Moro et al., 
2012).  In the present study the effects of L-NNA were examined on field stimulated tissues.  
The lack of effect following inhibition of NO synthase suggests that NO is not released as a 
co-transmitter in this tissue and does not influence nerve induced responses. 
 
Only recently has the urothelium/lamina propria been shown to possess contractile properties 
and most studies examining bladder neurogenic responses do not state whether the 
urothelium/lamina propria was removed or intact.  This may explain the variation in results 
reported in the literature.  In human tissue for example, some studies have reported that EFS-
induced bladder contractions are abolished by atropine (Sibley, 1984), while others have 
reported atropine-insensitive contractions (Sjogren et al., 1982, Tagliani et al., 1997).  It is 
possible that the atropine-resistant contraction found in a number of studies across a range of 
species actually arose from the urothelium/lamina propria rather than the detrusor muscle 
itself. 
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7.6 CONCLUSIONS 
 
This study has shown that electrical depolarisation of the nerves present in the porcine 
urothelium and lamina propria results in a frequency-dependent contraction of the tissue.  
This contraction is sensitive to tetrodotoxin, but resistant to inhibitors of adrenergic, 
cholinergic and purinergic neurotransmission.  The identity of the neurotransmitter(s) has yet 
to be determined, but does not appear to be noradrenaline, acetylcholine or ATP and is 
unlikely to be a peptide. 
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Chapter 8  
 
 
 
 
 
  
Effects of mechanical removal of the urothelium from pig bladder dome 
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Published abstracts and conference presentation arising from this chapter: 
 
 
Moro, C., Sellers, D., Chess-Williams, R. The lamina propria is responsible for the generation of 
the spontaneous contractile activity of the urothelium/lamina propria. Proceedings of the 45th 
Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Scientific 
Meeting Perth: 2011. Available at: http://ascept2011.eproceedings.com.au/papers/p103.pdf 
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8.1  INTRODUCTION 
 
The urothelium plays a vital role as a barrier to the urine and dissolved substances in the 
bladder lumen.  This tissue is a specialised surface lining the inside of the bladder and is 
composed of three cell layers: basal cells, intermediate cells, and the umbrella cells which 
cover the superficial apical surface (Figure 8-1).  A range of mechanisms work together to 
assist in maintaining an effective urothelial barrier.  For example, a coating of 
glycosaminoglycans and proteoglycans forms on the outer surface of the umbrella cells and 
protects the cells from dissolved solutes in the urine (Hurst and Zebrowski, 1994, Grist and 
Chakraborty, 1994, Nickel and Cornish, 1994).  The apical surface of the umbrella cells also 
has a unique layer of plaques composed of uroplakins (Apodaca, 2004), a range of proteins 
expressed only in the urothelium, which form a unique and specialised barrier (Hu et al., 
2005, Garcia-Espana et al., 2006).  In addition, each cell in the urothelium maintains tight 
junctions between adjacent cells, composed of 4-6 interconnecting strands (Peter, 1978).  
These tight junctions form a physical barrier that is impermeable to solvents in the urine. 
 
As discussed in previous chapters of this thesis, the urothelium releases several chemical 
mediators such as ATP, acetylcholine and nitric oxide (Ferguson et al., 1997, Cheng et al., 
2011b, Munoz et al., 2011, Yoshida et al., 2008) which play a role in sensory signalling from 
the bladder (Birder, 2006).  This wide range of properties identifies the urothelium as an 
important cell layer in the overall regulation of bladder activity.  Previous chapters of this 
thesis have also shown the contractile activity of the urothelium/lamina propria.  However, 
there is no clear evidence for a contractile-mediating cell type in the urothelium, suggesting 
that most of the contractile activity likely arises from the lamina propria.  It is of interest to 
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identify whether the contractile properties of the bladder urothelium/lamina propria strips are 
influenced by the removal of the urothelium. 
 
Prior methods for cell removal 
 
Past studies have attempted to remove the inner lining from in vitro preparations of bladder 
while leaving the detrusor intact.  Examples of this include both pig (Hawthorn et al., 2000) 
and human samples (Chaiyaprasithi et al., 2003, Kumar et al., 2004).  However, the methods 
employed resulted in the removal of the urothelium and lamina propria, rather than just the 
urothelium.  In order to assess the influence of removal of the urothelium on contractility of 
the urothelium/lamina propria a method is required that removes only the apical layers. 
 
One method for removing only the endothelial cells from tissue preparations is by dabbing 
the surface with a paper towel, such as that used in blood vessels (Sade and Folkman, 1972).  
An alternative method involves gently rubbing the surface, as commonly used to remove the 
endothelium from blood vessels (Buchwalow et al., 2008).  This study utilised a cotton-
covered wire, although a variety of other tools have been used such as a wooden dowel 
(Moore et al., 2005) or other forms of mechanical debridement (Venugopalan et al., 1997, 
Baxter, 1995, Furchgott and Zawadzki, 1980). A recent study (Munoz et al., 2010) has 
utilised an adapted method in rat bladders, swiping the internal lining of the bladder with a 
cotton bud to remove the urothelium.  Munoz et al (2010) appeared to demonstrate a method 
to remove the urothelium without specifically damaging the lamina propria.  Alternatively, 
another study on pig bladder tissue removed only the urothelium by scraping the epithelial 
surface with a scalpel (Cheng et al., 2011b). 
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The present study aimed to identify which of the previously published methods is optimal for 
disrupting the majority of the porcine apical urothelial cells without damaging the underlying 
lamina propria.  In addition, removing the urothelium may influence the contractile activity 
identified in intact urothelial/lamina propria strips.  This was investigated by measurements 
of spontaneous activity and the responses to agonists, to distinguish if the pacemaker activity 
in the isolated tissue samples is inhibited following disruption to the urothelium. 
 
 
 
 
Figure 8-1: A schematic representation of a section of bladder wall illustrating the various 
cell layers. 
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8.2  METHODS 
 
8.2.1  Mechanical disruption of the urothelium 
 
Pig bladder was obtained and prepared as detailed in Chapter 2.  Strips of urothelium/lamina 
propria were carefully dissected with scissors from the wall of the bladder dome.  Several 
different methods were used to disrupt the urothelium and are detailed below. 
 
1. Dabbing the tissue with a paper towel 
2. A single longitudinal swipe with a cotton bud 
3. Two longitudinal swipes with a cotton bud 
4. Three longitudinal sweeps with a cotton bud 
5. Four longitudinal sweeps with a cotton bud 
6. A longitudinal scrape with the edge of a scalpel 
 
8.2.2  Histology 
 
Preparation of tissues for histology 
 
Immediately after preparation of the bladder samples, the separate tissues were fixed in 10% 
Neutral Buffered Formalin (Fronine, QLD, AUS) and left for 24 hours.  Following this, 
bladders were prepared for sectioning and staining by embedding in paraffin wax.  This was 
performed using the following protocol: 
 75% Ethanol for 1 hr at 4°C  90% Ethanol for 1 hr at 4°C  100% Ethanol for 1 hr at 4°C  1:1 Xylene:ethanol for 30 minutes  100% Xylene for 30 minutes  change of 100% Xylene, for 30 minutes 
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 1: 1 Xylene:Paraplast bath, for 1 hour at 57°C  Liquid Paraplast at 57°C for 1 hour.  Change of liquid Paraplast at 57°C for 1 hour 
 
Tissues were placed in aluminium rectangle moulds (Figure 8-2) and completely covered 
with liquid “Paraplast” tissue embedding medium (Oxford labware, St Louis, MO) using a 
Tissue-Tek TEC 111 Embedding Centre.  These paraffin moulds were left to set overnight.  
 
Serial sectioning 
 
The wax sections were placed in a freezer until set and then removed from the aluminium 
boats.  Strips of tissue embedded in paraffin were sectioned at 10 µm using a Reichert-Jung 
2040 Autocut Microtome.  Five sections across the tissue were sliced from each sample and 
placed on Starfrost microscope slides (ProSciTec, QLD, AUS) which were lightly coated 
with Mayers Egg Albumin.  This was prepared by beating an egg white and leaving it 
overnight in a tall cylinder. Liquid from the bottom of the cylinder was pipetted out and 
added to an equal volume of glycerol.  Sections were placed into heating racks at 57°C and 
left for 8 hours to dry prior to staining. 
 
 
Figure 8-2: Rectangular moulds of paraffin holding the bladder specimens prior to 
sectioning and staining.  
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8.2.3  Histological analysis 
 
Histology was performed using hematoxylin-eosin staining to determine the level of removal 
of the apical urothelial cells. Prior to staining with Haematoxylin and Eosin the paraffin was 
removed from the tissues using the following procedure: 
 100% Xylene, 1 minute  1: 1 Ethanol: Xylene, 3 minutes  100% Ethanol, 3 minutes  100% Ethanol, 3 minutes  90% Ethanol, 3 minutes  70% Ethanol, 3 minutes  Distilled water, 5 minutes 
 
The sections were stained using the following procedure:  Mayers hematoxylin (Fronine, Qld), 10 minutes  Scott's tap water, (blueing solution) 5 minutes 
o 4g Sodium hydrogen carbonate 
o 40g Magnesium sulphate 
o 2L Distilled water  Acid alcohol, 1 minute 
o 29mL Distilled water 
o 1mL Concentrated HCL 
o 70mL ethanol  Distilled water, 5 minutes  Eosin phloxine solution (Fronine, Qld), 4 minutes  Distilled water, 5 minutes 
 
 
After staining the tissues underwent the following process to remove the stain from the tissue:  70% Ethanol bath, 3 minutes  90% Ethanol bath, 3 minutes  100% Ethanol bath, 3 minutes  100% Ethanol bath, 3 minutes  50% Ethanol 50% xylene bath, 3 minutes   100% Xylene, 3 minutes  Left to dry overnight. 
 
A coverslip was fixed to the slide with Biomount.  Slides were then examined under a 
microscope for clarity in the image, and the individual layers of the bladder identified. 
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8.2.4  Tissue Setup 
 
Strips of urothelium/lamina propria 2 cm long were mounted in Krebs-bicarbonate solution, 
as described in Chapter 2.  The frequency of spontaneous contractions and baseline tension 
was recorded for control intact tissues and also those with a disrupted urothelium. 
 
8.2.5  Responses to agonists 
 
In separate experiments, samples of urothelium/lamina propria were dissected into 4 cm 
strips, and cut in half.  The two 2 cm strips were set up in pairs, with one left as control 
(intact), and one swiped three times with a cotton bud to disrupt the urothelium.  Frequency 
(cycles min-1), and tension (g) responses were obtained in the absence and presence of 
carbachol (1 µM, n = 8) and isoprenaline (1 µM, n = 8).  Responses to agonists were taken at 
the peak response and data obtained was analysed using paired Student’s t-tests 
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8.3  RESULTS 
 
Histological Studies 
 
8.3.1  Control Tissues 
 
In whole segments of bladder dome stained with hematoxylin-eosin, the urothelium, lamina 
propria and underlying detrusor were evident (Figure 8-3).  Following removal of the 
detrusor muscle, the urothelium and lamina propria were not damaged from the dissection 
process (Figure 8-4).  The umbrella cells were clearly intact and the process of preserving the 
tissues by fixation and embedding in paraffin wax was a successful method to retain the 
individual layers. 
 
 
Figure 8-3: Transverse section of the bladder dome stained with haematoxylin and eosin.  
This control tissue was not denuded.  The tissue beneath the urothelium and lamina propria is 
composed of detrusor smooth muscle (Magnification: 40x). 
 
 
 
 
Lumen of Urinary bladder 
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(Smooth muscle cells) 
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Mechanical disruption of the urothelium 
 
8.3.2  Effect of a single or double dab of the tissue with a paper towel 
 
An attempt was made to remove the urothelium using a method previously used on vascular 
endothelium, outlined by Sade and Folkman (1972).  Tissues were dabbed with a “Kimwipe” 
paper towel one or two times.  There was no observable difference between the urothelial 
cells of these tissues and those of controls (Figure 8-5, Figure 8-6).  
 
8.3.3  Effect of a single or double longitudinal swipe with a cotton bud 
 
Using an adapted method from Munoz et al. (2010), tissues underwent a single longitudinal 
swipe with a cotton bud.  There was a very slight compressing of the urothelium with this 
method, although the apical cell layers were still intact and not removed from the tissue. 
 
8.3.4  Effect of a single or double longitudinal swipe with a cotton bud 
 
Two longitudinal swipes with a cotton bud was effective at removing some portions of the 
urothelium, although the success was inconsistent. There were also regions of the apical layer 
which were left relatively intact (Figure 8-7). 
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8.3.5  Effect of three longitudinal sweeps with a cotton bud 
 
The effect of three longitudinal swipes with a cotton bud was also examined.  In these 
samples a large proportion of the urothelium was removed down to the basal layers.  This 
method produced a substantial disruption to the urothelium but left the lamina propria largely 
intact (Figure 8-8). 
  
8.3.6  Effect of four longitudinal swipes with a cotton bud 
 
Four swipes with cotton buds across the urothelial surface resulted in a clear and uniform 
disruption of the urothelium which was generally consistent throughout the samples (Figure 
8-9).  However, portions of the lamina propria were also disrupted, and large sections of the 
tissue underwent damage that affected the lamina propria.  
 
8.3.7  Effect of longitudinal scrape with the edge of a scalpel 
 
Scraping the tissue with a scalpel caused damage to both the urothelium and the lamina 
propria (Figure 8-10).  Although the majority of damage was observed along the urothelium, 
in some sections the scalpel broke through the urothelium and damaged the lamina propria.  
In these sections the scalpel had dug directly into the lamina propria, causing severe damage 
to large numbers of cells within. 
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Figure 8-4: Control urothelium/lamina propria tissues after dissection from the detrusor 
muscle. The urothelium (arrows) and lamina propria (LP) were easily identifiable and not 
damaged by the dissecting procedure (Magnification: Left image: 100x. Right image: 400x). 
 
 
 
 
Figure 8-5: Effect of dabbing the tissue once with a paper towel.  This method did not 
cause any clear disruption to the urothelium (U, arrows). Magnification: Left image: 100x. 
Right image: 400x 
 
 
 
 
Figure 8-6: Effect of dabbing the tissue two times with a paper towel.  Dabbing the tissue 
twice with a paper towel (Kimwipes) did not cause any clear disruption to the urothelium 
(Magnification: Left image: 100x. Right image: 400x). 
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Figure 8-7: Effect of two longitudinal swipes with a cotton bud.  Two swipes with cotton 
bud caused a very slight disruption to parts of urothelium (arrows) although the majority of 
the layer was kept intact (Magnification: Left image: 100x. Right image: 400x). 
 
 
  
Figure 8-8: Effect of three longitudinal swipes with a cotton bud.  Three swipes with 
cotton buds caused a clear and uniform disruption of the urothelium. This appeared consistent 
throughout the samples (Magnification: Left image: 100x. Right image: 400x). 
  
 
 
Figure 8-9: Effect of four longitudinal swipes with a cotton bud.  Four swipes with cotton 
buds caused a clear and uniform disruption of the urothelium (arrows) which was generally 
consistent throughout the samples.  However, portions of the lamina propria (LP) were also 
disrupted (Magnification: Left image: 100x. Right image: 400x). 
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Figure 8-10: Effect of a longitudinal scrape with the edge of a scalpel.  Scraping the tissue 
with a scalpel caused damage to the urothelium (arrows) and lamina propria (Magnification: 
Left image: 100x. Right image: 400x). 
  
 
 
 
8.4  CONCLUSION FROM HISTOLOGICAL STUDIES 
 
Upon histological analysis three swipes with a cotton bud was found to be the optimal 
method to successfully disrupt the urothelium without damaging the lamina propria.  This 
method was used for subsequent functional studies. 
 
8.4.1  Spontaneous activity of urothelium/lamina propria strips following removal of 
 the urothelium 
 
There was no significant difference in the frequency of spontaneous activity or baseline 
tension between the control tissues and those that underwent urothelium removal with three 
swipes of a cotton bud (3.06 ± 0.22 cycles min-1 vs 2.99 ± 0.26 cycles min-1 for frequency, 
1.57 ± 0.18g vs 1.57 ± 0.16g for tension, n = 8). 
  
 
 
LP
LP 
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8.4.2  Response to carbachol 
 
After a 60 minute equilibration, responses were obtained to carbachol (1 µM, n = 8).  The 
increase in contractile frequency induced by carbachol was similar between the control 
(Figure 8-11) and urothelium-denuded tissues (2.02 ± 0.80 cycles min-1 vs 1.55 ± 0.32 cycles 
min-1, Figure 8-12).  The increase in basal tension to carbachol was also similar in the two 
groups of tissues (3.27 ± 0.37g vs 1.57 ± 0.16g, Figure 8-13). 
 
8.4.3  Response to isoprenaline 
 
Isoprenaline (1 µM, n = 8) had a clear effect on the bladder, causing strong relaxations of the 
tissue.  The decrease in contractile frequency induced by isoprenaline was similar in control 
and urothelium-denuded tissues (0.88 ± 0.18 cycles min-1 vs 1.15 ± 0.22 cycles min-1).  In 
addition, the decrease in basal tension to isoprenaline was not significantly different between 
the two groups of tissues (1.01 ± 0.07g vs 1.35 ± 0.16g, Figure 8-14) 
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Figure 8-11: Representative traces depicting the baseline spontaneous contractile activity 
(top image) and the response to carbachol (at arrow, 1 µM, bottom image) in a control tissue 
 
 
 
 
  
 
 
Time (h:mm:ss) 
 
 
Figure 8-12: Representative traces depicting the baseline spontaneous contractile activity 
(top image) and the response to carbachol (at arrow, 1 µM, bottom image) in a tissue which 
had undergone longitudinal swiping three times with a cotton bud. 
 
 
 
 
 
 
T
en
si
on
 (
g)
 
T
en
si
on
 (
g)
 
 Page | 212 
 
 
 
Figure 8-13: The effect of carbachol (1 µM, n = 8) to frequency or tension on tissues that 
had undergone three swipes with a cotton bud (CB) compared to controls. There was no 
significant difference in the spontaneous contractile frequency or the tension response to 
carbachol. 
 
 
 
Figure 8-14: The effects of isoprenaline (1 µM, n = 8) to frequency or tension on the tissues 
after three swipes with a cotton bud (CB) as above.  There was no significant difference in 
the spontaneous contractile frequency or the relaxation responses to isoprenaline. 
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8.5  DISCUSSION 
 
Isolated strips of the urothelium and lamina propria develop spontaneous contractions which 
can be modulated via activation of the muscarinic and adrenergic receptor systems as 
discussed in previous chapters.  However, the mechanisms underlying this activity are 
unknown and it is not clear how the urothelium influences the overall activity of the bladder.  
It is likely that the cells involved in the generation, coordination and contractile function of 
the spontaneous activity lie within in the lamina propria rather than in the urothelium.  
Although still not proven, this hypothesis has been suggested by authors of prior studies 
examining this layer (Ikeda et al., 2007, Cheng et al., 2011b, Fry et al., 2012). 
 
It is known that removal of the urothelium/lamina propria affects detrusor contractions.  This 
has been shown in a study where contractile responses to electrical field stimulation in the 
feline bladder were significantly increased following urothelium/lamina propria removal 
(Levin et al., 1995).  Additionally, isolated pig bladder strips also demonstrated increased 
contractile responses to muscarinic receptor stimulation after urothelium/lamina propria 
removal, and this is thought to be due to an unknown urothelium derived inhibitory factor 
(Templeman et al., 2002b, Hawthorn et al., 2000).  Removal of the urothelium from rat 
bladder strips does not appear to affect basal release of nitric oxide or ATP (Munoz et al., 
2010).  However, in that study urothelial removal did produce a significant reduction in 
carbachol-induced release of nitric oxide and electrical-field stimulated release of ATP.   It 
was unclear whether these results related functionally to the spontaneous contractile activity 
of urothelium/lamina propria or solely on the contractile ability of the detrusor smooth 
muscle. 
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In an attempt to disrupt the urothelium while leaving the lamina propria intact, previously 
published methods for removal of this cell layer were investigated.  Histological examination 
showed that one or two dabs with a paper towel had no effect on the urothelium.  Although 
past studies have used this method successfully in vascular endothelium (Sade and Folkman, 
1972), it does not appear to influence the bladder urothelium to the same effect.  This is most 
likely due to the presence of a squamous epithelium in blood vessels compared to a 
transitional epithelium on the urothelium. 
 
Scraping with a scalpel, which has been used previously on pig bladders (Cheng et al., 
2011b), did effectively disrupt the urothelium.  However, this method appeared to ‘tear’ away 
sections of the lamina propria.  It is possible that careful use of a scalpel blade, giving 
consideration to the angle and direction of the blade, would be an effective method for 
collection of urothelial cells or removing the urothelium from small areas of the tissue. 
 
Mechanical methods for removing the apical layers via swabbing or rubbing the epithelial 
surface have also been used successfully in a range of tissues (Furchgott and Zawadzki, 1980, 
Buchwalow et al., 2008).  Additionally, longitudinal swiping has been successful in rat 
urinary bladder (Munoz et al., 2010).  One or two swipes with a cotton bud were ineffective 
at removing large proportions of urothelium from the luminal surface in the present study.  
This may differ from that experienced in vascular studies, due to the larger and potentially 
more robust nature of the porcine bladder urothelium in comparison to the endothelium in rat 
bladders or blood vessels.  However, three longitudinal swipes with a cotton bud consistently 
disrupted the urothelial layer across the tissue samples.  This method was less invasive and 
damaging to the lamina propria than scraping with a scalpel.  After this success, four swipes 
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with a cotton bud were attempted, but this method started to impact the underlying lamina 
propria. 
 
Upon confirming the validity of the removal method, paired functional experiments were 
performed to identify the impact of three swipes with a cotton bud on the lamina propria 
contractile activity.  The basal spontaneous frequency observed in previous chapters was still 
evident and not altered by urothelium removal.  In addition, responses to muscarinic receptor 
stimulation or β-adrenoceptor stimulation were also not affected by urothelial removal.  This 
suggests that the urothelium is not involved in mediating the spontaneous contractile activity 
of the urothelium/lamina propria.  This was interesting, as urothelial cells are known to 
express a range of receptors such as muscarinic (Wang et al., 1995), vanilloid, and adrenergic 
receptors (Birder et al., 2001).  Additionally, the urothelium can release a number of chemical 
mediators including acetylcholine (Yoshida et al., 2006); nitric oxide (Birder et al., 1998); 
and ATP (Ferguson et al., 1997).  Although some of these, such as ATP, can also be released 
from the urothelium and lamina propria (Sadananda et al., 2012, Sadananda et al., 2009), it 
was interesting to identify a lack of effect after removal of the urothelium. 
 
A diverse collection of cells reside within the lamina propria.  These include connective 
tissue, blood vessels, and afferent nerve fibres; as well as a range of cells types which include 
interstitial cells and fibroblasts (Johnston et al., 2010, McCloskey, 2010, Rasmussen et al., 
2009, Wiseman et al., 2003, Yu et al., 2011b, Woodman et al., 2011).  Additionally, a variety 
of immune cells are also present in the lamina propria, such as mast cells and dendritic cells 
(Christmas and Rode, 1991, Gardiner et al., 1986, Kummer et al., 2007, Yu and Hill, 2011).  
Within this layer, the interstitial cells most likely mediate contractile activity and the 
responses to receptor activation.  These cells have been discussed in Chapter 1, and it is 
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understood that they have the ability to contract and hold close associations with the calcium 
transients and spontaneous activity (Fry et al., 2007, Sui et al., 2008, Fry et al., 2012).  
Additionally, there is a possibility that these types of cells are involved in contractile activity 
during wound healing responses (Gabbiani, 2003).  Interstitial cells have also previously been 
suggested as the cell type mediating urothelial/lamina propria contractions in response to 
neurokin-A (Sadananda et al., 2008).  Therefore, it appears from past research that the 
interstitial cells are likely modulators for the observed responses demonstrated in strips of 
urothelium-removed lamina propria. 
 
In conclusion, disruption to the apical urothelial cells of the pig bladder could be 
accomplished by a swipe with a scalpel and swiping three times with a cotton-bud, but not by 
dabbing with a paper towel.  The optimal method for urothelium removal was determined to 
be three swipes with a cotton bud.  Disruption to this layer did not affect the rate of 
spontaneous contractions, the response to muscarinic receptor stimulation or the response to 
β-adrenoceptor activation of the underlying tissue.  This indicates that the phasic activity of 
the urothelium/lamina propria most likely arises from cells within the lamina propria and is 
independent of urothelial regulation. 
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Chapter 9  
 
 
GENERAL DISCUSSION 
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The urothelium/lamina propria is known to play an important role in the maintenance of 
normal bladder function via the release of chemical mediators.  In addition, the 
urothelium/lamina propria exhibits spontaneous contractile activity and this may influence 
contractions within the bladder.  This thesis investigated the factors mediating contractile 
activity of the bladder urothelium/lamina propria. 
 
9.1.1  The spontaneous activity of the urothelium/lamina propria 
 
An important part of this study was the clear classification of the urothelial/lamina propria 
spontaneous contractile activity.  This phasic activity occurs at a rate of 3 - 4 cycles per 
minute and develops spontaneously in vitro in urothelial/lamina propria tissue strips.  The 
ability of the urothelium/lamina propria to contract has been demonstrated previously in a 
range of studies inducing contraction in: the lamina propria from rabbit urethra after EFS or 
exogenous noradrenaline (Mattiasson et al., 1985a, Zygmunt et al., 1993); urothelium/lamina 
propria from rat bladder to the P2Y agonists ADP, UTP and UDP (Fry et al., 2012); guinea 
pig urothelium/lamina propria to EFS (Heppner et al., 2011); and pig urothelium/lamina 
propria to neurokinin A or carbachol (Sadananda et al., 2008).  The present study has further 
characterised this contractile activity. 
 
In an attempt to elucidate the underlying mechanisms for the urothelium/lamina propria 
spontaneous contractile activity a number of investigations were completed.  Although the 
urothelium/lamina propria receives a rich density of sensory and parasympathetic nerve fibres 
(Birder, 2011, Dickson et al., 2006), its spontaneous contractile activity was insensitive to 
tetrodotoxin in the present study, suggesting a non-neuronal mechanism of generation.  This 
was supported by EFS experiments, which showed that although nerve depolarisation could 
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evoke contractions, the frequency of spontaneous activity remained unaltered.  In addition, L-
NNA had no effect on the contractile response to EFS or the spontaneous contractile 
frequency and basal tension.  This finding for the urothelium/lamina propria was interesting, 
as neuronally-derived nitric oxide is thought to modulate spontaneous activity in detrusor 
smooth muscle, and as such, was considered a potential regulator for the urothelium/lamina 
propria (Meng et al., 2012).  However, although NOS-inhibition had no effect on 
spontaneous activity, the addition of NO donors did cause a relaxation in tension and 
decrease in contractile frequency in the urothelium/lamina propria.  These results suggest that 
this tissue can respond to nitric oxide through mechanisms within the urothelium/lamina 
propria, although NO is not released endogenously, as previously suggested by Munoz et al. 
(2010).  Prostaglandins were also considered to be potential mediators of urothelial/lamina 
propria activity, and are known to have cytoprotective functions within the gut mucosa and 
possibly in the urinary bladder (Milman, 2007).  However, in this study the spontaneous 
contractile frequency, basal tension or response to EFS were unaffected by the application of 
indomethacin. 
 
In the absence of any agonist, the spontaneous contractions of the urothelium/lamina propria 
were also unaltered following antagonism of muscarinic, purinergic, or adrenergic receptors, 
even though these receptors are known to be functionally active in the urothelium/lamina 
propria (Birder, 2011).  Neuropeptides are potential mediators of lower urinary tract function 
(Arms and Vizzard, 2011), yet the spontaneous contractile activity or responses to EFS were 
unaffected by the administration of antagonists for common neuropeptides.  Additionally, no 
effect was seen after the administration of capsaicin, which causes the release of 
neuropeptides (Szolcsanyi, 2004).  This lack of response is consistent with a recent study 
which identified that capsaicin was not involved in stimulating either contraction or release of 
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ATP from pig urothelium/lamina propria (Sadananda et al., 2012).  Also, an NK2 receptor 
antagonist had no effect on responses to EFS or on basal contractile activity, even though 
exogenous neurokinin-A is known to cause contraction (Sadananda et al., 2008).  Although 
these receptor antagonists do not affect urothelial/lamina propria activity or the responses to 
EFS, receptor activation did modulate the spontaneous contractions indicating that these 
receptors and systems may be important in regulation of frequency or generation of 
spontaneous contractile activity. 
 
9.1.2  Spontaneous contractile activity in the detrusor 
 
The urothelium/lamina propria may be involved in regulating the detrusor, where a degree of 
spontaneous contractile activity is also present (Sibley, 1984, Fry et al., 2010).  These 
detrusor contractions arise via myogenic spontaneous activity present in the detrusor (Levin 
et al., 1986) due to increases in the levels of sarcoplasmic calcium (Wu et al., 1995).  This 
increase can occur due to an influx of extracellular calcium via L-type or T–type channels 
(Montgomery et al., 1992, Sui et al., 2003), or by release from intracellular stores (Wu et al., 
2002, Fry et al., 1994).  This calcium influx initiates the detrusor contractions, which are 
followed by potassium-mediated repolarisations (Hashitani and Brading, 2003, Herrera et al., 
2000, Heppner et al., 1997, Young et al., 2008, Thorneloe and Nelson, 2003).  These 
processes result in contraction-relaxation phasic cycles. 
 
Detrusor spontaneous contractions during the filling stage occur during detrusor overactivity 
in both human (Mills et al., 2000) and pig bladder models of detrusor overactivity (Milicic et 
al., 2006) and this may be due to enhanced calcium oscillations in the detrusor muscle layers 
(Sui et al., 2009).  These oscillations are not unique to the detrusor and it is known that 
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calcium signals collectively regulate a variety of functions in muscle cells, including 
contractility, modulation of membrane potential and regulation of gene expression (Hill-
Eubanks et al., 2011). 
 
9.1.3 The influence of the urothelium/lamina propria on bladder activity 
 
It is evident that spontaneous activity within the urothelium/lamina propria likely influence 
bladder activity.  This has been demonstrated in a number of studies in animal models.  
Firstly, the presence of the urothelial/lamina propria enhances the spontaneous contractile 
activity in intact bladders (Ikeda and Kanai, 2008, Sui et al., 2008).  Secondly, intact tissues 
generate larger propagating calcium waves in the detrusor than that of denuded samples 
(Ikeda and Kanai, 2008, Sui et al., 2008, Fry et al., 2012).  Thirdly, calcium mapping 
techniques have shown that spontaneous calcium waves in rat bladders were generated from 
within the lamina propria and then spread outward towards the urothelium and detrusor 
(Ikeda et al., 2007, Kanai et al., 2007).  The phasic calcium transients were linked to 
spontaneous contractile activity in rats, and this activity was augmented by ADP, UTP and 
UDP, the specific purinergic agonists which stimulate P2Y receptors on lamina propria 
interstitial cells (Fry et al., 2012).  Fry et al (2012) suggested that these interstitial cells were 
instrumental in determining the contractile properties of bladders that exhibited overactivity. 
 
In the present study, the importance of calcium channels in regulating the urothelial/lamina 
propria contractile activity was further supported by the addition of nifedipine (1 µM, n = 8), 
which significantly inhibited the frequency (P < 0.05) and tension (P < 0.01) of contractions.  
This finding is consistent with a recent study which demonstrated that nifedipine abolished 
both the spontaneous contractions of the urothelium/lamina propria, and calcium transients in 
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guinea-pig bladders (Heppner et al., 2011).  Therefore, these results further suggest the 
involvement of calcium influxes from the urothelium/lamina propria in influencing bladder 
contractions. 
 
9.1.4  The role of interstitial cells within the lamina propria as the generators of 
contractile activity 
 
In the present study the importance of the lamina propria in regulating bladder spontaneous 
activity was investigated by debridement of the urothelium.  Disruption to the apical 
urothelial layer did not affect the rate of spontaneous contractions nor the responses to 
muscarinic receptor stimulation or β-adrenoceptor activation.  This thereby identified the 
lamina propria as the primary layer generating the spontaneous activity, although which cell 
type involved has not yet been determined.  However, it is likely to arise from interstitial cells 
within this layer. 
 
In the gastrointestinal tract interstitial cells have been widely researched and are understood 
to act as pacemaker cells, stretch receptors and intermediaries between nerve and smooth 
muscle cells (Sanders and Ward, 2006).  Throughout the lower urinary tract, such as in the 
prostate, interstitial cells are known to generate spontaneous calcium transients, yet these 
have not always been linked to contraction or pacemaker potential generation (Lam et al., 
2011).  Since the identification of interstitial cells in the bladder (Smet et al., 1996b) a 
number of hypotheses have been proposed implicating these cells in the maintenance of 
normal bladder function.  Interstitial cells form a network within the lamina propria 
(McCloskey, 2011), and may have a role in mediating the spontaneous activity of the bladder 
(Wiseman et al., 2003, Fry et al., 2004a, Gillespie et al., 2006b).  Lamina propria interstitial 
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cells not only elicit spontaneous electrical and calcium events but also respond to exogenous 
agonists such as ATP (Fry et al., 2007).  Interestingly, they appear responsible for the 
increased spontaneous calcium transients and contractile activity observed in the bladders of 
spinal cord transected mice (Ikeda and Kanai, 2008), a suggestion supported by reports of 
increased interstitial cell density within the lamina propria of experimental models of detrusor 
overactivity (associated with bladder outlet obstruction) in both rat (Kim et al., 2011) and 
guinea pig (Kubota et al., 2008).  Detrusor overactivity has shown to be associated with 
increased numbers of interstitial cells in human detrusor (Biers et al., 2006b), although this 
study only examined one patient with idiopathic detrusor overactivity and one with 
neurogenic detrusor overactivity.  Additionally, increases in gap junction expression between 
interstitial cells, demonstrated with connexion-43 staining, has been observed in human 
(Roosen et al., 2009) and rat (Ikeda et al., 2007) neurogenic overactive bladders, and 
morphological changes in these cells are also seen in patients with this condition (Gevaert et 
al., 2011). 
 
9.1.5  Modulation of urothelial/lamina propria activity 
 
Increases in urothelial/lamina propria spontaneous activity 
 
During urodynamic observations, patients with overactive bladder who have unexpected 
spontaneous contractions during the filling stage can be diagnosed with detrusor overactivity 
(Al-Ghazo et al., 2011, Abrams et al., 2002).  The mechanisms underlying this bladder 
disorder are not known, but the fact that the urothelium/lamina propria develops spontaneous 
contractions suggests a potential influence.  Therefore, mechanisms that result in increases to 
frequency or tension of the urothelium/lamina propria activity warrant investigation. 
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In the detrusor smooth muscle, stimulation of muscarinic M3-receptors is known to result in 
contractions (Fetscher et al., 2002, Chess-Williams, 2002a).  On the urothelium/lamina 
propria the nicotinic receptor agonist DMPP did not affect contractile activity.  However, 
muscarinic receptor agonists did increase the rate and basal tension of spontaneous 
contractions via the M3 muscarinic receptor.  Also, after tissue distension the spontaneous 
contractile frequency of the urothelium/lamina propria was increased.  This increase in 
frequency was not mediated via ATP, NO or prostaglandins, but via acetylcholine acting via 
the M3-receptors. The finding that stretch activates M3-muscarinic receptors within the 
urothelium/lamina propria and thus increases the rate of contractions implicates these 
receptors with a potential role in modulating the spontaneous activity. 
 
The additional finding that stretch-induced increases in spontaneous contractile rate were 
insensitive to tetrodotoxin supports the idea that during the storage phase of micturition, 
acetylcholine is released from the urothelial cells rather than nerves.  This links to current 
research, whereby human bladder strips release increased non-neuronal acetylcholine during 
stretch, which is significantly greater with the presence of the urothelium/lamina propria 
(Yoshida et al., 2004b), and also enhanced with age (Yoshida et al., 2006).  This has not 
solely been observed in tissue experiments, as non-neuronal acetylcholine is also released 
during hypotonic stretching of cultured urothelial cells (Hanna-Mitchell et al., 2007).  This 
stretch-induced acetylcholine release likely influences detrusor function.  
Electrophysiological studies in rats have shown that responses to both carbachol and stretch 
commence in the urothelial layers, whereby the calcium and membrane potential transients 
begin near the urothelial-lamina propria interface before spreading to the detrusor (Kanai et 
al., 2007).  This suggests that stimulation of the muscarinic receptors in the 
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urothelium/lamina propria during stretch possibly contributes to calcium-mediated 
spontaneous contractions in the detrusor. 
 
Within the lamina propria the M3-muscarinic receptor subtype is present on interstitial cells, 
as demonstrated in immunohistochemical studies (Grol et al., 2009).  An additional 
importance for these lamina propria M3-receptors is suggested by their upregulation in 
obstructed guinea pig bladders (Grol et al., 2011).  This increased receptor density may 
present a mechanism that underlies the increased sensitivity to muscarinic stimuli from 
cholinergic agonists, observed in guinea pig models of bladder obstruction (de Jongh et al., 
2007a).  Additionally, an increased density of urothelial/lamina propria M2 and M3 
muscarinic receptors is associated with overactive bladder in humans (Mukerji et al., 2006b) 
and in a bladder outlet obstruction models in rats (Kim et al., 2008), further implicating a role 
for these receptors in pathological states. 
 
In the present study the predominant response to noradrenaline in the urothelium/lamina 
propria was relaxation via the β-adrenoceptors, however, mRNA was found to be present for 
all α-adrenoceptor subtypes.  Surprisingly, in the presence of propanolol, the addition of 
exogenous noradrenaline resulted in significant increases to frequency and tension in strips of 
urothelium/lamina propria.  This effect was also seen with α1-adrenoceptor agonists, which 
increased the spontaneous contractile frequency and tension via the α1A/L-adrenoceptor 
subtype.  Interestingly tamsulosin, an α1-adrenoceptor antagonist used clinically, was able to 
depress these increases in frequency and tension at low concentrations.  α1-adrenoceptor 
antagonists have been successfully used for many years as treatments for benign prostate 
hyperplasia (Lepor et al., 2012, Nickel, 2003).  The main target for their therapeutic action is 
the α1A-adrenoceptor mediated contraction of smooth muscle in the prostate which constricts 
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the urethra (Ventura et al., 2011).  However, new clinical evidence suggests that α1-
adrenoceptor antagonists may also act on other areas of the lower urinary tract and potentially 
alleviate lower urinary tract symptoms, such as urgency, through mechanisms independent of 
prostatic smooth muscle tone (Yoshida et al., 2012, Barendrecht et al., 2008, Chess-Williams, 
2002b).  It is not clear which regions in the bladder contain functionally active α-
adrenoceptors, although there is data supporting mRNA and protein expression of these 
receptors in the rat urothelium (Yanase et al., 2008, Ishihama et al., 2006) and human lamina 
propria (Kurizaki et al., 2011).  Two studies identified decreases in maximum micturition 
pressure during urodynamic analyses in patients administered silodosin, an α1A-selective 
adrenoceptor antagonist (Yamanishi et al., 2010, Matsukawa et al., 2009).  The effect of these 
drugs has been further demonstrated in a rat model, where tamsulosin increases urine flow 
but also reduces bladder overactivity (Okutsu et al., 2011).  There is a scarcity of functionally 
active postjunctional α1-adrenoceptors located on the detrusor muscle (Goepel et al., 1997, 
Michel and Vrydag, 2006, Yamada and Ito, 2011), and as such, the data presented in this 
thesis suggests that the clinical α1-adrenoceptor antagonists might act on receptors within the 
urothelium/lamina propria to alleviate symptoms of overactive bladder.  This potential for 
these drugs is of considerable interest and may provide future pharmacological treatments. 
 
There remain a range of other receptor systems within the urothelium and lamina propria that 
when stimulated, increase contractile activity and hence warrant future research.  The 
urothelium/lamina propria is known to contract in response to stimulation of neurokinin-2 
receptors (Sadananda et al., 2008), and both frequency and tension were increased following 
administration of neurokinin-A (Chapter 7).  Histamine also caused an increase in baseline 
tension of 15 ± 2% (10 µM, n = 12, p < 0.001) although it did not increase the frequency of 
contractions.  Excessive angiotensin II activity has been suggested as a contributing factor for 
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lower urinary tract symptoms (Comiter, 2012), and an increase in tension and frequency was 
observed in the present study upon addition of exogenous angiotensin II (100 nM, P < 0.01, n 
= 8).  The additional increases in frequency and tension observed with prostaglandin E2 (P < 
0.01, n = 8) are also consistent with a recent study demonstrating its effect on enhancing 
spontaneous activity in the mouse urinary bladder (Kobayter et al., 2012).  Past research has 
identified prostaglandin release in both human (Abrams et al., 1979, Jeremy et al., 1987, 
Mikhailidis et al., 1987) and dog (Gilmore and Vane, 1971) bladder samples, and although 
application of indomethacin had no effect on the urothelium/lamina propria basal 
spontaneous contractile activity in the present study, abnormal prostaglandin release may 
contribute to lower urinary tract symptoms.  Thus, drugs targeting NK2, angiotensin II or 
prostaglandin E2 receptors may potentially be of clinical use in pathologies of the bladder. 
 
Decreases in urothelial/lamina propria spontaneous activity 
 
Mechanisms within the bladder which reduce the frequency of spontaneous contractions 
present novel therapeutic targets which may alleviate some symptoms of bladder pathology.  
This is evident with the range of new β-adrenoceptor agonists currently undergoing 
successful clinical trials as therapeutic treatments for overactive bladder (Gulur and Drake, 
2010, Gras, 2012).  In the urothelium/lamina propria, the predominant response to 
noradrenaline was found to be a relaxation and inhibition of spontaneous contractile activity 
via β-adrenoceptors.  This relaxation to noradrenaline is enhanced following antagonism of 
the α-adrenoceptors.  Inhibitory effects on the urothelium/lamina propria were also observed 
with other β-adrenoceptor agonists, and mediated predominantly via β2-adrenoceptors. 
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The urothelium/lamina propria was sensitive to NO which reduced the tension and slowed the 
rate of spontaneous activity.  However, there did not appear to be any spontaneous NO 
release or muscarinic receptor-mediated NO release.  The beneficial effects of administration 
of NO have been investigated previously, whereby oral nitrates were found to improve peak 
urinary flow rates and reduce residual urine volume in patients with bladder outlet 
obstruction (Klotz et al., 1999).  However, there was no significant change to micturition 
parameters in asymptomatic patients and although the effectiveness of NO is still uncertain 
the present study implicates the urothelium/lamina propria as a target for future trials of such 
agents. 
 
9.1.6  The physiological role of the urothelial/lamina propria contractile activity 
 
It is unknown exactly why the bladders of many species exhibit spontaneous contractions, yet 
a range of hypotheses have been presented since their initial discovery in humans, pigs and 
rabbit bladders (Sibley, 1984).  These contractions may stimulate nerves in the lamina propria 
(Gillespie, 2004a); maintain muscular tone (Fry et al., 2010); allow the individual muscle 
bundles to adjust their length in response to filling (Brading, 2006); or directly influence the 
detrusor to maintain normal continence during the filling stage. 
 
Another hypothesis put forward in this thesis is that an additional action of the spontaneous 
urothelial/lamina propria contractions might be to maintain tight junctions between the 
umbrella cells in the apical urothelial layer.  As the bladder fills the urothelium stretches to 
allow for a greater surface area, to accommodate an increasing volume of urine.  The 
interstitial cells under the urothelium might contract in order to pull together the cells on the 
upper surface, keeping them tightly connected during stretching.  Throughout bladder filling, 
 Page | 229 
urothelial cells could release acetylcholine to act on M3 receptors and stimulate faster lamina 
propria contractions, pulling the urothelial cells together and assisting with the maintenance 
of a tight apical-layer junction.  Thus, the urothelial/lamina propria spontaneous contractile 
activity could act as an additional protective system which responds to the intensity of stretch 
and thus prevents the apical cell layer from reducing its barrier function or overstretching.  
Maintaining consistently tight and stable connections between umbrella cells throughout the 
filling stage would also contribute to the preservation of the uroplakin and GAG layers which 
coat the apical surface.  It would be of great interest to investigate these various hypotheses 
for the roles of spontaneous urothelial/lamina propria contractions in future studies. 
 
9.1.7  Implications for future drug development and future directions for the 
research described in this thesis 
 
The muscarinic receptor-mediated increases to the spontaneous contractile activity of the 
urothelium/lamina propria may have important clinical implications.  Muscarinic antagonists 
are the most common treatments for bladder overactivity (Sellers and Chess-Williams, 2012) 
and drugs used clinically to alleviate the symptoms of overactive bladder: darifenacin, 
oxybutynin, tolterodine and solifenacin, were used on the urothelium/lamina propria to 
identify their effects in mediating frequency and tension increases to carbachol.  All four 
drugs were able to depress muscarinic receptor-mediated and stretch-induced increases in 
spontaneous contractile activity.  The antagonism by these clinical antimuscarinics at the 
muscarinic receptors on the urothelium/lamina propria, which has a higher density of 
muscarinic receptors compared to the detrusor (Hawthorn et al., 2000), suggests an additional 
mechanism of action of these agents when alleviating symptoms associated with overactive 
bladder.  
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There was a higher contractile frequency in the urothelial/lamina propria strips compared to 
intact-bladder or detrusor strips, suggesting a limited influence of the urothelial/lamina 
propria in regulating normal bladder contractions.  Although the link between in vitro 
urothelial/lamina propria contractions and in vivo whole-bladder contractions has never been 
ascertained, the urothelial activity may be more tightly coupled in diseased states of the 
bladder, where increased rates and amplitudes of contractions during the filling stage are 
associated with overactive bladder (Al-Ghazo et al., 2011).  It has been demonstrated in rat 
bladders that calcium transients arise in the urothelium before propagating to the detrusor 
(Kanai et al., 2007).  This urothelial spontaneous activity and its potential to spread to the 
detrusor layer (Fry et al., 2007) suggests that abnormal rates of spontaneous activity shown in 
some bladder diseases may be generated from the urothelium/lamina propria.  This would 
result with an increased spontaneous activity in the detrusor during filling, such as that 
observed by urodynamics in sufferers of detrusor overactivity. 
 
Further investigation into the functional roles of the spontaneous activity in the 
urothelial/lamina propria and the potential increased coupling to detrusor contractions in 
disease will provide a better understanding of the underlying causes in bladder malfunction.  
As a target for pharmacological treatment, the urothelium/lamina propria presents a novel site 
which responds to receptor stimulation to modulate and regulate spontaneous activity.  If 
malfunction of this tissue presents as a cause or mediator of bladder overactivity, its 
functionally active receptors and activity may be selectively targeted in treatments. 
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9.1.8  Final remarks 
 
This thesis has identified the receptor systems modulating the spontaneous contractile activity 
of the urothelium/lamina propria.  It is clear that the urothelium/lamina propria plays 
important roles in the maintenance of normal bladder function.  A greater understanding of 
the functionally active receptors and systems in this tissue will enable novel therapeutic 
targets to be identified and investigated.  Future avenues of research may further identify the 
relationships between these systems in the normal and pathological states of the human 
bladder. 
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